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Abstract 
Over the past few decades metals in medicine have played to play a significant role, especially 
after the discovery of the anticancer properties of cisplatin. However, acquired and intrinsic 
resistance, toxicity and a host of side-effects have encouraged the research for new metal 
based anticancer agents. Organometallic complexes have proved to be successful anticancer 
agents and several have commenced clinical trials. The aim of this study was to prepare and 
characterize trinuclear platinum group organometallic complexes and investigate their in vitro 
activity. 
The first series of ester containing complexes were prepared. The ligands were generated by 
the preparation of Schiff base ligands obtained from the condensation of 4-
aminophenylmethanol and either benzaldehyde, 2-pyridinecarboxaldehyde or 
salicylaldehyde. Trimeric ester ligands were prepared from these monomeric ligands by 
reaction with trimesoyl chloride. The trimeric ligands were used to prepare a new series of 
trinuclear polyester organometallic complexes using the dimeric precursors, [Ru(η6-p-
PriC6H4Me)Cl2]2, [Rh(η5-C5Me5)Cl2]2 or [Ir(η5-C5Me5)Cl2]2. The Schiff base ligands act as 
bidentate donors to each metal. All compounds were characterized using nuclear magnetic 
resonance (NMR) and Fourier transform infrared (FT-IR) spectroscopy, elemental analysis 
(EA) and electron impact (EI) or electrospray ionization (ESI) mass spectrometry. Model 
mononuclear analogues were prepared and the molecular structures of selected compounds 
were determined by single crystal X-ray diffraction analysis. The mono- and trimeric ligands 
and the metal complexes were evaluated for inhibitory effects against the human ovarian 
cancer cell lines A2780 (cisplatin-sensitive) and A2780cisR (cisplatin-resistant), and the model 
human skin fibroblast cell line, KMST-6. Upon coordination of the metal center an increase in 
the activity against the ovarian cancer cells is observed, compared to the free ligands. The 
trinuclear complexes displayed the greatest antiproliferative activity and exhibited selectivity 
over the non-tumorigenic skin cells. 
The second series of new trinuclear and model mononuclear cationic monodentate Rh(III), 
Ir(III) and Ru(II) complexes with alkylated 1,3,5-triaza-7-phosphaadamantane (PTA) moieties 
were prepared. Monoalkylation of the PTA moiety was achieved by reaction with 
1,3,5-tris-(bromomethyl)benzene for the trimeric ligand or benzylbromide for the monomeric 
ligand. The trinuclear cationic complexes were prepared from the dimeric precursors, 
[Ru(η6-p-PriC6H4Me)Cl2]2, [Rh(η5-C5Me5)Cl2]2 or [Ir(η5-C5Me5)Cl2]2, and characterized using 
NMR and IR spectroscopy, HR-ESI-mass spectrometry and elemental analysis. The ligands 
coordinate to the metals via the phosphorous of the PTA, and this was confirmed by 
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appropriate shifts in the 31P NMR spectra. The cytotoxicities of all alkylated PTA compounds 
were investigated against WHCO1 esophageal cancer cell. The monomeric and trimeric 
ligands displayed no activity. The trinuclear Rh(III) and Ir(III) complexes were more active than 
the mononuclear analogues. The Ir(III) mononuclear complex proved to be the most cytotoxic 
and 1H NMR model studies demonstrated its DNA binding ability, while UV-Vis studies 
demonstrated the ability of the iridium mononuclear complex to interact with the double helix 
structure of Red Salmon testes DNA. 
The third series consists of new water soluble Rh(III) and Ir(III) sulfonated complexes. The 
trimeric ligand was prepared via a Schiff base condensation between tris-2-(aminoethyl)amine 
and 5-sulfonatosalicylaldehyde. Anionic trinuclear complexes were prepared from the dimeric 
precursors, [Ru(η6-p-PriC6H4Me)Cl2]2, [Rh(η5-C5Me5)Cl2]2 or [Ir(η5-C5Me5)Cl2]2. Rh(III) and Ir(III) 
complexes were also prepared by displacement of the labile metal-chloro ligand by reaction 
with pyridine, 4-methylpyridine, 4-phenylpyridine and 4-ferrocenylpyridine. The sulfonated 
complexes were characterized using NMR and IR spectroscopy, HR-ESI-mass spectrometry 
and elemental analysis. The cytotoxicities of all sulfonated compounds were investigated 
against WHCO1 cancer cells and the metal complexes displayed promising activity, while the 
ligands showed no activity. Several of the trinuclear complexes exhibited comparable activity 
to that of cisplatin. 1H NMR model studies demonstrated the most active compound’s DNA 
binding ability.  
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Abbreviations and Symbols 
o   degrees 
oC   degrees Celsius 
Å   angstrom(s) 
μM   micromolar 
λmax   wavelength with maximum absorbance 
 
2D   two dimensional 
 
A2780   cisplatin sensitive human ovarian cancer cells 
A2780cisR  cisplatin resistant human ovarian cancer cells 
ATR   attenuated total reflectance 
 
13C{1H}   proton decoupled carbon-13 
CDCl3   deuterated chloroform 
(CD3)2CO  deuterated acetone 
CD3OD  deuterated methanol 
(CD3)2SO  deuterated sulfoxide 
cisR   cisplatin-resistant 
COSY   correlation spectroscopy 
Cp*   1,2,3,4,5-pentamethylcyclopentadienyl 
 
d   doublet 
dd   doublet of doublets 
D2O   deuterium oxide 
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DCM   dichloromethane 
DMSO   dimethylsulfoxide 
DNA   deoxyribonucleic acid 
 
EA   elemental analysis 
EI-MS   electron impact mass spectrometry 
ESI-MS  electrospray ionization mass spectrometry 
HR-ESI-MS  high resolution electrospray ionization mass spectrometry 
EtOH   ethanol 
Et2O   diethyl ether 
 
Fc   ferrocenyl 
FDA   food and drug administration 
FT-IR   fourier transform infrared spectroscopy 
 
g   gram(s) 
5'-GMP  guanosine 5′-monophosphate 
 
HEK   human embryonic kidney cells 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HR   high-resolution 
HSQC   heteronuclear single quantum correlation 
Hz   hertz 
 
IC50   50% inhibitory concentration 
iPrOH   isopropyl alcohol 
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IR   infrared 
 
J   coupling constant 
 
KMST-6  normal human fibroblast skin cells 
 
m   multiplet 
MeOH   methanol 
MHz   megahertz 
mol   mole(s) 
mmol   millimole(s) 
MP   melting point 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
m/z   mass to charge ratio 
 
NaBPh4  sodium tetraphenylborate 
NMR   nuclear magnetic resonance 
 
p-cy   para-cymene 
PGM   platinum group metal(s) 
31P{1H}   proton decoupled phosphorous-31 
ppm   parts per million 
PTA   1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane 
pyr   pyridine 
 
RAPTA  ruthenium-arene PTA 
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RI   resistance index 
RNA pol II  ribonucleic acid polymerase II 
 
s   singlet 
sep   septet 
SI   selectivity index 
 
t   triplet 
THF   tetrahydrofuran 
 
UV/Vis   ultraviolet-visible 
 
WHCO1  human esophageal cancer cells 
 
XRD   X-ray diffraction 
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Chapter 1: Introduction and Literature 
Review 
 
1. Overview of Cancer 
One of the leading global causes of death is cancer (Figure 1.1). The World Health 
Organization defines cancer as “the uncontrolled growth and spread of cells”. In 2012 there 
were 32.6 million people living worldwide with cancer, while there were 8.2 million deaths due 
to cancer and 14.1 million new cases of cancer.[1] Furthermore, these numbers are expected 
to grow in the coming decades. The four most common types include: lung, female breast, 
bowel and prostate cancer.  
 
 
Figure 1.1: Map showing cancer incidences per 100 000 people compared to global averages 
by country.[1] 
 
Surgery and radiotherapy dominated cancer treatment up until 1950. In the 1940s 
chemotherapy began as an alternative, when nitrogen mustards (HN2, Figure 1.2) were used 
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to treat lymphomas. In the ensuing decades, much research has moved toward new drugs 
which inhibit growth and spread of malignant tissue. Cancer patients have seen an 
improvement in life expectancy or cures as new research has progressed. 
 
 
Figure 1.2: HN2 or mustine, a nitrogen mustard, is a non-specific DNA alkylating agent. 
 
One of the struggles with chemotherapy is the lack of selectivity and the undesired side-effects 
with this treatment. The side effects include nausea, vomiting and may even include renal 
failure. Currently, the drugs which are in clinical use obtain their selectivity by relying on the 
high metabolic rates of tumors.[2] However, this leads to the unintentional toxicity to bone 
marrow and the gastrointestinal tract, as these tissues and organs undergo constant cellular 
replacement. 
In addition, the occurrence of resistance to chemotherapies represents a major issue. This 
can be intrinsic or acquired resistance. Intrinsic resistance is based on mutations that can 
spontaneously occur in cell proliferation due to genetic instability.[3] Contrastingly, acquired 
resistance only develops post-exposure to the chemotherapeutics.  
Since the introduction of chemotherapy to treat cancer, a plethora of compounds has been 
investigated to overcome these hurdles. 
 
1.1. Metals in Cancer Treatment 
Metal-based drugs offer novel mechanisms of action and aim to achieve a more targeted 
approach,[4] which will likely result in greater selectivity and fewer side effects. Metal-based 
drugs are able to coordinate multiple different ligands in a three dimensional manner and thus 
offer many tailored advantages over organic and carbon based drugs.[5] Carbon based 
compounds are unable to contain the wide variety of geometries, kinetic properties and 
coordination numbers that are attained by metal complexes.[6] 
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1.1.1. Platinum-based Complexes 
Michele Peyrone, in 1844, first described cis-diamminedichloroplatinum(II) (cisplatin, Figure 
1.3), originally known as Peyrone’s chloride.[7] More than a century passed before Barnett 
Rosenberg, in 1965, serendipitously discovered its anticancer activity.[8] Cisplatin is most 
active against solid tumors found in testes and ovaries,[9] and is the world’s most widely used 
anticancer drug.[10-12] Stumbling upon this was a significant milestone in medicinal inorganic 
chemistry.  
 
Figure 1.3: Cisplatin, a platinum based anticancer complex, or Peyrone’s Chloride. 
 
The target of cisplatin is DNA,[9] particularly the DNA base guanine, where stable DNA-Pt 
complexes with intra-strand cross-links are formed[13-15] and DNA alteration prevents further 
replication. This was shown by the laboratory of Lippard, where transcription of RNA pol II was 
inhibited[16] and cell apoptosis was induced. 
Drug resistant tumors severely limit the clinical applications of cisplatin.[17] There are 4 main 
reasons for resistance to cisplatin. These can be classed as:  
(a) Increase in tolerance to cisplatin-DNA adducts and failure of cell death pathways, 
(b) Activation of repairing mechanisms of platinum-DNA adducts, 
(c) Inactivation by thiol-containing species, and 
(d) Insufficient drug accumulation 
To overcome the issues of resistance, analogues of cisplatin were investigated.[18] This was 
achieved by replacing the readily exchangeable chloride ligands with others which reduced 
the rate of aquation.[19] These second generation FDA approved platinum drugs (Figure 1.4) 
are in current use and include oxaliplatin which is used for advanced colorectal cancer 
treatment, and carboplatin which is mainly used for ovarian, lung, head and neck cancers. 
 
Figure 1.4: Second generation Pt drug complexes, oxaliplatin (left) and carboplatin (right). 
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1.1.2. Alternative Metals as Therapeutic Agents 
Apart from Pt anticancer agents, other metal-based anticancer drugs have been 
investigated.[20] These have been further studied as they result in fewer side effects. New 
metal-based anticancer drugs have the potential to overcome platinum resistance, reduce 
toxic side effects and widen the spectrum of cancer types which can be treated.  
In particular, other platinum group metals, such as rhodium, iridium and ruthenium have been 
an exciting point of interest, despite their cost, within the field of antitumor drug design.[21] The 
inclusion of a ferrocenyl moiety has in some cases shown a marked increase in activity.[22] 
 
1.1.2.1. Rhodium(III) 
Little research has gone into rhodium-based drugs, which makes them ideal candidates for 
further development of anticancer drugs. Rhodium and iridium lend themselves to easy 
coordination to N,N’-, N,P-, N,O- or C,N-donor ligands. A few studies have been reported on 
Rh(III) compounds with antitumor activity.[23-25] The simple complex mer-[RhCl3(NH3)3] 
reported decades ago exhibited anticancer properties.[26-27] Sheldrick and co-workers 
prepared half-sandwich Rh(III) complexes from pyridyl ligands which displayed 
antiproliferative activity.[28-30] 
In the case of cyclometalated Rh(III) arene systems, in which a metal-carbon bond is formed 
to an anionic aromatic ring, good antitumor activity is observed. Smith and co-workers reported 
on some mononuclear cyclometalated Rh(III) half-sandwich complexes (Figure 1.5, left) 
cytotoxic against cisplatin-sensitive human ovarian cancer cells, A2780, and cisplatin-resistant 
cells, A2780cisR.[31] The complexes showed good selectivity when tested against normal 
human embryonic kidney cells, HEK. In another study by Smith and co-workers neutral 
(Figure 1.5, left and right) and cationic complexes (Figure 1.5, center) with 
pentamethylcyclopentadienyl (η5-C5Me5) Rh(III) were prepared, based on 2-iminopyridyl and 
salicylaldimines ligands.[32] 
 
 
Introduction  Chapter 1 
 
5 | P a g e  
 
 
Figure 1.5: Cyclometalated naphthaldimine (left), 2-Iminopyridyl (center) and salicylaldimine 
(right) Rh(III) metal complexes for anticancer study. 
 
It was reported that these complexes display moderate antitumor activity against A2780 and 
A2780cisR cell lines.  
Keppler and co-workers prepared aqueous stable rhodium(III) complexes of a general formula 
[Rh(η5-C5Me5)(L)Cl] (where L = 1,2-dimethyl-3-hydroxy-pyridin-4(1H)-one or 2-pyridine 
carboxylic acid; Figure 1.6).[33] 
 
 
Figure 1.6: Rh(III) complexes prepared from 1,2-dimethyl-3-hydroxy-pyridin-4(1H)-one (left) 
2-pyridine carboxylic acid (right) for anticancer study. 
 
These complexes displayed moderate in vitro cytotoxicities against human ovarian 
carcinomas (CH1), colon carcinomas (SW480) and non-small cell lung carcinomas (A549). 
The moderate activity is attributed to the complexes high stability and the consequent 
incapability to form aqua species by displacement of the chloro-ligand.  
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1.1.2.2. Iridium(III) 
The low spin 5d6 iridium(III) complexes have often been thought to be inert[34-35] and yet the 
number of organometallic iridium complexes are quite extensive.[36-53] π-Bonded carbon-
bound arenes impart a balance between hydrophobicity and hydrophilicity that is required for 
targeting biomolecules and cellular uptake.[54-56] The Cp* ligand is negatively charged and 
stabilizes Ir(III) complexes.  
Sadler and co-workers prepared a series of Ir(III) half-sandwich complexes, with various 
functionalized arene systems, of the general formula [Ir(η5-Cpx)(XY)Cl]0/+ where Cpx = Cp*, 
tetramethyl(phenyl)cyclopentadienyl (CpPh) or tetramethyl(biphenyl)cyclopentadienyl (CpBiph), 
and XY = 1,10-phenanthroline, 2,2’-bipyridine, ethylenediamine or picolinate, (Figure 1.7).[36] 
 
 
Figure 1.7: Some Ir(III) arene complexes studied as anticancer complexes. 
 
It was found that the activity of the complexes increased as the arene was exchanged from 
Cp* to CpPh and then to CpBiph, which was the most active in the nanomolar range.  
Sadler and co-workers, for comparison, then extended the series to cyclometalated Ir(III) 
complexes (Figure 1.8) of the general formula [Ir(η5-Cpx)(C^N)Cl] where Cpx = Cp*, CpPh or 
CpBiph, C^N = 2-(p-tolyl)pyridine, 2-phenylquinoline, 2-(2,4-difluorophenyl)pyridine or 2-
phenylpyridine.[48] 
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Figure 1.8: A series of cyclometalated Ir(III) complexes that show promising cytotoxicity.[48] 
 
All complexes showed potent cytotoxicity towards human ovarian cancer cells A2780. A 
similar trend was observed for that of the cyclometalated complexes, in comparison to that of 
the XY donor complexes previously made, with the activity of the arenes found to be Cp* < 
CpPh < CpBiph, which was the most active in the sub-micromolar range. The high potency of 
the CpBiph was attributed to the extended phenyl rings and its ability to intercalate with DNA.[23, 
48] 
Work done by Kollipara and co-workers shows that half-sandwich PGM complexes with 
bithiazole ligands (Figure 1.9) with the general formula [M(arene)(L)Cl], where M = Ru, Rh or 
Ir; arene = p-cymene or Cp*; L = 2,2’-dimethyl-4,4’-bithiazole, 2,2’-diamino-4,4’-bithiazole or 
2,2’-diphenyl-4,4’-bithiazole, are active against two human breast carcinoma cell lines, MDA-
MB-231 and T47D.[47] Interestingly, the Ir(III)-based complexes were found to be more active 
than the Ru(II) and Rh(III) complexes under both aerobic and hypoxic conditions. This may be 
attributed towards a large number of reasons, including the hydrophobicity, cell uptake or 
possible DNA binding.[36] 
 
 
Figure 1.9: A series of bithiazole-containing metal complexes, where the Ir(III) complexes 
were the most active against human breast carcinoma cells. 
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1.1.2.3. Ferrocene 
Ferrocene, [Fe(η5-C5H5)2], a sandwich compound discovered[57-58] and characterized[59-60] in 
the 1950s led to the reporting of many publications in just two decades.[61] It has been said 
that this may have been the start of a new Iron Age.[62] 
It has been shown that many compounds containing a ferrocenyl moiety exhibit good antitumor 
activity.[63] Work by Costa-Lotufo, Jaouen and co-workers reported that the introduction of a 
ferrocenyl moiety to 1,1,2-triphenylbut-1-ene, which had been previously regarded as inactive, 
induced a concentration decrease in cancer cell viability.[64] 2-Ferrocenyl-1,1-diphenylbut-1-
ene (Figure 1.10) caused cell death by apoptosis, due to interference with the cell cycle in the 
G1G0 phase, while necrosis was only observed at the highest concentration tested. 
 
Figure 1.10: 2-Ferrocenyl-1,1-diphenylbut-1-ene (left) showed superior antitumor activity 
compared to the organic analogue, 1,1,2-triphenylbut-1-ene (right). 
 
Jaouen and co-workers also prepared a large series of ferrocenophane tetrasubstituted olefin 
derivatives (Figure 1.11) which exhibited high cytotoxicity against human independent breast 
MDA-MB-231 and prostate PC3 cancer cells.[65]  
 
Figure 1.11: Ferrocenophane derivatives that exhibit high antitumor activity. 
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The activity of these ferrocenyl-derived compounds is well into the nanomolar range. This 
potent antitumor activity is attributed to the ferrocene moiety. Lead compounds were selected 
for screening against the NCI-DTP 60-cell line panel and the mean cytotoxicity over the cell 
lines tested was better than cisplatin. 
Nieto and co-workers prepared heterobimetallic dinuclear Pt(II)-ferrocenyl complexes 
(Figure 1.12) which showed antitumor activity in the low micromolar range in several cancer 
cell lines.[66] 
 
Figure 1.12: Heterobimetallic Pt(II) complexes with β-aminoethylferrocenes.  
 
Smith and co-workers prepared polynuclear RAPTA complexes coordinated to bidentate N,O- 
or N,N-donor amine ligands (Figure 1.13). Nine of the twelve compounds slowed the 
proliferation of ovarian cancer cells by more than half at a 5 µM Fe concentration.[67] 
 
 
Figure 1.13: Ferrocenyl-derived polynuclear N,O- and N,N-RAPTA complexes. 
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1.1.2.4. Ruthenium(II) 
Currently, ruthenium-containing metal complexes appear to be the best alternatives to Pt 
drugs as they accumulate in cells which undergo rapid division like tumors. Ru metal centers 
mimic iron and bind to the protein transferrin,[68] which transports Fe into cells. Within 
tumorigenic cells transferrin protein receptors are overly expressed.[69] However, Ru has 
higher affinity for ‘soft’ ligands than Fe and exhibits slower binding kinetics with high stability 
constants. 
Recently it has become apparent that DNA is not the primary target molecule of ruthenium-
arene complexes, as findings have shown that these systems bind to enzymes and target 
biologically important proteins instead.[70-72] This new insight assists with the understanding of 
the activity of these complexes.  
Different ruthenium complexes display various mechanisms which lead to their anticancer 
activity. One accepted mode of action is the formation of Ru-aqua complexes by the aquation 
of the labile Ru-Cl bond. These complexes often then interact with DNA to form adducts, or 
intercalate between DNA base pairs through available arene systems or interact with proteins 
and other important biological molecules. 
An attractive feature of Ru is that it has access to a range of oxidation states (II, III and IV) 
under physiological conditions and interchanging between these different oxidation states 
within the cell is easily attainable because of the low energy barriers between them.  
The first Ru(III) complexes to enter clinical trials were trans-
[RuIIICl4(dimethylsulfoxide)imidazole], NAMI-A (Figure 1.14, left) and indazolium trans-
[RuIIICl4(indazole)], KP1019 (Figure 1.14, right).[73-76] The activity of these imidazolium and 
indazolium stabilized anionic Ru(III) complexes can be explained by their activation by cellular 
reduction to Ru(II), which is able to coordinate to biomolecules and further explains their 
increased reactivity.[20, 77-79] However in the case of KP1019 only mild treatment-related 
toxicities were displayed, which encouraged further development. The latest lead drug to come 
out of this class of compounds is the more water-soluble sodium salt analogue, NKP1339 
(Figure 1.14, right) which has successfully completed a clinical phase I trial and is on the edge 
of clinical application.[80] NKP1339 targets GRP78, which regulates the endoplasmic reticulum 
stress and is up-regulated in cancer cells, and NKP1339 results in down-regulation which 
leads to tumor cell death.[81] 
 
Introduction  Chapter 1 
 
11 | P a g e  
 
 
Figure 1.14: NAMI-A (left), KP1019 (center) and NKP1339 (right). 
 
Reports show that NKP1339 interacts with serum proteins and has a high affinity towards 
proteins in the bloodstream, namely transferrin and albumin.[82-83] These two proteins behave 
as transport and delivery agents for ruthenium complexes.[84] NKP1339 displayed near 4-fold 
enhanced mean survival of the hepatoma xenograft Hep3B when used in combination with 
Sorafenib, a tyrosine kinase inhibitor and approved drug for advanced renal cancer.[80, 85] 
Ru(III) complexes are more inert than complexes formed with Ru(II) and often drugs are 
administered as Ru(III). This causes less damage to healthy cells, increasing selectivity, and 
the metal is reduced to Ru(II) in cancer cells,[69] which tend to contain a more chemically 
reducing environment. This environment is due to the increased metabolic rate of the rapidly 
dividing cell and its remoteness from the blood supply, both of which cause a lower 
concentration of molecular oxygen. This theory has undergone intense scrutiny and criticism. 
Of interest amongst the organometallic Ru complexes are the half-sandwich Ru complexes, 
which have been extensively explored as they have shown potential as anticancer agents.[86-
87] Pioneering in this field are the works by Dyson and Sadler.[86, 88-108]  
The arene moiety promotes diffusion of the complex into the cell through the membrane by its 
hydrophobic nature. The biological properties of the complex can be modulated by occupying 
a variety of mono-, bi- and tridentate ligands in the remaining three coordination sites. 
Sadler and co-workers prepared a Ru(II) arene complex, [Ru(η6-biphenyl)(en)Cl][PF6] 
(RM175, Figure 1.15, en = ethylenediamine).[109] RM175 displays good activity against A2780 
human ovarian cancer cells and is comparable to cisplatin. In addition, RM175 shows 
moderate activity against the cisplatin resistant cell line.[94] 
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Figure 1.15: The structure of RM175. 
 
Dyson and co-workers prepared complexes of the general formula [Ru(η6-arene)(PTA)Cl2] 
(RAPTA, where PTA = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane).[96, 103, 110-114] RAPTA-C, 
[Ru(η6-p-cymene)(PTA)Cl2] was found to be relatively inactive in vitro yet it was active against 
lung metastasis in CBA mice.[112] The Rh(III) and Ir(III) analogues containing 1,2,3,4,5-
pentamethylcyclopentadiene, Cp*, were prepared for investigation for inhibition of enzymes.[44] 
The Rh(III) and Ir(III) analogues (Figure 1.16) were found to be inactive compared to 
RAPTA-C. The greater activity of RAPTA-C was attributed to its ability to form stronger metal-
sulfur bonds at the active site of cathepsin B, a lysosomal cysteine protease involved in protein 
degradation and antigen processing. 
 
 
Figure 1.16: RAPTA-C (left) and η5-C5Me5 derivatives Rh(III) (center) and Ir(III) (right). 
 
1.2. Multinuclearity 
Initially platinum-based anticancer drugs remained the focus of the development of new drugs 
to replace cisplatin. By increasing the DNA inter-strand cross-links and thus increasing the 
number of moieties which have DNA affinity, scientists aim to increase the activity of Pt 
complexes. Farrell’s trinuclear cationic complex (BBR3464, Figure 1.17) [μ-trans-
Pt(NH3)2{trans-PtCl(NH3)2{NH2(CH2)6NH2}}2][NO3]4 demonstrated the ability to overcome 
cisplatin resistance,[115] yet was not approved. 
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Figure 1.17: BBR3464, a cationic trinuclear Pt complex. 
 
Jansen and co-workers prepared a tetranuclear analogue of BBR3464 based on a 
1,4-diaminobutanepoly(propyleneimine) scaffold (Figure 1.18). This tetraplatinum based 
complex, DAB(PA-tPt-Cl)4, showed an ability to bind to the model nucleoside guanine- 5′-
monophosphate ( 5'-GMP), at each Pt metal, through N7 on the model base pair.[116] This Pt 
complex showed only moderate anticancer activity against two separate mouse leukemia cell 
lines, L1210/0 and L1210/2, and was less cytotoxic against several human tumor cell lines. 
 
 
Figure 1.18: DAB(PA-tPt-Cl)4, a cationic tetranuclear Pt complex. 
 
Since then some focus has remained on multinuclearity,[117-120] while a shift in interest of the 
metal used has swung to others. Sadler and co-workers prepared a dinuclear complex, 
[{Ru(η6-biphenyl)Cl(en)}2-(CH2)6]2+ (Figure 1.19, left), which is capable of double DNA 
intercalation through induced-fit recognition by epimerization at the stereogenic centers.[121] 
The intercalation properties of the mononuclear analogue are significantly lower than those of 
the dinuclear complex, and this was attributed to the ability of both the free phenyl rings being 
able to intercalate and cause cross-linking and interstrand cross-links within the DNA. 
Keppler and co-workers have shown that the activity of pyridine linker-derived ruthenium-
arene dinuclear complexes is related to the length and lipophilicity of the linkers. The most 
cytotoxic complex contains a 32-carbon-long linker chain (Figure 1.19, right).  
Introduction  Chapter 1 
 
14 | P a g e  
 
 
 
Figure 1.19: Dinuclear ruthenium-arene complexes which exhibit high cytotoxicity. 
 
The increasingly high activity of these complexes is due to the enabling ability of the 
complexes to cross-link biological molecules with longer chains.[54, 122] 
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1.3. Concluding Remarks 
The exponentially increasing number of diagnosed cases of cancer threatens all. 
Complications arising from the acquired or intrinsic resistance to currently used 
chemotherapies, along with the general toxicity and poor selectivity to differentiate from normal 
healthy tissues or organs, demands the development of new compounds to overcome these 
and other hurdles. 
Polynuclear PGM complexes have become of interest in bioorganometallic chemistry with 
specific design for use as anticancer chemotherapeutics. The evidence of their anticancer 
activity provides encouragement for further research and development of this class of 
complexes. 
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1.4. Aim and Specific Objectives of this Thesis 
 
1.4.1. Aims 
There have been many monometallic arene complexes synthesized for antitumor activity 
investigation. There is still much room for research to improve on multinuclearity, activity and 
selectivity. In general, this research project aimed to: 
 Prepare and characterize new trimeric ligands. 
 
 Coordinate the PGMs Rh(III), Ir(III) or Ru(II) to form polynuclear complexes. 
 
 Evaluate these complexes for their biological activity as anticancer agents. 
 
1.4.2. Objectives 
 
1.4.2.1. Synthetic Objectives 
This project focused on the synthesis of mono- and polynuclear Rh(III), Ir(III) and Ru(II) 
complexes, which were characterized using a range of analytical and spectroscopic 
techniques. These complexes are divided into three classes of compounds, based on the 
different ligand types to which the metals are coordinated.  
1. The preparation of new different polyester ligands and their coordination to PGMs 
(Figure 1.20). The different polyester ligands coordinated to the metal arenes in a 
bidentate manner (C,N-, N,N- or N,O-chelating). Benzyl alcohol mononuclear 
complexes were also prepared for comparative purposes.  
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Figure 1.20: The general structure of polyester rhodium(III), iridium(III) and ruthenium(II)-
arene complexes. 
 
2. The synthesis of a new trimeric cationic ligand based on alkylated PTA, by 
quaternization of a nitrogen, for coordination to PGMs (Figure 1.21). Mononuclear 
analogues were also prepared. 
 
 
Figure 1.21: Tri- (left) and mononuclear (right) rhodium(III), iridium(III) and ruthenium(II)-
arene complexes based on alkylated PTA ligands with a benzyl central core. 
 
3. The bidentate (N,O-) coordination of Rh(III) and Ir(III) Cp* fragments to mono- and 
trimeric anionic sulfonated ligands to form water-soluble complexes. The chlorides 
were displaced by a series of N-donor ligands to form sulfonated cationic complexes 
(Figure 1.22). 
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Figure 1.22: Sulfonated tri- (left) and mononuclear (right) rhodium(III) and iridium(III)-Cp* 
complexes. 
 
All compounds have been characterized using analytical and spectroscopic techniques. These 
include NMR and FT-IR spectroscopy, elemental analysis and mass spectrometry. 
 
1.4.2.2. Biological Evaluation 
After characterization of the complexes, ensuring purity, all the trinuclear metal-arene 
complexes were evaluated for in vitro antitumor activity in either human ovarian cancer cells 
(A2780 and A2780cisR) or human esophageal cancer cells (WHCO1). Ovarian cancer was 
selected due to its prevalence in women is one of the leading causes of cancer related 
deaths.[123] Selectivity was investigated, for selected complexes, by analyzing cytotoxicity 
against normal human fibroblasts (KMST-6). 
NMR experiments were performed to study the stability and interactions of the most active 
complexes with model DNA 5'-GMP and small biological molecules. 
The ability of the alkylated PTA complexes to interact with Red Salmon testes DNA was 
studied by UV-Vis spectroscopy, to complement the NMR studies. 
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Chapter 2: Synthesis, Characterization 
and Antitumor Activity of Trinuclear 
Rh(III), Ir(III) and Ru(II) Functionalized 
Aromatic Esters 
 
2. Introduction 
Ester functional groups increase the lipophilic nature of compounds and can promote the 
transport of the molecule through membranes.[1-2] Because of this, esters are important within 
the field of medicinal chemistry.  
There are several examples of bioactive compounds which contain ester functionality. These 
include bezafibrate (Figure 2.1a), an oral hypolipidemic agent,[3] derivatives of cinnamic acid 
(Figure 2.1b), which exhibit in vitro antiinflammatory effects[4] and esters prepared from 4-
acetyl-2-(2-hydroxyethyl)-5,6-bis(4-chlorophenyl)-2H-pyridazin-3-one (Figure 2.1c) used as 
antihypertensive agents.[5] Reports show that trivanillic ester polyphenols (Figure 2.1d) exhibit 
cytostatic biological properties and have the ability to inhibit kinase enzymes in tumors 
resistant to pro-apoptotic stimuli.[6] 
Large macromolecular molecules containing ester moieties have been reported to act as 
micelles or in conjuction with coordinated known drugs to show cytotoxicity.[7-11] These 
systems result in enhanced targeting of tumors and improved efficiency of the treatment.[12-14] 
Polyester dendrimers display excellent advantages as drug delivery vehicles due to their low 
toxicity and demonstrate biodegradability.[15] 
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Figure 2.1: Aromatic ester precursors bezafibrate (a) and cinnamic acid (b), ester pyridazin 
derivatives (c) and cytostatic trivanillates (d) studied for different bioactivities. 
 
Reports showing the incorporation of ruthenium-arene to mononuclear or dinuclear esters 
provide evidence of their anticancer activity. A RAPTA complex (Figure 2.2 left) with an 
ethacrynoate ester as part of the arene was found to have superior activity in inhibition of 
glutathione-S-transferases than the Ru complex and the ethacrynic acid.[16-18] Hu and co-
workers prepared ruthenium-arene complexes with 5-fluorouracil-1-methyl isonicotinate 
(Figure 2.2 right) which was moderatively more active against the human hepatocellular 
carcinoma cells, BEL-7402, than 5-fluorouracil.[19]  
 
 
Figure 2.2: RAPTA complex with ethacrynate derivatized arene (left) and 5-fluorouracil-1-
methyl isonicotinate ruthenium-arene complex (right). 
 
Dyson and co-workers prepared mono- and dinuclear ferrocenyl pyridine based linker 
dinuclear complexes [Ru(η6-arene)Cl2]2(NC5H4OOC-C5H4FeC5H4-COOC5H4N), where arene 
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= hexamethylbenzene or p-cymene (Figure 2.3), which were twice as active as their 
mononuclear analogues.[20] 
 
  
Figure 2.3: Mono- (left) and dinuclear (right) pyridyl ester ruthenium-arene complexes. 
 
Smith and co-workers prepared a series of di- and tripyridyl ester rhodium(III), iridium(III) and 
ruthenium(II)-arene complexes (Figure 2.4). The free ligands and the dinuclear systems were 
inactive against human ovarian cisplatin sensitive (A2780) and cisplatin resistant cancer cells 
(A2780cisR), while the trinuclear complexes showed moderate activity and selectivity, by 
evaluation against human embryonic kidney (HEK) cells.[21] 
 
 
Figure 2.4: Di- (left) and trinuclear (right) pyridyl ester rhodium(III), iridium(III) and 
ruthenium(II)-arene complexes. 
 
In this chapter, the synthesis, characterization and biological evaluation of new trinuclear 
ester-containing rhodium(III), iridium(III) and ruthenium(II)-arene complexes is described. 
Mononuclear analogues were also prepared for comparison. Spectroscopic and analytical 
techniques were used to support and confirm the suggested structures, and these are 
discussed herein, along with the biological activity of these complexes. 
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2.1. Synthesis and Characterization of C,N-Benzaldimine, N,N-Pyridylimine and N,O-
Salicylaldimine Ligands 
The Schiff base products 4-(benzylideneamino)benzyl alcohol, 2.1,[22] and 
4-(salicylideneamino)benzyl alcohol, 2.3,[23] were synthesized using known methods. 
4-(Pyridylideneamino)benzyl alcohol, 2.2, was prepared by reacting 4-aminophenylmethanol 
with 2-pyridinecarboxaldehyde (Scheme 2.1). 
 
 
Scheme 2.1 Synthesis of C,N-benzaldimine, N,N-pyridylimine and N,O-salicylaldimine 
ligands 2.1-2.3. 
 
The reactants were stirred at room temperature for 12 hours in ethanol. Ligand 2.2 was 
precipitated using hexane and isolated as a pale brown solid in 86% yield. 2.2 is soluble in 
most organic solvents such as dichloromethane, chloroform, methanol, ethanol and 
dimethylsulfoxide. Spectroscopic (1H NMR, 13C{1H} NMR and FT-IR spectroscopy) and 
analytical data (elemental analysis and mass spectrometry) confirmed the structural integrity 
of 2.2. 
The 1H NMR and 13C{1H} NMR spectra of 2.2 were recorded in deuterated chloroform (CDCl3) 
and were comparable with the benzaldimine[22] and salicylaldimine[23] analogues.  
The 1H NMR spectrum of 2.2 (Figure 2.5) shows a downfield shift in the signals assigned for 
the aromatic phenyl C-H protons from δ 6.60 ppm and δ 7.09 ppm to δ 7.21 ppm and δ 7.35 
ppm respectively, and resonate in a similar range to 2.1[22] and 2.3,[23] as reported in literature. 
This downfield shift may be as a result of the electron withdrawing effects of the newly formed 
imine moiety. The pyridyl protons resonate in the aromatic region, δ 7.40 ppm to δ 8.72 ppm. 
The signal assigned to the imine proton appears as a singlet at δ 8.60 ppm (Table 2.1), while 
the doublet at δ 8.72 ppm is assigned for the proton para to the pyridyl nitrogen. The signal 
for the two aliphatic protons appears at δ 4.74 ppm.  
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Figure 2.5 1H NMR spectrum of N,N-pyridylimine ligand 2.2 in CDCl3. 
 
The 13C{1H} NMR spectrum of 2.2 displayed the expected carbon signals. Signals for the 
aromatic carbons appear in the region δ 154 – 121 ppm and a signal at δ 160.42 ppm is 
assigned as the imine carbon. The aliphatic carbon results in a signal at δ 64.83 ppm (Table 
2.1). 
The use of infrared (FT-IR) spectroscopy confirmed that the Schiff base product 2.2 did form 
and this was identified by the presence of an stretching vibration at 1630 cm-1, which is 
assigned to the newly formed C=Nimine bond (Table 2.1). Band are observed at 1583 cm-1 due 
to the C=Npyridyl stretching and at 1021 cm-1 for the C-O bond vibration. 
 
 
Table 2.1 Selected spectroscopic and analytical data for N,N-pyridylimine ligand 2.2. 
Compound 1H NMR 
(Imine, -CH2) [ppm]a 
13C{1H} NMR 
(Imine, -CH2) [ppm]a 
IR 
(Imine) [cm-1]b 
MS 
[m/z]c 
2.2 8.60, 4.73 160.42, 64.83 1630 [M]+ = 212.07 
aRecorded in CDCl3; bRecorded as KBr pellet; cEI-MS. 
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Electron impact mass spectrometry (EI-MS) analysis of 2.2 reveals a base peak for the product 
formed at m/z 212.07 [M]+ (Table 2.1). After extensive drying under vacuum elemental analysis 
(EA) data for 2.2 found calculated experimental data within acceptable limits. 
Next, the trimeric ester-containing ligands 2.4-2.6 were prepared by reaction of 2.1-2.3 with 
trimesoyl chloride in the presence of the base trimethylamine, to mop up hydrochloric acid 
formed, in dichloromethane (Scheme 2.2). All three ligands were isolated in high yields as air 
and moisture stable solids, which are soluble in most organic solvents. 
 
 
Scheme 2.2 Synthesis of trinuclear C,N-benzaldimine, N,N-pyridylimine and N,O-
salicylaldimine ester ligands 2.4-2.6. 
 
The 1H NMR and 13C{1H} NMR spectra of 2.4-2.6 were recorded in CDCl3 and notable shifts 
are evident of the formation of the ester moiety. Upon formation of the ester functional group 
the signals observed in the 1H NMR spectrum for the aliphatic protons shift downfield to δ 5.37 
– 5.42 ppm from δ 4.65 – 4.83 ppm. The presence of the benzene core is confirmed by the 
presence of a sharp singlet in the region δ 8.85 – 8.95 ppm (Table 2.1), due to the strong 
electron withdrawing effect of the ester moieties. The signals for the phenyl and benzyl or 
pyridyl or salicyl protons remain relatively unchanged.  
A deshielding effect is also observed in the 13C{1H} NMR spectra of 2.4-2.6 where signals for 
the aliphatic carbons shift to δ 66.94 – 67.91 ppm from ca. δ 65 ppm for 2.1-2.3. The most 
deshielded signals at δ 164.58 – 165.25 ppm are attributed to the carbonyl carbon of the newly 
formed ester moiety. The presence of the benzene core result in resonance signals at δ 130.25 
– 131.46 ppm and δ 133.10 – 134.80 ppm (Table 2.2). The signals for the phenyl, imine and 
benzyl or pyridyl or salicyl carbons remain relatively unchanged. 
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Table 2.2 Selected spectroscopic and analytical data for trinuclear esters 2.4-2.6. 
Compound 
Number 
1H NMR 
(-CH2, core) 
[ppm]a 
13C{1H} NMR 
(core) [ppm]a 
FT-IR 
[C-C(O)-O, 
C=O] [cm-1]b 
EI-MS  
[M+3H]3+ [m/z]c 
2.4 5.41, 8.92 130.25, 133.10 1231, 1724  266.15 
2.5 5.45, 8.95 130.43, 134.12 1324, 1719 265.28 
2.6 5.37, 8.85 131.46, 134.80 1232, 1728 280.10 
aRecorded in CDCl3; bRecorded as KBr pellet; cESI-MS. 
 
FT-IR spectroscopy reveals that the νC=O bond vibration, of the esters of 2.4-2.6, is in the 
region 1719 – 1728 cm-1. The C-C(O)-O bond within the ester results in a vibration which is 
assigned to strong absorption bands which are observed around 1231 – 1234 cm-1. No shift 
is observed in the absorption band associated with the C=Nimine or C=Npyr bond vibration upon 
esterification. 
 
Figure 2.6 ESI mass spectrum of trinuclear N,O-salicylaldimine ligand 2.6. 
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Further evidence for the formation of the ester and trimeric nature of 2.4-2.6 is supported by 
electrospray ionization mass spectrometry (ESI-MS), which shows peaks assigned as the 
adduct [M+3H]3+ for each ligand. For 2.4 m/z = 266.15, 2.5 m/z = 265.28 and 2.6 m/z = 280.10 
(Figure 2.6). After extensive drying under vacuum, EA data for 2.4-2.6 showed calculated 
experimental data within acceptable limits. 
 
2.2. Synthesis and Characterization of C,N-Benzaldiminato, N,N-Pyridylimine and N,O-
Salicylaldiminato PGM Complexes 
Ligands 2.1-2.6 were reacted with the metal-containing precursors, 
dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer, dichloro(pentamethylcyclo-
pentadienyl)iridium(III) dimer or dichloro(p-cymene)ruthenium(II) dimer to yield the 
corresponding mononuclear complexes 2.7-2.14 (Scheme 2.3) or trinuclear complexes 2.15-
2.22 (Scheme 2.4).  
 
 
Scheme 2.3 Synthesis of mononuclear C,N-benzaldiminato, N,N-pyridylimine and N,O-
salicylaldiminato complexes 2.7-2.14. 
 
The complexes 2.7-2.14 were prepared using similar methods. For the N,N-bidentate 
complexes the appropriate ligand and dimer were stirred in methanol or a mixture of ethanol 
and dichloromethane followed by addition of sodium hexafluorophosphate to precipitate the 
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cationic products 2.9-2.11 and 2.17-2.19. For the C,N- and N,O-bidentate complexes, the 
appropriate ligand and sodium acetate were stirred in methanol or a mixture of ethanol and 
dichloromethane followed by addition of the appropriate dimer. The resulting products 2.7, 2.8, 
2.12-2.16 and 2.20-2.22 were precipitated from the reaction using diethyl ether. Complexes 
2.7-2.22 were isolated as air and moisture stable yellow, orange or red solids in moderate to 
high yields and are soluble in most organic solvents. 
 
 
Scheme 2.4 Synthesis of trinuclear C,N-benzaldiminato, N,N-pyridylimine and N,O-
salicylaldiminato complexes 2.15-2.22. 
 
The mono- and trinuclear C,N-cyclometalated ruthenium(II) complexes were unable to be 
isolated. Various solvents including methanol, ethanol and dichloromethane were used with a 
number of bases, such as sodium and potassium acetate. However, the red solid obtained 
revealed mixtures of unreacted ligand 2.1 or 2.4 and dichloro(p-cymene)ruthenium(II) dimer. 
Difficulty in obtaining C,N-cyclometalated ruthenium(II) complexes has been reported.[24-25] 
Complexes 2.7-2.22 are new compounds and were fully characterized with several 
spectroscopic and analytical techniques, including X-ray crystallography. Evidence for 
bidentate coordination occurring via the imine nitrogen and the cyclometalated benzyl carbon 
or the pyridyl nitrogen or the phenolic oxygen to the metal arene were obtained from the NMR 
and FT-IR analyses. 
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The 1H NMR spectra of complexes 2.7-2.22 were recorded in CDCl3, with the exception of the 
N,N-pyridylimine complexes, 2.9-2.11 and 2.17-2.19, which were recorded in deuterated 
acetone, (CD3)2CO, and show relevant peaks for the proposed structures.  
The 1H NMR spectra for the C,N-benzaldiminato complexes 2.7, 2.8, 2.15 and 2.16 all show 
an upfield shift of the imine proton from ca. δ 8.92 ppm to ca. δ 8.16 ppm for the rhodium(III) 
or δ 8.33 ppm for the iridium(III) complexes (Table 2.3). Metal coordination via the imine 
nitrogen leads to less electron density in the hydrogen of the adjacent carbon because of back 
bonding between the empty π* orbital of the imine nitrogen and a full d-orbital of the bonded 
metal. The 13C{1H} NMR spectra of the C,N-benzaldiminato complexes gave the expected 
number of carbon signals for the given structures. An upfield shift was observed for the 
resonance of the imine carbon from ca. δ 160.54 ppm to ca. δ 170.96 ppm.  
 
Table 2.3 Selected spectroscopic and analytical data for C,N-benzaldiminato complexes 2.7, 
2.8, 2.15 and 2.16. 
Compound 
Number 
1H NMR 
(imine) [ppm]a 
13C{1H} NMR 
(imine) [ppm]a 
FT-IR 
Imine (complex, 
ligand) [cm-1]b 
ESI-MS  
[M-nCl]n+ 
[m/z]c 
2.7 8.17 172.29 1588, 1626 448.11d 
2.8 8.30 175.46 1583, 1626 538.17d 
2.15 8.15 173.79 1614, 1628 500.11e 
2.16 8.35 176.07 1613, 1628 590.16e 
aRecorded in CDCl3; bRecorded as KBr pellet; cESI-MS; dn = 1; en = 3. 
 
Further evidence to support coordination of the metal to the imine nitrogen is seen in the 
infrared spectra. A shift in the νC=Nimine absorption band to lower wavenumbers, ca. 1586 cm-1 
for the mononuclear or ca. 1614 cm-1 for the trinuclear complexes, in comparison to the 
uncoordinated ligand, ca. 1627 cm-1, confirms coordination of the metal. These shifts are due 
to the electron withdrawing nature of the coordinated metal which causes a weakening of the 
νC=Nimine bond and results in the shift of the stretching vibration to lower wavenumbers. ESI-MS, 
in the positive mode, was used to assist in characterizing the proposed structures of the 
C,N-cyclometalated complexes. The mononuclear complexes 2.7 and 2.8 exhibited a cationic 
base peak corresponding to the loss of the chloro-ligand of the metal, while the trinuclear 
complexes 2.15 and 2.16 showed triply charged base peaks corresponding to the loss of three 
chloro-ligands. 
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The 1H NMR spectra for the N,N-pyridylimine complexes 2.9-2.11 and 2.17-2.19 all show a 
downfield shift of the imine proton from ca. δ 8.57 ppm to ca. δ 8.95 ppm for the rhodium(III) 
or δ 9.77 ppm for the iridium(III) or δ 8.94 ppm for the ruthenium(II) complexes (Table 2.4). 
The 13C{1H} NMR spectra of the N,N-pyridylimine complexes gave the expected number of 
carbon signals for the proposed structures. A downfield shift was observed for the resonance 
of the imine carbon from ca. δ 160.46 ppm to ca. δ 167.80 ppm. ESI-MS results show 
molecular ion peaks with a loss of the PF6- counter-ion for the N,N-pyridylimine complexes 
2.9-2.11 and 2.17-2.19. 
 
Table 2.4 Selected spectroscopic and analytical data for N,N-pyridylimine complexes 2.9-2.11 
and 2.17-2.19. 
Compound 
Number 
1H NMR 
(imine) [ppm]a 
13C{1H} NMR 
(imine) [ppm]a 
FT-IR 
Imine (complex, 
ligand) [cm-1]b 
ESI-MS  
[M-nPF6]n+ 
[m/z]c 
2.9 8.95 166.62 1598, 1630 485.09d 
2.10 9.35 168.09 1622, 1630 575.14d 
2.11 8.91 167.65 1628, 1630 483.08d 
2.17 8.95 168.49 1617, 1597 537.75e 
2.18 9.42 168.49 1617, 1597 627.14e 
2.19 8.97 167.44 1611, 1597 536.17e 
aRecorded in (CD3)2CO; bRecorded as KBr pellet; cESI-MS; dn = 1; en = 3. 
 
The 1H NMR spectra for the N,O-salicylaldiminato complexes 2.12-2.14 and 2.20-2.22 all 
showed an upfield shift of the imine proton from ca. δ 8.56 ppm to ca. δ 7.93 ppm for the 
rhodium(III), ca. δ 8.00 ppm for the iridium(III) or ca. δ 7.84 ppm for the ruthenium(II) 
complexes (Table 2.5). The 13C{1H} NMR spectra of the N,O-salicylaldiminato complexes gave 
the expected number of carbon signals for the given structures. An upfield shift is observed 
for the resonance of the imine carbon from ca. δ 162.83 ppm to ca. δ 164.46 ppm for the 
rhodium(III) and ruthenium(II) complexes, while a downfield shift to ca. δ 160.96 ppm is 
observed for the iridium(III) complexes. The N,O-salicylaldiminato complexes display a shift 
of the C=Nimine stretching vibration to lower wavenumbers from ca. 1621 cm-1 to ca. 1613 cm-1. 
Similarly to the C,N-cyclometalated complexes, the N,O-salicylaldiminato complexes 
displayed molecular ion base peaks which correspond to the loss of the chloro-ligand. 
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Table 2.5 Selected spectroscopic and analytical data for N,O-salicylaldiminato complexes 
2.12-2.14 and 2.20-2.22. 
Compound 
Number 
1H NMR 
(imine) [ppm]a 
13C{1H} NMR 
(imine) [ppm]a 
FT-IR 
Imine (complex, 
ligand) [cm-1]b 
ESI-MS  
[M-nCl]n+ 
[m/z]c 
2.12 7.90 164.39 1617, 1620 464.11d 
2.13 7.99 160.94 1610, 1620 554.17d 
2.14 7.94 164.40 1612, 1620 462.10d 
2.20 7.96 164.58 1612, 1622 516.10e 
2.21 8.01 161.03 1613, 1622 605.50e 
2.22 7.73 164.46 1614, 1622 514.10e 
aRecorded in CDCl3; bRecorded as KBr pellet; cESI-MS; dn = 1; en = 3. 
 
In the 1H NMR spectra of the pentamethylcyclopentadienyl derivatives the methyl protons of 
the pentamethylcyclopentadienyl ligand are observed at ca. δ 1.31 – 1.60 ppm (Figure 2.7).  
 
 
Figure 2.7 1H NMR spectrum of the trinuclear N,O-salicylaldiminato complex 2.21. 
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The aromatic carbon atoms of the ring are observed in the 13C{1H} NMR spectra at ca. δ 97.61 
– 93.64 ppm for the rhodium(III) and ca. δ 85.75 - 90.35 ppm for the iridium(III) complexes, 
while the carbon resonances for the methyl substituents are observed at ca. δ 7.96 – 8.93 
ppm for the rhodium(III) (Figure 2.8) and ca. δ 7.66 – 8.76 ppm for the iridium(III) complexes. 
 
 
Figure 2.8 13C{1H} NMR spectrum of the mononuclear C,N-benzaldiminato complex 2.7. 
 
In the 1H NMR spectra of the p-cymene derivatives, 2.12-2.14 and 2.20-2.22, the aromatic 
protons of the p-cymene ring display four distinct doublets in the region δ 6.11 – 4.28 ppm 
(Figure 2.9). The splitting of these signals into individual signals is attributed to the formation 
of a chiral center at the metal atom. A multiplet is observed between δ 2.82 – 2.52 ppm is 
assigned to the single proton of the isopropyl group, while the methyl protons on the isopropyl 
group exhibit one doublet per methyl group in the range δ 1.13 – 1.11 ppm. A singlet is 
observed at δ 2.30 – 2.01 ppm and is assigned as the methyl group para to the isopropyl 
moiety on the p-cymene ring.  
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Figure 2.9 1H NMR spectrum of the mononuclear N,N-pyridylimine complex 2.11. 
 
In the 13C{1H} NMR spectra the methyl carbons of the isopropyl moiety are observed as two 
signals at ca. δ 22.32 ppm and ca. δ 21.81 ppm, due to their existence in different 
environments. Similarly, the four aromatic carbons exhibit four separate signals in the range 
ca. δ 87.80 – 78.08 ppm (Figure 2.10). Signals at δ 103.12 ppm and δ 100.00 ppm were 
assigned for the quaternary carbons of the aromatic ring, while a signal at δ 30.98 was 
attributed to the tertiary carbon of the isopropyl group and the most upfield observed signal at 
ca. δ 18.50 ppm was assigned to the methyl carbon para to the isopropyl moiety. 
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Figure 2.10 13C{1H} spectrum of the mononuclear N,N-pyridylimine complex 2.11. 
 
Elemental analysis results for the rhodium(III), iridium(III) and ruthenium(II) complexes are 
consistent with the calculated values for the proposed structures of 2.7-2.22. 
 
2.3. X-ray Crystallography 
The molecular structures of the mononuclear complexes 2.7-2.14 were confirmed by single 
crystal XRD. Crystals of the C,N-benzaldiminato and N,O-salicylaldiminato complexes were 
grown by slow diffusion of hexane into a solution of chloroform, while hexane and acetone 
were used for the N,N-pyridylimine complexes. No suitable crystals were obtained for the 
trinuclear complexes. Tables 1-3 (Chapter 5 - Experimental) summarizes the crystal data and 
refinement parameters for 2.7-2.14. 
The complexes adopt the expected pseudo-tetrahedral or “piano-stool” geometry around the 
metal center. The metal coordinates to the pentamethylcyclopentadienyl or p-cymene ligand, 
one chloride ligand and either the C,N-, N,N- or N,O-ligand in a bidentate-chelating mode 
through its imine nitrogen and its cyclometalated carbon (Figure 2.11), pyridyl nitrogen or 
phenolic oxygen (Figure 2.12), respectively. 
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Complexes 2.7-2.11 all crystallize in the triclinic space group P-1, while 2.12 crystallizes in the 
orthorhombic Pna21 space group, 2.13 crystallizes in the monoclinic P21 and 2.14 crystallizes 
in the monoclinic Cc space group. The M-Nimine bond distance ranges between 2.089 – 2.121 
Å, while the M-Cl bond length is significantly longer and ranges between 2.393 – 2.443 Å.  
A comparison can be drawn from the second non-imine donor bond involved in the bidentate 
chelation of the metal to the ligand. The C,N-benzaldiminato complexes 2.7 and 2.8 exhibit a 
M-C bond distance in the range 2.038 – 2.046 Å, while the N,N-pyridylimine complexes have 
a M-Npyr bond distance of 2.097 – 2.105 Å and the N,O-salicylaldiminato complexes have a 
M-O bond length of 2.073 – 2.080 Å. Thus, for the complexes 2.7-2.14 it can be said that the 
following bond lengths have the following relationship: M-C < M-O < M-Npyr. 
The bond angles formed by the metal center are near orthogonal. However the C-M-Nimine 
bond angles of 2.7 and 2.8 are as small as ca. 78° and the Npyr-M-Nimine bond angles of 2.9-
2.11 are the smallest at ca. 76°. Complexes 2.7-2.14 exhibit similar geometric parameters and 
these are in agreement with other analogous rhodium(III), iridium(III) and ruthenium(II) 
mononuclear complexes reported in literature.[26-34] 
 
 Figure 2.11 Molecular structures of 2.7 (left) and 2.8 (right) with hydrogen atoms omitted for 
clarity. 
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Figure 2.12 Molecular structures of 2.9 (top left), 2.10 (top right), 2.11 (center left), 2.12 
(center right), 2.13 (bottom left) and 2.14 (bottom right) with hydrogen atoms omitted for clarity. 
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2.4. In vitro Biological Activity 
The in vitro antitumor activity of the ligands 2.1-2.6, the mono- 2.7-2.14 and trinuclear 
complexes 2.15-2.22 was established against cisplatin-sensitive A2780 and cisplatin-resistant 
A2780cisR human ovarian cancer cell lines. The toxicity of these compounds was also 
explored by using the normal human fibroblast skin cell line KMST-6 (Table 2.7). Cisplatin was 
tested against all three cell lines as a comparison. 
The ligands 2.1-2.6 (Table 2.7) and mononuclear complexes 2.7-2.14 exhibit poor or no 
activity in either the A2780 or A2780cisR cell lines. It is evident that upon coordination of a 
half-sandwich organometallic moiety to a ligand there is an increase in cytotoxicity (Figure 
2.13).  
 
Table 2.7. IC50 values determined against A2780 and A2780cisR human ovarian cancer cells, 
and KMST-6 normal skin tissue cells for ligands 2.1-2.6. 
Compound 
Number 
Ligand Metal 
IC50 (μM) 
A2780 SIa A2780cisR SIb RIc KMST-6 
2.1 C,N-  >200 - 132.51 ± 5.98 1.35 - 179.33 ± 4.24 
2.2 N,N-  >200 - 156.41 ± 2.37 1.20 - 188.38 ± 6.33 
2.3 N,O-  >200 - >200 - - 157.05 ± 2.82 
2.4 C,N-  42.42 ± 1.71 2.53 172.88 ± 6.23 0.62 4.08 107.48 ± 2.77 
2.5 N,N-  87.63 ± 3.49 1.30 68.25 ± 1.48 1.67 0.78 114.10 ± 3.72 
2.6 N,O-  169.96 ± 3.16 0.75 55.98 ± 3.28 2.27 0.33 127.02 ± 0.65 
aKMST-6/A2780; bKMST-6/A2780cisR; cA2780cisR/A2780. 
 
The trinuclear complexes 2.15-2.22 display the greatest cytotoxicity in the A2780 or 
A2780cisR cell lines. This increase in activity can be attributed to the increased number of 
metal centers present. The relationship between the number of metal atoms coordinated and 
the activity has been established previously for PGM complexes.[3, 32-36] The two most active 
compounds are the cationic N,N-pyridylimine complexes. The trinuclear iridium(III) complex 
2.18 displays the greatest activity in the cisplatin sensitive A2780 cell line with an IC50 value = 
11.58 μM, while the trinuclear rhodium(III) complex 2.17 displays similar activity in the cisplatin 
resistant cell line A2780cisR with an IC50 value = 10.61 μM. The activity of 2.18 is still, however, 
one order of magnitude lower than that of the IC50 value of cisplatin in A2780 cells, while the 
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activity of 2.17 is comparable to that of cisplatin. The increased activity of cationic complexes 
have been previously reported.[32, 34] This might be attributed to the electrostatic interactions 
between the cationic complexes and the anionic sugar-phosphate backbone of DNA.[37] 
 
 
Figure 2.13 Effect of coordination of a metal on the cytotoxicity against A2780 and A2780cisR 
cells, shown for ligands 2.2 and 2.5 and mono- 2.9-2.11, trinuclear complexes 2.17-2.19 and 
cisplatin. 
 
Table 2.8. IC50 values determined against A2780 and A2780cisR human ovarian cancer cells, 
and KMST-6 normal skin tissue cells for CN-complexes 2.7, 2.8, 2.15 and 2.16. 
Complex 
Number 
Ligand Metal 
IC50 (μM) 
A2780 SIa A2780cisR SIb RIc KMST-6 
2.7 
C,N- 
Rh 89.32 ± 2.79 1.00 125.63 ± 2.80 0.71 1.41 89.24 ± 4.24 
2.8 Ir 174.81 ± 7.14 1.07 117.66 ± 3.11 1.61 0.67 189.99 ± 5.87 
2.15 3 Rh 37.71 ± 1.58 0.71 35.78 ± 2.24 0.74 0.95 26.59 ± 5.92 
2.16 3 Ir 19.20 ± 1.91 0.55 20.03 ± 0.73 0.53 1.04 10.56 ± 0.25 
aKMST-6/A2780; bKMST-6/A2780cisR; cA2780cisR/A2780. 
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Table 2.9. IC50 values determined against A2780 and A2780cisR human ovarian cancer cells, 
and KMST-6 normal skin tissue cells for NN-complexes 2.9-2.11 and 2.17-2.19. 
Complex 
Number 
Ligand Metal 
IC50 (μM) 
A2780 SIa A2780cisR SIb RIc KMST-6 
2.9 
N,N- 
Rh 128.64 ± 3.64 0.88 74.71 ± 6.16 1.52 0.58 113.78 ± 2.37 
2.10 Ir 141.88 ± 1.19 0.71 80.20 ± 1.71 1.25 0.57 100.54 ± 5.01 
2.11 Ru 187.08 ± 8.25 0.71 84.72 ± 3.16 1.57 0.45 133.16 ± 3.16 
2.17 3 Rh 34.34 ± 1.94 1.26 10.61 ± 0.40 4.09 0.31 43.39 ± 3.72 
2.18 3 Ir 11.58 ± 4.35 7.29 41.45 ± 3.28 2.04 3.58 84.40 ± 1.16 
2.19 3 Ru 46.29 ± 0.85 1.56 60.50 ± 0.56 1.19 1.31 72.13 ± 1.48 
aKMST-6/A2780; bKMST-6/A2780cisR; cA2780cisR/A2780. 
 
Table 2.10. IC50 values determined against A2780 and A2780cisR human ovarian cancer 
cells, and KMST-6 normal skin tissue cells for NO-complexes 2.12-2.14 and 2.20-2.22. 
Complex 
Number 
Ligand Metal 
IC50 (μM) 
A2780 SIa A2780cisR SIb RIc KMST-6 
2.12 
N,O- 
Rh 63.08 ± 5.32 1.77 133.64 ± 3.56 0.84 2.12 111.84 ± 3.67 
2.13 Ir 107.00 ± 3.95 1.09 109.91 ± 5.92 1.06 1.03 116.20 ± 4.35 
2.14 Ru 69.86 ± 6.99 1.54 100.22 ± 3.95 1.07 1.43 107.48 ± 1.19 
2.20 3 Rh 30.47 ± 1.12 2.63 36.93 ± 0.65 1.91 1.21 80.20 ± 1.96 
2.21 3 Ir 30.79 ± 1.16 2.76 50.49 ± 3.08 1.66 1.64 85.04 ± 3.64 
2.22 3 Ru 33.38 ± 2.44 2.94 36.93 ± 1.12 2.66 1.11 98.28 ± 3.11 
Cisplatin  Pt 1.97 ± 3.41 22.36 18.90 ± 0.81 2.33 9.59 44.04 ± 1.97 
aKMST-6/A2780; bKMST-6/A2780cisR; cA2780cisR/A2780. 
 
The establishment of the selectivity of antitumor agents for cancerous cells over non-
tumorigenic cells is important. The in vitro activity of 2.1-2.22 was investigated against normal 
KMST-6 cells. To measure the potency of the tested compounds towards only tumorigenic 
cells, the selectivity index (SI) was calculated as the ratio of the IC50 of KMST-6 to the IC50 of 
A2780 or A2780cisR cells.[38] Optimal SI values are in excess of SI > 1. The trinuclear N,N-
pyridylimine and N,O-salicylaldiminato complexes 2.17-2.22 show moderate selectivity 
towards the tumorigenic ovarian cells (Figure 2.14). The SI ranges from as low as 1.19 for 
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2.19 in A2780cisR up to 7.29 for 2.18 in A2780. The trinuclear C,N-benzaldiminato complexes 
2.15 and 2.16 display poor selectivity and general toxicity against the cells tested, as the 
calculated SI values were < 1. 
 
 
 
Figure 2.14 Cytotoxicity of trinuclear complexes 2.17-2.19 and cisplatin against A2780, 
A2780cisR and non-tumorigenic KMST-6 cells for selectivity comparison. 
 
The resistance index (RI) can be calculated as a ratio of the IC50 of A2780cisR to the IC50 of 
A2780 cells.[39] This index determines the resistance of the complexes in the A2780 cisplatin-
sensitive cell line as opposed to the A2780cisR cisplatin-resistant cell line, this comparison 
between activities in the two cell lines allows for inferences to be made into if mechanisms of 
action are similar to that of cisplatin. All the mononuclear N,N-pyridylimine complexes 2.9-2.11 
display RI values lower than 1, as they are more active in the A2780cisR cisplatin-resistance 
cells, with no cross-resistance observed (Figure 2.15). Most of the trinuclear complexes 
display similar activity in both the A2780 and A2780cisR cell lines, and thus the RI values are 
approximately ≈ 1, and display no cross-resistance to cisplatin. Exceptions are the trinuclear 
rhodium(III) N,N-pyridylimine complex 2.17 and the trinuclear iridium(III) N,N-pyridylimine 
complex 2.18, which display RI values of 0.31 and 3.58 due to their high activities in the 
A2780cisR and A2780 cell lines, respectively (Figure 2.16). Cisplatin shows a significant 
decrease in activity from the A2780 to the A2780cisR cell lines with a RI ≈ 10.  
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Overall, all the complexes show no cross resistance to cisplatin as the RI values ≈ 1 and in 
most cases the cytotoxicities are roughly comparable in both tumorigenic cell lines tested. This 
suggests a different mode of action to that of cisplatin. 
 
 
Figure 2.15 Effect of varying the bidentate donor atoms and the metal arene on the cytotoxicity 
against A2780 and A2780cisR, plotted as the resistance index (RI), where RI = IC50 of 
A2780cisR / IC50 of A2780. 
 
It is important to note that all these bidentate complexes evaluated in this study against the 
A2780 and A2780cisR cell lines displayed increased cytotoxicity in comparison to the 
monodentate metal complexes previously reported.[21] This displays the greater activity of the 
chelate effect, which has been exhibited by other bidentate[35, 40] complexes. 
 
2.5. Stability in Aqueous Media and DMSO 
Prior to further testing, the stability of drugs in solution needs to be established. It has been 
reported that mononuclear metal complexes that contain a chloride ligand after uptake into 
the cell are activated by substitution of the labile M-Cl bond to an intermediate M-aqua species. 
The formation of this activated aqua species can be observed by NMR spectroscopy.[41-42] 
Therefore, to further understand the cytotoxicity of the complexes, a stability investigation was 
performed on selected complexes. The stability of the complexes in a 50:50 mixture of 
deuterated-dimethylsulfoxide, (CD3)2SO, and water was studied. This solution was chosen as 
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it represents the method in which the stock solutions are prepared for cytotoxic studies. The 
stability was monitored using 1H NMR spectroscopy over time at the physiological temperature 
of 37 oC. 
The trinuclear N,N-pyridylimine complexes 2.17-2.19 display the greatest activities; thus the 
trinuclear iridium(III) complex 2.18, which displays the greatest activity, and its mononuclear 
analogue 2.10 were chosen, for testing, along with 2.13, the mononuclear N,O-
salicylaldiminato iridium(III) equivalent. The trinuclear iridium(III) complex 2.18 and the two 
mononuclear complexes 2.10 and 2.13 all show stability in a mixture of (CD3)2SO and water, 
as monitored by 1H NMR spectroscopy. After 24 hours in solution none of the aforementioned 
complexes showed signs of degradation, as the spectra remained unchanged over the tested 
time (Figure 2.16). 
 
Figure 2.16 1H NMR spectra of mononuclear 2.10 (top two spectra) and trinuclear complex 
2.18 in (CD3)2SO and H2O (50:50) as recorded over 24 hours. 
 
The stability towards aqueous media of these complexes might be a possible cause of the low 
cytotoxicity of this series of complexes as the active aqua species is not observed to form. 
This might suggests that these complexes operate via some other mode of action to those 
which undergo hydrolysis and form the aqua species. 
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2.6. Interactions with Model DNA 5'-GMP  
Administered drugs encounter many important biological molecules and often interact with 
these, which affects the activity of the compounds. Ruthenium-arene complexes have a strong 
affinity towards DNA[43-44] and mechanistic studies report that these complexes bind selectively 
to the nucleotide base-pair guanine.[45-46] Thus, interactions between the mononuclear N,N-
pyridylimine 2.10 or N,O-salicylaldiminato 2.13 iridium(III) complexes and the nucleotide 5'-
GMP in (CD3)2SO and water 50:50 at 37 oC was monitored by 1H NMR spectroscopy for 24 
hours.  
The cationic N,N-pyridylimine complex 2.10 showed no signs of interactions with 5'-GMP and 
the nucleotide was unable to displace the chloride ligand (Figure 2.17c). However, the neutral 
N,O-salicylaldiminato complex 2.13 did interact with the nucleotide and shifts in the 
resonances of the signals in the 1H NMR spectrum were observed after 24 hours (Figure 
2.17e).  
 
 
Figure 2.17 1H NMR spectra of (a) 5′-GMP, (b) 2.10, (c) reaction mixture of 2.10 with 5′-GMP, 
(d) 2.13, (e) reaction mixture of 2.13 with 5′-GMP. 
 
The signal for the proton at C8 on 5'-GMP was observed to shift downfield from δ 8.04 ppm to 
δ 8.88 ppm. Similar shifts in signals in the 1H NMR spectra of ruthenium(II) complexes have 
been reported.[45] This suggests that 2.13 interacts with 5'-GMP by coordination to N7 by 
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displacing the chloride ligand and resulting in a cationic species stabilized by the chloride ion 
(Figure 2.18). This evidence supports the suggestion that the neutral complexes target DNA, 
while the cationic complexes have other important targets, possibly proteins, or have a 
different mode of action.  
 
Figure 2.18 Proposed structure of the product of the reaction between 2.13 with 5′-GMP. 
 
2.7. Calculated Lipophilicity Determination: log P 
In addition to the size and multinuclearity of the trinuclear complexes, this series of compounds 
contains ester functionalities. Log P is a quantification of a compounds hydrophilicity and is 
used in determining if a compound can diffuse into cells. The lipophilicity of the monomeric 
ligands 2.1-2.3 and the trimeric ester containing ligands 2.4-2.6 was calculated using 
MarvinSketch[47] (Table 2.11). It is evident that upon formation of the ester moiety in 2.4-2.6 
the ligands become more lipophilic, as shown by the calculated log P values (Table 2.11). 
 
Table 2.11. The log P Values determined by Marvin Sketch of monomeric and trimeric ligands 
2.1-2.6 and cytotoxicities in A2780, A2780cisR and KMST-6. 
Compound Number log Pa A2780 A2780cisR KMST-6 
2.1 3.08 >200 132.51 ± 5.98 179.33 ± 4.24 
2.2 2.54 >200 156.41 ± 2.37 188.38 ± 6.33 
2.3 2.78 >200 >200 157.05 ± 2.82 
2.4 12.78 42.42 ± 1.71 172.88 ± 6.23 107.48 ± 2.77 
2.5 11.15 87.63 ± 3.49 68.25 ± 1.48 114.10 ± 3.72 
2.6 11.87 169.96 ± 3.16 55.98 ± 3.28 127.02 ± 0.65 
aLog P values calculated using MarvinSketch V. #5.9.4 
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A correlation is seen between the log P and the cytotoxicity. The increased activity of the ester 
containing trimeric ligands 2.4-2.6 as compared to that of the monomeric ligands 2.1-2.3 might 
be the result of increased cellular uptake, as the more lipophilic ligands are able to cross 
cellular membranes. 
Calculated electrostatic potential surfaces[47] of the trimeric C,N-benzaldimine ligand 2.4 are 
shown (Figure 2.19) on a space filling model of the ligand, at different orientations. Red 
indicates an area of electron-deficiency, which is localized around the core due to the three 
ester functionalities, while blue is representative of electron-rich areas, which coincide with 
the aromatic rings. 
 
 
Figure 2.19 Calculated electrostatic potential maps[47] depicting the difference in polarity of 
the trimeric C,N-benzaldiminato ligand 2.4 at different orientations. 
 
2.8. Overall Summary 
A series of new mononuclear 2.7-2.14 and trinuclear 2.15-2.22 rhodium(III), iridium(III) and 
ruthenium(II) complexes based on C,N-benzaldimine, N,N-pyridylimine, N,O-salicylaldimine 
ligands were synthesized. The compounds were all characterized by various spectroscopic 
and analytical techniques, namely 1H, 13C{1H} NMR and infrared spectroscopy, mass 
spectrometry and elemental analysis. Single crystal XRD was utilized to obtain the molecular 
structures of the mononuclear complexes 2.15-2.22 and confirm the proposed structures. 
Coordination of the metal occurs in a bidentate fashion through the imine nitrogen and the 
benzyl-carbon, pyridyl-nitrogen or phenolic-oxygen atoms. 
The in vitro antitumor activity of all the compounds was evaluated against the A2780 and 
A2780cisR ovarian cancer cell lines. It should be noted that bidentate chelation results in 
improved activity. The trinuclear complexes 2.15-2.22 exhibit the highest activity and display 
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no cross-resistance to cisplatin. In particular the trinuclear N,N-pyridylimine complexes 2.17 
and 2.18 are the most active and the C,N-benzaldiminato complexes display poor selectivity 
towards normal KMST-6 cells. The N,O-salicylaldiminato complexes display evidence of 
interactions with 5'-GMP via the N7 atom, yet the cationic N,N-pyridylimine complexes do not. 
This suggests that DNA may be a possible target for the neutral complexes, while other targets 
may be important for the cationic complexes. 
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Chapter 3: Synthesis, Characterization 
and Antitumor Activity of New Trinuclear 
Alkylated PTA containing Rh(III), Ir(III) 
and Ru(II) complexes 
3. Introduction 
Due to its’ water solubility, PTA has been used to assist in solubilizing some organometallic 
complexes.[1-2] RAPTA complexes have shown to exhibit selective and potent antitumor 
activity[3-4] particularly in vivo against metastatic[5] and primary tumors.[6] PTA-derived 
compounds seem to impart a pH-dependent activity which provides an opportunity to be 
biologically active. 
PTA and its derivatives easily undergo alkylation at one of the equivalent nitrogen atoms 
introducing a positive charge. It was established soon after the first preparation of PTA that it 
can be methylated at an N-atom by methyl iodide.[7-8] Alkylation has shown to increase 
hydrophilicity of the PTA moiety to afford water-soluble complexes.[9-13]  
Alkylated RAPTA analogues have been found to interact with model DNA bases, which is a 
commonly acknowledged mechanism of action, for this class of compounds, explaining their 
antitumor activity.[13] Alkylated Rh- and Ir-PTA half-sandwich analogues have not been 
explored extensively, although displaying promising antitumor activity.[14] 
Kathó and co-workers prepared a water-soluble monodentate dinuclear Ru(II) complex 
[Ru2(η6-p-cymene)2Cl2{(PTA)CH2C6H4CH2(PTA)}][Cl]2 (Figure 3.1) but no biological 
application of this compound was studied.[15] 
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Figure 3.1 Dinuclear [Ru2(η6-p-cymene)2Cl2{(PTA)CH2C6H4CH2(PTA)}][Cl]2. 
 
In this chapter, the preparation and characterization of a new trimeric tricationic alkylated PTA-
based ligand is described. This trimeric ligand was used to prepare trinuclear rhodium-Cp*, 
iridium-Cp* and ruthenium-arene complexes. Mononuclear analogues were also prepared for 
comparison. The proposed structures were confirmed using spectroscopic and analytical 
techniques. The discussion of the biological activity of these complexes is included. 
 
3.1. Synthesis and Characterization of Cationic Alkylated Ligands 
The monomeric cationic alkylated PTA ligand 3.1[12] was synthesized using known methods. 
The bromide analogue was used to prepare 1,3,5-tris(chloromethyl)benzene by simple 
halogen metathesis[16] and was reacted with PTA to afford 3.2.  
The reactants were refluxed in acetone to afford the cationic alkylated PTA salt 3.2, which was 
filtered on a Hirsch funnel and washed with tetrahydrofuran and copious amounts of 
dichloromethane. 3.2 was isolated as a hygroscopic beige salt with a near stoichiometric yield 
of 97% and is soluble in water, dimethylsulfoxide and methanol yet insoluble in 
dichloromethane, tetrahydrofuran and diethylether. Spectroscopic (1H NMR, 13C{1H} 31P{1H} 
NMR and FT-IR spectroscopy) and analytical data (elemental analysis and mass 
spectrometry) confirmed the proposed structure of the trimeric ligand 3.2. 
The 1H, 13C{1H} and 31P{1H} NMR spectra of 3.2 were recorded in deuterium oxide (D2O) and 
were comparable with the monomeric analogue.[12] A single nitrogen of the PTA moiety was 
alkylated once and only mono-alkylation was observed. Evidence for this is shown in the 1H 
and 13C{1H} NMR spectra. 
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Scheme 3.1 Synthesis of cationic alkylated PTA ligands 3.1 and 3.2. 
 
In the 1H NMR spectrum of 3.2, the proton resonance of the benzyl core is observed as a 
sharp singlet at δ 7.95 ppm. Evidence for alkylation of the PTA is observed in the splitting 
pattern of the –CH2 protons of the PTA. Upon quaternization of the nitrogen atom the protons 
exist in an AB spin system and are assigned as either axial or equatorial. Other alkylated PTA 
compounds with –CHAxHEq protons have been reported previously.[10, 17-19] 
Upon alkylation of the PTA cage the six sets of –CH2 protons exist in four environments (Figure 
3.2). As a result of alkylation three quartets and one doublet are observed in the 1H NMR 
spectrum. In the case of 3.2, the most downfield quartet for the four protons of N-CH2-N+ 
(Figure 3.2 at blue position 1) is observed at δ 5.14 ppm (JH-H = 12 Hz), a less intense quartet 
for two protons is observed at δ 4.63 ppm (JH-H = 9 Hz) of N-CH2-N (Figure 3.2 at orange 
position 2) and the third quartet for four protons of P-CH2-N (Figure 3.2 at green position 3) 
appears upfield at δ 4.02 ppm (JH-H = 9 Hz). A doublet at δ 4.47 ppm (JH-H = 6 Hz) was assigned 
as the two protons of P-CH2-N+. 
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Figure 3.2 A representative example of a 1H NMR spectrum displaying the four different alkyl 
environments of an alkylated PTA ligand. 
 
Signals in the 13C{1H} NMR spectrum at δ 139.38 ppm and δ 127.67 ppm were assigned as 
the secondary and tertiary carbons of the aromatic benzyl core, respectively. The –CH2 
carbons between the aromatic core and the PTA cages exhibited signals at δ 65.23 ppm.  
Heteronuclear Spin-Quantum Coupling Spectroscopy (HSQC) allows identification of which 
protons are coupling with other nuclei, such as 13C, and allow for the correlation of which 
protons are situated on their respective carbons. Use of  [1H-13C] HSQC NMR spectroscopy 
aided with the assignment of the signals for the –CH2 carbons of the PTA moiety (Figure 3.3).  
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Figure 3.3 [1H- 13C] HSQC NMR spectrum of trimeric alkylated PTA ligand 3.2 in D2O. 
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The alkylation of the PTA moiety was further confirmed by the presence of four signals in the 
13C{1H} NMR spectrum. The signals at δ 79.18 ppm and δ 69.46 ppm were assigned as N-
CH2-N+ and N-CH2-N, respectively. Two doublets, due to the carbons coupling with the NMR 
spin-active phosphorous, at δ 52.93 ppm (JP-C = 24 Hz,) and δ 45.61 ppm (JP-C = 14 Hz) were 
assigned as P-CH2-N+ and P-CH2-N, respectively.  
The presence of a singlet in the 31P{1H} NMR spectrum at δ -81.95 ppm (Table 3.1) attested 
to the presence of only one phosphorous species and the purity of 3.2. Furthermore, high 
resolution electrospray ionization mass spectrometry (HR-ESI-MS) which shows m/z = 
196.0998 for the trimeric ligand, after the loss of the three stabilizing chloride anions, as [M-
3Cl]3+-. This mass spectrometry data confirms the triple charge of the ligand. These spectral 
data assignments are comparable with the alkylated PTA dimer ligand prepared by Kathó and 
co-workers.[20] 
 
Table 3.1 31P{1H} NMR resonance signals and mass spectral data for compounds 3.1 and 3.2. 
Compound 31P{1H} NMR  
[ppm]a 
HR-ESI-MS  
[M-nCl]n+ [m/z] 
3.1 -82.61 248.1307b 
3.2 -81.95 196.0998c 
aRecorded in D2O; bn = 1; cn = 3. 
 
The tricationic salt 3.2 displayed elemental analysis percentages outside of acceptable limits, 
despite extensive drying, and these were due to the hygroscopic nature of the ligand. 
Recalculation of the percentages with the inclusion of water gave percentages within 
acceptable limits. In the 1H NMR spectrum a peak assigned as water was observed, which 
supports the inclusion of water in the sample. 
 
3.2. Synthesis and Characterization of Trinuclear Rhodium(III), Iridium(III) and 
Ruthenium(II) PGM Complexes 
Reaction of the alkylated PTA ligands 3.1 or 3.2 with the precursors 
dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer, dichloro(pentamethylcyclo-
pentadienyl)iridium(III) dimer or dichloro(p-cymene)ruthenium(II) dimer yielded the 
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mononuclear complexes 3.3-3.5 (Scheme 3.2) or the trinuclear complexes 3.6-3.8 (Scheme 
3.3).  
 
 
Scheme 3.2 Synthesis of mononuclear cationic alkylated PTA complexes 3.3-3.5. 
 
The complexes 3.3-3.5 were prepared by stirring the appropriate ligand and dimer together as 
a solution at room temperature. For the preparation of the trinuclear complexes, the reactants 
were stirred in a mixture of methanol and dichloromethane, while ethanol was used in 
preparing the mononuclear complexes. The resulting complexes 3.3-3.8 were precipitated 
from the reaction using diethyl ether as red, orange or yellow hygroscopic solids in moderate 
yields. The complexes are water-soluble and are soluble in most organic solvents. The 
mononuclear complexes 3.3-3.5 exhibited greater water solubility, in the range 14-21 mg/ml, 
than the trinuclear complexes 3.6-3.8 which displayed aqueous solubility in the range 3-12 
mg/ml. 
Complexes 3.3-3.8 are new and characterization with analytical and spectroscopic techniques 
was performed. Confirmation of the monodentate coordination occurring through the PTA 
phosphorous was obtained from the NMR analyses. The NMR spectra of 3.3-3.8 were 
recorded in deuterium oxide, D2O, and show relevant peaks which confirm the proposed 
structures. 
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Scheme 3.3 Synthesis of trinuclear cationic alkylated PTA complexes 3.6-3.8. 
 
In both the 1H and 13C{1H} NMR spectra the signals for the protons and carbons of the aromatic 
core and the -CH2 bridge linking the core to the PTA remained largely unchanged.  
For the mononuclear complexes 3.3-3.5 a multiplet is observed in the 1H NMR spectra for the 
four aromatic benzyl protons at ca. δ 7.57 ppm and a sharp singlet is observed at ca. δ 4.36 
ppm for the –CH2 protons linking the benzyl ring to the PTA. For the trinuclear complexes 3.6-
3.8, a singlet is observed for the benzyl core at ca. δ 7.86 ppm and another singlet at ca. δ 
4.37 ppm for the -CH2 protons. 
In the 13C{1H} NMR spectra of the mononuclear complexes 3.3-3.5 four signals are observed 
in the range δ 124.20 – 134.21 ppm for the benzyl carbons. Two signals, which are assigned 
to the aromatic core, are observed for the trinuclear complexes 3.6-3.8 at ca. δ 126.91 ppm 
and ca. δ 142.42 ppm. The upfield signal at δ 126.91 ppm was assigned as the tertiary carbon 
of the aromatic core and the downfield signal at δ 142.42 ppm was assigned as the secondary 
carbon, due to 1H, 13C HSQC coupling. 
The most significant shifts in the 1H and 13C{1H} NMR spectra were for the signals assigned 
to that of the PTA cage. These shifts are attributed due to coordination of the metal-arene to 
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the phosphorous of the PTA. The resonances assigned to the PTA cage for the complexes 
3.3-3.8 are recorded in Table 3.2, and ligands 3.1 and 3.2 have been included for comparison.  
The largest shifts in the 1H NMR spectra upon coordination were observed in the signals 
assigned to as P-CH2-N+ and P-CH2-N (Table 3.2). The signals assigned to the protons of P-
CH2-N+ shifted downfield upon coordination of the metal-arene from δ 4.29 ppm to ca. δ 4.46 
ppm for the mononuclear complexes 3.3-3.5 and from δ 4.47 ppm to ca. δ 4.56 ppm in the 
trinuclear complexes 3.6-3.8. Similarly, the signals assigned to the protons of P-CH2-N 
displayed a larger downfield shift from δ 3.94 ppm to ca. δ 4.30 ppm for the mononuclear 
complexes 3.3-3.5 and from δ 4.00 ppm to ca. δ 4.28 ppm in the trinuclear complexes 3.6-3.8. 
 
Table 3.2 1H and 13C{1H} NMR resonance signals for the PTA cages of compounds 3.1-3.8. 
Compound 1H NMR [ppm] 13C{1H} NMR [ppm] 
N-CH2-N+ N-CH2-N P-CH2-N+ P-CH2-N N-CH2-N+ N-CH2-N P-CH2-N+ P-CH2-N 
3.1a 5.03 4.57 4.29 3.94 79.61 69.97 52.74 46.10 
3.2b 5.12 4.78 4.47 4.00 79.18 69.46 52.93 45.61 
3.3a 5.08 4.70 4.47 4.38 79.28 69.38 51.48 46.08 
3.4a 5.10 4.60 4.48 4.24 81.19 71.06 51.85 46.82 
3.5a 5.09 4.69 4.43 4.27 79.28 69.33 52.23 48.17 
3.6b 5.16 4.96 4.53 4.27 80.62 69.27 49.45 45.82 
3.7b 5.18 4.64 4.52 4.24 80.70 69.48 49.31 45.12 
3.8b 5.89 5.13 4.63 4.34 80.57 69.11 55.64 48.01 
aRecorded in CD3OD; bRecorded in D2O. 
 
In the 1H NMR spectra of the rhodium pentamethylcyclopentadienyl derivatives, 3.3 and 3.6, 
the methyl protons of the pentamethylcyclopentadienyl ligand exhibit a doublet at ca. δ 1.71 
ppm (JH-P = 4 Hz). Sharp and co-workers previously reported a Rh(II)-Cp* complex which 
exhibited a similar proton-phosphorous coupling, which resulted in the signals for the protons 
of the pentamethylcyclopentadienyl ring in the 1H NMR spectrum appearing as a doublet which 
integrates for 15 protons.[21] In the iridium(III) pentamethylcyclopentadienyl derivatives, 3.4 
and 3.7, a doublet is observed upfield at ca. δ 1.76 ppm (JH-P = 4 Hz) and this is assigned to 
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the methyl protons. In the 13C{1H} NMR spectra the aromatic carbons of the 
pentamethylcyclopentadienyl ring are observed at ca. δ 101.99 ppm for the rhodium(III) and 
at ca. δ 95.49 ppm for the iridium(III) complexes. The methyl substituents on the 
pentamethylcyclopentadienyl ring display signals further upfield at ca. δ 9.03 ppm for the 
rhodium(III) (Figure 3.4) and at ca. δ 9.12 ppm for the iridium(III) complexes. 
 
 
Figure 3.4 13C{1H} NMR spectrum of complex 3.3. 
 
The signals for the aromatic protons of the p-cymene ring in the 1H NMR spectrum of the 
trinuclear ruthenium(II) complex 3.8 are observed as a multiplet in the range δ 5.86 – 5.92 
ppm. The methyl protons of the p-cymene moiety appear as a singlet at δ 2.04 ppm and as a 
doublet upfield at δ 1.20 ppm (J = 7 Hz). In the 13C{1H} NMR spectrum of 3.8 the signals at δ 
108.32 ppm, δ 99.23 ppm, δ 89.04 ppm, δ 86.57 ppm provide confirmation of the aromatic 
carbons of the p-cymene ring. Further upfield, resonances at δ 21.33 ppm and δ 30.78 ppm 
were assigned to the isopropyl moiety and the methyl carbon of the p-cymene ring exhibited 
a signal at δ 17.93 ppm. 
The downfield shift in the singlet, for the iridium(III) or ruthenium(II) complexes, or doublet, for 
the rhodium(III) complexes, observed in the 31P{1H} NMR spectra of complexes 3.3-3.8 provide 
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evidence that coordination to the metal arene occurs via the phosphorous in the PTA cage 
(Figure 3.5).  
 
 
Figure 3.5 31P{1H} NMR spectra of 3.1-3.8 displaying the downfield shift of the free ligands 
(black), iridium(III) (teal), rhodium(III) (gold) and ruthenium(II) (purple) complexes with mono- 
(above) and trinuclear (below). 
 
For the rhodium(III) complexes a doublet was observed in the 31P{1H} NMR spectra at δ -24.63 
ppm (1JRh-P = 150 Hz) for 3.3 and at δ -22.89 ppm (1JRh-P = 151 Hz) for 3.6 (Table 3.3). The 
doublet is attributed to the phosphorous-rhodium coupling and further corroborates the 
rhodium coordination to the phosphorous. The 1J coupling constants are consistent with 
similar rhodium(III)-phosphanes reported.[13, 22-24] The iridium(III) complexes 3.4 and 3.7 
display the most upfield singlets in the 31P{1H} NMR spectra of the alkylated PTA complexes 
at δ -48.77 ppm and at δ -46.52 ppm, respectively. Far upfield chemical shifts are common for 
iridium(III)-phosphanes.[25] This shielding effect is due to the significantly larger shielding 
constant of iridium(III) in comparison to that of rhodium(III) and ruthenium(II), which are 
comparable.[26] This explains why the resonances in the 31P{1H} NMR spectra for the 
rhodium(III) and ruthenium(II) complexes are clustered together in the narrow range δ -24.63 
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to -20.23 ppm. The ruthenium(II) complex 3.8 exhibits a signal at -23.03 ppm and this is 
consistent with the observed resonances for the known mono-[27] and binuclear[15] analogues. 
 
Table 3.3 31P{1H} NMR resonance signals and HR-ESI-MS data for the complexes 3.3-3.8. 
Compound Number 31P{1H} NMR [ppm] HR-ESI-MS [m/z] 
3.3a -24.63 (d, 1JRh-P = 150 Hz)c 558.0898 [M-Cl]+ 
3.4a -48.77 (s) 646.1473 [M-Cl]+ 
3.5a -20.23 (s) 554.0833 [M-Cl]+ 
3.6b -22.89 (d, 1JRh-P = 151 Hz)d 478.0514 [M-5Cl+2H]3+ 
3.7b -46.52 (s) 570.1178 [M-5Cl+2H]3+ 
3.8b -23.03 (s) 480.0599 [M-5Cl+2H]3+ 
aRecorded in CD3OD; bRecorded in D2O. 
HR-ESI-Mass spectral analysis of complexes 3.3-3.8, display base peaks which were 
assigned as fragments of the molecular ion which correspond to the formula weight of the 
proposed structures (Table 3.3). The mononuclear alkylated PTA complexes 3.3-3.5 exhibit 
m/z peaks which were assigned to the ion with the loss of the stabilizing chloride counter-ion 
[M-Cl]+ and were consistent with the expected isotopic mass distribution pattern of the 
respective metal. The trinuclear complexes 3.6-3.8 show a m/z base peak which corresponds 
to the triple charged adduct [M-5Cl+2H]3+. 
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Figure 3.6 Calculated (top) and experimental (bottom) expanded HR-ESI-MS traces for 
mononuclear alkylated PTA complexes 3.3 (left), 3.4 (center) and 3.5 (right). 
 
The alkylated PTA complexes 3.3-3.8 displayed elemental analysis percentages outside of 
acceptable limits, despite extensive drying, and similarly upon recalculation of the percentages 
with the inclusion of water gave percentages within acceptable limits. In the 1H NMR spectrum 
a peak assigned as water was observed, which supports the inclusion of water in the sample. 
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3.3. In vitro Biological Activity 
The in vitro cytotoxicity of the mono- and trinuclear alkylated PTA compounds 3.1-3.8 was 
established against WHCO1 human esophageal cancer cells. This squamous cell carcinoma 
of the esophagus was selected due to the significant prevalence of this form of cancer in 
African countries.[28] 
 
Table 3.4 IC50 values determined against WHCO1 human esophageal cancer cells for 
compounds 3.1-3.8. 
Compound 
Number 
Metal 
IC50 (μM) 
WHCO1 
3.1 - >250 
3.2 - >250 
3.3 Rh 94.1 ± 8.2 
3.4 Ir 48.3 ± 8.8 
3.5 Ru 105.3 ± 6.4 
3.6 3 Rh 61.2 ± 10.0 
3.7 3 Ir 111.5 ± 4.2 
3.8 3 Ru 66.0 ± 9.6 
Cisplatin Pt 9.2 ± 0.1[29] 
 
Ligands 3.1-3.2 were inactive against the WHCO1 cells. The dependence of the presence of 
a coordinated metal is seen in the increase in activity for complexes 3.3-3.8 from the ligands 
3.1-3.2. The rhodium(III) and ruthenium(II) complexes displayed a size dependent activity 
relationship (Figure 3.7). The trinuclear alkylated PTA complexes 3.6 and 3.8 exhibited IC50 
values of 61.2 μM and 66.0 μM, respectively displaying enhanced activity over the 
mononuclear analogues 3.3 and 3.5. This increase in cytotoxicity can be attributed to the 
increase in the number of metal centers.[30-32] It should be noted that the mononuclear alkylated 
PTA iridium(III) complex 3.4 displayed the greatest activity in the WHCO1 cell line, with an 
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IC50 value of 48.3 μM (Table 3.4) and shows greater than a two fold increase in cytotoxicity 
compared to its corresponding trinuclear iridium(III) analogue 3.7 (Figure 3.7).  
 
Figure 3.7 Cytotoxicity of alkylated PTA compounds 3.1-3.8 and cisplatin against WHCO1. 
 
Since the cytotoxicity of 3.4 in WHCO1 superseded that of the entire series, the aqueous 
stability and ability of 3.4 to interact with small molecules of biological importance, was 
investigated and monitored by NMR spectroscopy. The aim of these studies is to provide 
mechanistic insight to rationalize the observed biological activities of these complexes. 
 
3.4. Aqueous Stability 
Metal complexes appear to undergo a number of different processes in vivo, including ligand 
substitution to form aqua species.[33] Aqueous stability investigation is an important part of 
preclinical testing of potential drug candidates. These hydrolysis studies clarify the stability of 
complexes in solution.  
The aqueous stability of 3.4 in D2O was investigated to assess the ability of this complex to 
form the activated aqua species. D2O was chosen as a media as it represents the solvent with 
which this series of complexes are dissolved in to prepare the stock solutions for in vitro 
cytotoxicity studies. Using 1H and 31P{1H} NMR spectroscopy the stability was monitored over 
48 hours at the physiological temperature of 37 oC. 
After 48 hours in solution the mononuclear alkylated PTA iridium(III) complex 3.4 showed no 
sign of aqueous instability. Both the 1H and 31P{1H} NMR spectra remained constant over the 
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tested time. The lack of the appearance of any other signals, such as degradation species, in 
the 31P{1H} NMR spectra confirm the aqueous stability of 3.4 (Figure 3.8). 
 
 
Figure 3.8 31P{1H} NMR spectra showing the aqueous stability of mononuclear 3.4 in D2O 
over 48 hours. 
 
The stability of 3.4 in aqueous media suggests that the active aqua species is unable to form, 
in this iridium(III) complex. This could explain the relatively low cytotoxicity of this alkylated 
PTA complex, being the most active against WHCO1 cells. Thus, the cytotoxicity of these 
complexes is due to some other mode of action and is not because of aquation to form the 
active aqua species. Though 3.4 is inert in water, it has been reported that in the presence of 
other ligands (such as in biological media), complexes do in fact coordinate to molecules of 
biological importance.[34] 
 
3.5. Interactions with Model DNA 5'-GMP 
One of the most important targets for PGM anticancer complexes is regarded to be DNA. PGM 
complexes initially bind to the negatively charged phosphate backbone of DNA yet guanine 
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residues are considered to be the preferred binding target due to the softer nucleobase donor 
atoms.[35] Changes to the secondary structure of DNA as a result of coordination prevent 
further replication or transcription. However this should not be mistaken for the potential sole 
mode of action. 
The ability of the mononuclear alkylated PTA complex 3.4 to interact with the DNA model 
nucleotide 5'-GMP in D2O at 37 oC was monitored by 1H and 31P{1H} NMR spectroscopy for 
48 hours. 
 
 
Figure 3.9 1H NMR spectra in D2O of (a) 3.4 (black), (b) 5′-GMP (red) and (c) reaction mixture 
of 3.4 with 5′-GMP (blue). 
 
Equimolar amounts of 5'-GMP and 3.4 were reacted together and the DNA model, 5'-GMP, 
was observed to coordinate to the metal via the N7 atom complex. A downfield shift is observed 
in the 1H NMR spectrum of the reaction of the signal for the proton, H8, adjacent to N7 from δ 
8.22 ppm (Figure 3.9b) to δ 8.40 ppm (Figure 3.9c). The equivalence of the integration of this 
signal to the doublet upfield at δ 6.02 ppm (3J = 7 Hz), assigned as the proton on the carbon 
bonded to the guanosine base pair, confirms its identity as H8. The split nature of this signal 
could be attributed to coupling with the NMR spin-active phosphorous of the PTA moiety or 
potentially the formation of diastereoisomers. Similar shifts for iridium(III) complexes have 
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been observed (See Chapter 2). The multiplet observed at (Figure 3.9a) δ 7.57 ppm assigned 
to the H1-H3 of the phenyl ring split into the three signals at (Figure 3.9c) δ 7.25 ppm (d, 3J = 
8 Hz, 2H, H3), δ 7.45 ppm (t, 3J = 8 Hz, 2H, H2) and δ 7.66 ppm (d, 3J = 6 Hz, 1H, H1). This 
was confirmed by two-dimensional (2D) 1H-1H correlation (COSY) NMR spectroscopy as the 
signals at δ 7.66 ppm (H1) and δ 7.25 ppm (H3) both exhibited coupling with δ 7.45 ppm (H2). 
In the 31P{1H} NMR spectrum of the mixture of 3.4 and 5'-GMP, a shift in the signal for 3.4 
occurred from δ -48.77 ppm to δ -19.88 ppm along with the appearance of a new signal at 
δ -2.42 ppm. These two signals are assigned as the 3.4-5'-GMP complexation product, with 
the most upfield signal being assigned to the PTA moiety and the downfield signal being 
assigned to the nucleotide. This data compliments the observation of the shift of the proton 
signal for H8 in the 1H NMR spectrum and that coordination occurs though N7.[36] It has been 
reported for other transition metals that metals may coordinate to mononucleotides through 
N7 and/or via the phosphate moiety of the sugar backbone.[37-38] 
 
3.6. Interactions with Histidine 
Ruthenium(III) complexes (N)KP1339 and NAMI-A, which are currently undergoing clinical 
trials, have high affinities for proteins,[39-43] due to their nitrogen and sulfur content, and it is 
supposed that this may be a reason for their selectivity and ability of targeting tumor cells.[44] 
Transferrin, the protein responsible for supplying cells with iron used in cell growth and 
division, is present in plasma and other bodily fluids and easily accessible for binding metal 
based drugs. It has been reported that NAMI-A and KP1019, the predecessor of (N)KP1339 
and imadozolium salt analogue, bind to transferrin on the histidine residue in place of iron. 
The amino acid, l-histidine is a good constituent of proteins and was thus chosen for this study. 
The mononuclear complex 3.4 was reacted with an equimolar amount of histidine in an 
aqueous solution. Interactions between 3.4 and the amino acid were confirmed by shifts 
observed in the 1H and 31P{1H} NMR spectra (Figure 3.10). The downfield shifts of the signals 
at δ 7.05 ppm and δ 7.76 ppm (Figure 3.10b) to δ 7.12 ppm and δ 7.92 ppm (Figure 3.10c) 
respectively indicate that coordination is most likely occurring at the tertiary nitrogen on the 
imidazole ring of the amino acid by displacement of the iridium-chloride to form a cationic 
species. 
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Figure 3.10 1H NMR spectra in D2O of (a) 3.4 (black), (b) histidine (brown) and (c) reaction 
mixture of 3.4 with histidine (turquoise). 
 
In the 31P{1H} NMR spectrum of the mixture of 3.4 and histidine a shift in the signal for 3.4 
occurred from δ -48.77 ppm to δ -51.51 ppm, confirming coordination of histidine.  
 
3.7. DNA Binding Study 
It should be clear that the simple reaction of metal ions with isolated nucleotides is not 
conclusively comparable to that with double-stranded DNA.[45] To further probe the ability of 
3.4 to interact with the macromolecule DNA, UV-Vis absorption studies were performed with 
Red Salmon testes DNA, isolated from the sperm cells. This is a good source of non-
mammalian DNA from the species Oncerhynchus keta. This non-mammalian DNA suffices for 
this in vitro DNA interaction study and is commonly used to monitor DNA interactions via UV-
Vis spectroscopy.[46-52] 
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Figure 3.11: UV absorption spectra of 0.33 mM 3.4 in 0.2 mM HEPES buffer, pH 7.4, in H2O 
in the absence (bottom blue) and then in the presence of increasing concentration of Red 
Salmon testes DNA. 
 
It is known that the hormone and neurotransmitter, Norepinephrine binds to DNA and results 
in a red hyperchromic shift at λmax.[53] On the other hand a red hypochromic shift at λmax in the 
UV absorption spectra is observed upon incremental addition of DNA to Schiff base containing 
Cu(II), Co(II) and Ni(II) complexes.[54] Shifts in intensities or bands in the UV absorption spectra 
are indicative of interactions between DNA and metal complexes.[55-56] 
Changes in the absorbance are commonplace in the UV absorption spectra of DNA, due to 
the nature of its double helix. Hyperchromic shifts are associated with the electrostatic binding 
of complexes to the macromolecule which in turn causes partial unwinding of the double helix 
and exposes more DNA base pairs. Hypochromic shifts are related to complexes which exhibit 
the ability to intercalate with DNA.[57] 
The absorbance of 3.4, in a HEPES buffered solution at pH 7.4, at 303 nm increased 
(hyperchromic shift) upon incremental addition of DNA. The DNA concentration was increased 
to a final concentration of 12.86 nM. In addition to this hyperchromic effect a blue shift of λmax 
was observed from 303 nm to 293 nm (Figure 3.11). 
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Figure 3.12: UV absorption spectra of 0.33 mM 3.4 in 0.2 mM HEPES buffer, pH 7.4, in H2O 
at λ = 293 nm with increasing concentrations of Red Salmon testes DNA. 
 
It should be clarified that the hyperchromic effect, where the absorbance of the solution 
increased from 0.87 to 1.06 (Figure 3.12), is more than the sum of the absorbance of the DNA 
or metal complex components and thus it can be inferred that the binding of 3.4 to DNA results 
in this shift. 
 
3.8. Overall Summary 
Six new rhodium(III), iridium(III) and ruthenium(II) complexes 3.3-3.8 were synthesized from 
the ligands 3.1-3.2, which were prepared from the alkylation of PTA. 3.1-3.8 were prepared in 
poor to excellent yields and were characterized using NMR spectroscopy and mass 
spectrometry. 1H and 31P{1H} NMR spectroscopy show that the ligand coordinates to the 
metal-arene through the phosphorous of the alkylated PTA in a monodentate fashion.  
The cationic alkylated PTA PGM complexes 3.3-3.8 exhibit low to moderate antiproliferative 
activity against the esophageal WHCO1 cancer cell line. The rhodium(III) and ruthenium(II) 
trinuclear complexes 3.6 and 3.8, respectively, displayed greater activity than their 
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mononuclear analogues. It is unclear as to why the mononuclear complex 3.4 is the most 
active of this series. Future investigative studies can be performed to probe understanding 
into this anomaly. The mononuclear complex 3.4 showed aqueous stability and confirmed the 
ability of alkylated PTA PGM complexes to interact with 5'-GMP, by coordination via the N7 
atom, and histidine as confirmed by NMR studies. 3.4 also displayed the ability to interact with 
Red Salmon testes DNA and resulted in a hyperchromic blue shift of λmax. 
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Chapter 4: Synthesis, Characterization 
and Antitumor Activity of New Trinuclear 
Sulfonated Rh(III), Ir(III) and Ru(II) 
Complexes 
4. Introduction 
Sulfonated compounds experience a high degree of water solubility and this is an attractive 
chemical property in the field of anticancer research. However, little research towards the 
application as potential antitumor agents has been explored. 
Chachoyan and Sagradyan prepared sodium diphenylphosphinebenzene-m-sulfonate (DPM) 
complexes with Rh(I) and Ru(II) (Figure 4.1).[1] Toxicity and antitumor activities of these 
complexes were investigated in mice and rats containing tumors which were transplanted. 
Both the ruthenium(II) and rhodium(I) complexes were found to be nontoxic, LD100 = 
1000 - 1250 mg/kg, and they both exhibited antitumor activity. 
 
 
Figure 4.1: Water soluble sulfonated complexes [Rh(DPM)3Cl] (left) and [Ru(DPM)2Cl2] (right). 
 
Wang and co-workers prepared a Ru(II) complex, [Ru(bpy)2(py-SO3)]+, where bpy = 2,2’-
bipyridine and py-SO3 = pyridine-2-sulfonate (Figure 4.2).[2] This complex dissociates its 
sulfonated pyridine ligand upon irradiation from light within the visible spectrum, where λ > 
470 nm. DNA was found to be photocleaved by the production of free radical species from the 
homolysis. 
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Figure 4.2: Homolysis of [Ru(bpy)2(py-SO3)]+ upon irradiation, resulting in radical formation 
for DNA cleavage. 
 
Garcia and co-workers prepared a water-soluble sulfonated ruthenium-arene complex, 
[Ru(C5H5)(DPM)(2,2’-bipy)][CF3SO2] (Figure 4.3) which was found to target the 
endomembrane system and disrupt golgi bodies and mitochondria.[3] The cytotoxic activity 
against a set of human cancer cell lines was investigated (A2780, A2780cisR, MCF7, 
MDAMB231, HT29, PC3 and the non-tumorigenic V79). 
 
 
Figure 4.3: Sulfonated ruthenium(II) arene complex, [Ru(C5H5)(DPM)(2,2’-bipy)][CF3SO3]. 
 
Bergamini and co-workers prepared the first examples of PTA zwitterionic complexes, 
[PtCl2(PTA+C3H6SO3-)2] and [RuCl(PPh3)Cp(PTA+C3H6SO3-)] from sultones (Figure 4.4).[4] The 
antiproliferative activity of the complexes and the ligand were tested against the cisplatin 
sensitive human ovarian cell line, A2780, and the cisplatin resistant human ovarian cell line 
SKOV3. 
 
Sulfonated Rh(III), Ir(III) and Ru(II) complexes  Chapter 4 
 
85 | P a g e  
 
 
Figure 4.4: [PtCl2(PTA+C3H6SO3-)2] (left) and [RuCl(PPh3)Cp(PTA+C3H6SO3-)] (right). 
 
The incorporation of the sulfonate moiety results in an increase of water solubility, which is 
desirable for potential anticancer complexes which generally have low water solubility. Many 
mononuclear sulfonated metal complexes exhibit significant antitumor actitivity, as previously 
highlighted. This potency may be do to the ionic nature which the sulfonate moeity provides. 
To date and to the best of my knowledge, no sulfonated polynuclear metal-arene systems 
have been developed or reported. In this chapter, the synthesis, characterization and 
biological evaluation of new trinuclear sulfonated rhodium(III) and iridium(III) 
pentamethylcyclopentadienyl complexes are described. For comparative purposes, 
sulfonated mononuclear analogues were also prepared. The discussion of spectroscopic and 
analytical techniques used to confirm the proposed metal complex structures and the 
biological activity of these metal complexes is contained within this chapter. 
 
4.1. Synthesis and Characterization of Water-Soluble Sulfonated Anionic Complexes 
The mono- and trimeric ligands 4.1 and 4.4 were synthesized using known methods.[5] Ligands 
4.1 and 4.4 were reacted with the precursors dichloro(pentamethylcyclopentadienyl)-
rhodium(III) dimer or dichloro(pentamethylcyclopentadienyl)iridium(III) dimer to yield the 
corresponding mononuclear anionic complexes 4.2-4.3 (Scheme 4.1) or trinuclear anionic 
complexes 4.5-4.6 (Scheme 4.2). 
The mono- 4.2-4.3 and trinuclear anionic complexes 4.5-4.6 were prepared by stirring the 
appropriate ligand and sodium acetate in ethanol followed by addition of the appropriate dimer. 
The resulting products 4.3-4.4 and 4.5-4.6 were isolated as hygroscopic red or yellow to brown 
solids, in low to moderate yields, and are soluble in water and most polar organic solvents. 
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Scheme 4.1 Synthesis of mononuclear sulfonated N,O-salicylaldiminato anionic complexes 
4.2-4.3. 
 
 
 
Scheme 4.2 Synthesis of trinuclear sulfonated N,O-salicylaldiminato anionic complexes 
4.5-4.6. 
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The mono- and trinuclear N,O-salicylaldiminato ruthenium(II) anionic complexes were unable 
to be isolated. Various solvents including methanol, ethanol, dichloromethane and acetone 
were used in the presence of bases such as sodium acetate and sodium hydride. However, 
1H NMR analysis of the brown oils or powders obtained only revealed mixtures of unreacted 
ligand 4.1 or 4.4 and dichloro(p-cymene)ruthenium(II) dimer with no coordinated product 
formed. No further attempts were performed to coordinate ruthenium(II) to these systems. 
The new anionic complexes 4.2-4.3 and 4.5-4.6 were fully characterized using several 
spectroscopic and analytical techniques. Coordination to the metal-arene is bidentate in 
nature. Evidence of the coordination occurring via the imine nitrogen and phenolic oxygen to 
the metal-arene were obtained from the NMR and IR analyses. 
The NMR spectra of complexes 4.2-4.3 and 4.5-4.6 were recorded in (CD3)2SO and show 
relevant peaks for the proposed structures. 
The 1H NMR spectra for the mono- and trinuclear sulfonated N,O-salicylaldiminato anionic 
complexes 4.2-4.3 and 4.5-4.6 all show an upfield shift of the imine proton to ca. δ 8.04 ppm 
from δ 8.58 ppm for the mononuclear anionic complexes 4.2-4.3 or to ca. δ 8.14 ppm from δ 
8.56 ppm for the trinuclear complexes 4.5-4.6 (Table 4.1). The absence of the downfield signal 
for the phenolic proton of the ligands 4.1 and 4.4 at ca. δ 13.84 ppm confirms that metal 
coordination occurs via the imine nitrogen and phenolic oxygen.  
 
Table 4.1 Selected spectroscopic and analytical data for N,O-salicylaldiminato anionic 
complexes 4.2-4.3 and 4.5-4.6. 
Compound 
Number 
1H NMR 
(imine) [ppm]a 
13C{1H} NMR 
(imine) [ppm]a 
FT-IR 
Imine [cm-1]b 
HR-ESI-MS  
[m/z]c 
4.2 8.02 163.58 1623 514.0308 [M-Na]- 
4.3 8.05 160.67 1621 604.0961 [M-Na]- 
4.5 8.17 165.10 1618 373.1396 [M-3Cl+Na]4+ 
4.6 8.10 162.20 1617 583.1314 [M-3Cl]3+ 
aRecorded in (CD3)2SO; bRecorded with ATR; c4.2-4.3 performed in positive mode, 4.5-4.6 performed in negative 
mode. 
 
The 13C{1H} NMR spectra of the anionic complexes 4.2-4.3 and 4.5-4.6  gave the expected 
number of carbon signals. For the rhodium(III) complexes 4.2 and 4.5 a downfield shift for the 
imine carbon to ca. δ 164.34 ppm from the reported literature value of ca. δ 162.1 ppm was 
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observed,[5] while conversely for the iridium(III) complexes 4.3 and 4.6 an upfield shift to ca. 
δ 161.44 ppm is observed. 
In the 1H NMR spectra for complexes 4.2-4.3 and 4.5-4.6 the methyl protons of the 
pentamethylcyclopentadienyl ligand are observed at ca. δ 1.44 ppm (Figure 4.5). The signals 
for the protons H1 and H3 of the n-propyl chain of the mononuclear complexes 4.2-4.3 are 
observed as triplets at ca. δ 3.89 ppm, H3, and ca. δ 0.87 ppm, H1. The signal for the protons 
H2 in the mononuclear complexes 4.2-4.3 coalesce with the signal for the methyl protons H12.  
 
 
Figure 4.5 1H NMR spectrum of mononuclear N,O-salicylaldiminato anionic complex 4.2. 
 
In the 13C{1H} NMR spectra for the complexes 4.3-4.6 the carbon resonances of the 
pentamethylcyclopentadienyl ring are observed at ca. δ 95.68 ppm for the rhodium(III) and ca. 
δ 84.43 ppm for the iridium(III) complexes. The carbon signals for the methyl substituents on 
the arene are observed at ca. δ 8.38 ppm for the rhodium(III) and ca. δ 8.36 ppm for the 
iridium(III) complexes (Figure 4.6).  
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Figure 4.6 13C{1H} NMR spectrum of trinuclear N,O-salicylaldiminato anionic complex 4.6. 
 
The signals in the 13C{1H} NMR spectra for the aliphatic carbons in the mononuclear anionic 
complexes 4.2-4.3 of the n-propyl chain are observed at ca. δ 67.03 ppm, C3, ca. δ 23.43 
ppm, C2, and ca. δ 11.21 ppm, C1. The aliphatic carbon atoms of the trinuclear anionic 
complexes 4.5-4.6 display signals at ca. δ 63.33 ppm, C1, and ca. δ 55.60 ppm, C2. 
The signal in the 1H NMR spectra for the aliphatic –CH2 protons H1, adjacent to the nitrogen 
core, in the trinuclear anionic complexes 4.5-4.6 coalesce with the signal for the methyl 
protons H11 of the pentamethylcyclopentadienyl, in both cases. This is observed in the two 
dimensional 1H-13C HSQC NMR spectrum (Figure 4.7). In the trinuclear complexes the signal 
for H2 of the tris-2-(5-sulfinatosalicylaldimine ethyl)amine ligand is observed as a multiplet at 
either δ 4.00 ppm, 4.5, or δ 4.33 ppm, 4.6. This multiplicity can be explained by the introduction 
of a chiral center at the coordinated metal-arene. 
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Figure 4.7 1H-13C HSQC NMR spectrum of trinuclear N,O-salicylaldiminato anionic complex 
4.6. 
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The sulfonated N,O-salicylaldiminato anionic complexes 4.2-4.3 and 4.5-4.6 display a shift in 
the C=Nimine stretching vibration to lower wavenumbers. The mononuclear anionic complexes 
4.2-4.3 display a shift from 1634 cm-1 to ca. 1622 cm-1 (Figure 4.8), while the trinuclear anionic 
complexes 4.5-4.6 display a shift from 1635 cm-1 to ca. 1618 cm-1. These shifts to lower 
frequencies are as a result of a weaker C=Nimine bond due to the electron-withdrawing nature 
of the aromatic ring and the coordinated metal center. Similar shifts in the stretching frequency 
for the C=Nimine have been reported.[6]  
 
 
Figure 4.8 IR spectra displaying range of 1500-1700 cm-1 of N,O-salicylaldiminato anionic 
compounds 4.1-4.6. 
 
Mass spectral analysis confirmed the proposed structures. The mononuclear anionic 
complexes 4.2-4.3 display molecular-ion base peaks which correspond to the loss of the 
sodium ion in the negative mode, [M-Na]-, and the loss of the chlorido ligand in the positive 
mode, [M-Cl]+. The trinuclear iridium(III) anionic complex 4.6 displays a base peak which 
corresponds to the loss of three chlorido ligands in the positive mode, [M-3Cl]3+, while the 
trinuclear rhodium(III) complex 4.5 displays a peak which is assigned as a sodium adduct, 
[M-3Cl+Na]4+. 
Elemental analysis results of the rhodium(III) and iridium(III) anionic complexes displayed 
percentages outside of acceptable limits due to the hygroscopic nature of the complexes 
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4.2-4.3 and 4.5-4.6. Recalculation of the percentages with the inclusion of water gave 
percentages within acceptable limits. 
 
4.2. Synthesis and Characterization of Sulfonated Complexes 
Ligands 4.1 and 4.4 were reacted with the precursors, dichloro(pentamethylcyclopentadienyl) 
rhodium(III) dimer or dichloro(pentamethylcyclopentadienyl)iridium(III) dimer followed by an 
N-pyridyl donor ligand to displace the metal-chloro ligand. The N-pyridyl donor ligands used 
were: pyridine, 4-methylpyridine, 4-phenylpyridine, 4-ferrocenylpyridine. The resulting 
mononuclear complexes 4.7-4.14 (Scheme 4.3) or trinuclear complexes 4.15-4.22 
(Scheme 4.4) were isolated as tetraphenylborate salts.  
 
 
Scheme 4.3 Synthesis of trinuclear sulfonated N,O-salicylaldiminato complexes 4.7-4.14. 
 
The mono- 4.7-4.14 and trinuclear complexes 4.15-4.22 were prepared by stirring the 
appropriate ligand and sodium acetate in ethanol followed by addition of the appropriate dimer 
and N-donor ligand. The resulting products 4.7-4.14 were precipitated from the reaction using 
iso-propanol and were isolated as hygroscopic red to yellow or brown solids, in low to good 
yields, and are soluble in most polar organic solvents. The sulfonated complexes 4.7-4.22 
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suffered a decrease in water solubility due to the presence of the tetraphenylborate salt 
counterion and these complexes were only partially water soluble. 
 
 
Scheme 4.4 Synthesis of trinuclear sulfonated N,O-salicylaldiminato complexes 4.15-4.22. 
 
The complexes 4.7-4.22 are new compounds and were fully characterized with spectroscopic 
and analytical techniques. NMR and FT-IR analyses confirm the bidentate nature of the 
coordination of the imine nitrogen and phenolic oxygen with pyridine-ligand derivatives 
coordinated to the metal-arene. 
The NMR spectra of complexes 4.7-4.22 were recorded in deuterated dimethylsulfoxide, 
(CD3)2SO, and show relevant peaks for the proposed structures. 
All the mono- and trinuclear sulfonated N,O-salicylaldiminato complexes 4.7-4.22 in the 1H 
NMR spectra exhibit an upfield shift of the signal for the imine proton relative to the free ligand. 
The rhodium(III) complexes 4.7-4.10 and 4.15-4.18 exhibit the greatest shift of the signal for 
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the imine upon coordination to the metal-Cp* for this signal from δ 8.58 ppm to ca. δ 8.24 ppm. 
The signal for the rhodium(III) complexes is further upfield in comparison to the iridium(III) 
complexes 4.11-4.14 and 4.19-4.22 which shifted to ca. δ 8.41 ppm from δ 8.56 ppm. The 
range of the imine signals, δ 8.16 – 8.65 ppm, for the N,O-salicylaldiminato complexes 
4.7-4.22 with the N-donor ligand are further downfield than the range of the imine signals of 
the N,O-salicylaldiminato complexes 4.3-4.6, δ 8.02 – 8.17 ppm. This deshielding effect can 
be attributed to the presence of the N-pyridyl ligand which displaces the metal-chloro ligand 
and results in a positive metal center and exposes the methyl protons of the 
pentamethylcyclopentadienyl ligand to a greater magnetic field and thus resonate downfield. 
The 13C{1H} NMR spectra of the complexes 4.7-4.22 gave the expected number of carbon 
signals. All sulfonated N,O-salicylaldiminato complexes 4.7-4.22 exhibited a downfield shift in 
the signal for the imine carbon upon coordination to the metal-Cp*. For the mononuclear 
rhodium(III) complexes 4.7-4.11 a shift for the signal of the imine carbon to ca. δ 165.93 ppm, 
and for the trinuclear rhodium(III) complexes 4.15-4.18 a shift for the signal of the imine carbon 
to ca. δ 163.00 ppm from the reported literature value of ca. δ 162.1 ppm was observed.[5] For 
the mono- and trinuclear iridium(III) complexes 4.11-4.14 and 4.19-4.22 a shift to ca. δ 163.48 
ppm is observed. 
In the 1H NMR spectra of complexes 4.7-4.22 the methyl protons of the 
pentamethylcyclopentadienyl ligand are observed at ca. δ 1.54 ppm, which is downfield of the 
signals of the methyl protons of the pentamethylcyclopentadienyl ligand of complexes 4.3-4.6.  
In the 13C{1H} NMR spectra of complexes 4.7-4.22 the carbons of the 
pentamethylcyclopentadienyl ring are observed at ca. δ 95.11 ppm for the rhodium(III) and ca. 
δ 91.95 ppm for the iridium(III) complexes. The carbon signals for the methyl substituents on 
the arene are observed at ca. δ 8.11 ppm for the rhodium(III) (Figure 4.3) and ca. δ 7.94 ppm 
for the iridium(III) complexes. These trends for similar signals were previously observed in 
Chapter 2 and 3. 
For complexes 4.7-4.22, the signals in the 1H NMR spectra for the protons and the carbon 
atoms in the 13C{1H} NMR spectra of the n-propyl chain and tris-2-(5-sulfinatosalicylaldimine 
ethyl)amine scaffold display comparable chemical shifts as for those previously mentioned for 
the anionic complexes 4.2-4.3 and 4.5-4.6.  
Additional evidence to attest to the successful coordination of the N-donor ligand and 
displacement of the chlorido ligand was confirmed by NMR spectroscopy. The presence of a 
downfield diagnostic doublet signal in the 1H NMR spectra for the protons adjacent to the 
nitrogen of the pyridyl ligand confirms the coordination of the N-donor ligand (Figure 4.9). This 
doublet for H13 in the mononuclear complexes 4.7-4.14 and H12 in the trinuclear complexes 
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4.15-4.22 is observed in the range δ 8.41 – 8.89 ppm. In the 13C{1H} NMR spectra the signals 
for C13 in the mononuclear complexes 4.7-4.14 and C12 in the trinuclear complexes 4.15-
4.22 is observed in the range δ 149.46 – 153.71 ppm. 
 
 
Figure 4.9 1H NMR spectrum of N,O-salicylaldiminato rhodium(III) pyridyl complex 4.7. 
 
In the sulfonated N,O-salicylaldiminato complexes 4.8, 4.12, 4.16 and 4.20, where 
4-methylpyridine has displaced the chlorido ligand, a diagnostic signal is present upfield for 
the methyl group para- to the nitrogen of the pyridine ring. In the 1H NMR spectra this methyl 
group exhibits a singlet in the range δ 2.34 – 2.78 ppm. As shown in the representative 
example of complex 4.8, 2D 1H-13C HSQC NMR was used to assign all the signals in the 1H 
and 13C{1H} NMR spectra (Figure 4.10). The signal for the methyl protons assigned as the 
singlet at δ 2.38 ppm displays coupling into a carbon resonance which lies in the aliphatic 
range at δ 20.40 ppm, confirming the presence of the 4-methylpyridyl ligand. 
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Figure 4.10 1H-13C HSQC NMR spectrum of mononuclear N,O-salicylaldiminato complex 4.8. 
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Where 4-phenylpyridine was used to displace the metal-chloro ligand in the sulfonated N,O-
salicylaldiminato complexes 4.9, 4.13, 4.17 and 4.21 the aromatic region of the 1H NMR 
spectra displayed many signals due to the large number and variety of aromatic protons. 2D 
1H-1H COSY NMR spectroscopy proved to be particularly useful in assigning the aromatic 
signals in the 1H NMR spectra. A representative example of complex 4.9 displays assigned 
signals in the 1H-1H COSY NMR spectrum (Figure 4.11).  
 
 
Figure 4.11 Aromatic region of 1H-1H COSY NMR spectrum of trinuclear N,O-salicylaldiminato 
complex 4.9. 
 
In the 4-ferrocenylpyridine containing sulfonated N,O-salicylaldiminato complexes 4.10, 4.14, 
4.18 and 4.22 many of the 1H and 13C{1H} NMR spectra displayed similarities to those of the 
complexes containing the 4-methylpyridine ligand. In the 1H NMR two singlets of equal 
intensity in the range δ 4.57 – 5.12 ppm were assigned as the protons of the substituted Cp 
ring. Further upfield a large singlet was observed at ca. δ 4.07 ppm which was assigned as 
the unsubstituted Cp ring. The representative example of complex 4.10 displays assigned 
signals in the 1H NMR spectrum (Figure 4.12). In the 13C{1H} NMR spectra the tertiary carbon 
atom of the Cp ring was assigned as ca. δ 77.69 ppm, the aromatic carbons of the substituted 
Cp ring were assigned as ca. δ 71.75 ppm and ca. δ 70.15 ppm and the aromatic carbons of 
the unsubstituted ring as ca. δ 67.50 ppm. 
Sulfonated Rh(III), Ir(III) and Ru(II) complexes  Chapter 4 
 
98 | P a g e  
 
 
 
Figure 4.12 1H NMR spectrum of mononuclear N,O-salicylaldiminato complex 4.10. 
 
Similarly, like complexes 4.2-4.3 and 4.5-4.6, the sulfonated N,O-salicylaldiminato complexes 
4.7-4.22 display a shift in the C=Nimine stretching vibration to lower wavenumbers. The N-
pyridine containing complexes 4.7, 4.11, 4.15 and 4.19 display a shift from ca. 1635 cm-1 to 
ca. 1619 cm-1, while the N-methylpyridine containing complexes 4.8, 4.12, 4.16 and 4.20 
display a shift to ca. 1618 cm-1, the N-phenylpyridine containing complexes 4.9, 4.13, 4.17 and 
4.21 display a shift to ca. 1611 cm-1 and the N-ferrocenylpyridine containing complexes 4.10, 
4.14, 4.18 and 4.22 display a shift to ca. 1609 cm-1. These shifts to lower frequencies by 
varying the N-pyridyl donor ligand are due to a weakening of the C=Nimine bond due to the 
electron withdrawing nature of the N-donor ligand (Figure 4.13), with the N-ferrocenylpyridine 
ligand being the most electron withdrawing. 
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Figure 4.13 IR spectra over range 1550-1675 cm-1 of N,O-salicylaldiminato complexes 
4.15-4.18. 
 
Mass spectral analysis confirmed the proposed structures. The mononuclear complexes 4.7-
4.14 display a base peak in the positive mode which corresponds to the proton adduct which 
has undergone loss of the tetraphenylborate counterion, the sodium and the N-donor ligand. 
The rhodium(III) complexes 4.7-4.10 display the proton adduct at ca. 480 and at ca. 570 for 
the iridium(III) complexes 4.11-4.14. The trinuclear rhodium(III) complexes 4.15-4.18 display 
a base peak which corresponds to the sodium adduct with an overall charge of +4, and which 
has undergone a loss of the tetraphenylborate counterions and the N-donor ligands. The 
trinuclear iridium(III) complexes 4.19-4.22 display a base peak which corresponds to the 
acetonitrile and potassium adduct with an overall charge of +5, and which has undergone a 
loss of the tetraphenylborate counterions, the sodium ions and the N-donor ligand. The 
rhodium(III) complexes 4.15-4.18 display the proton adduct at ca. 373, while this is found at 
ca. 405 for the iridium(III) complexes 4.19-4.22.  
Elemental analysis results of the rhodium(III) and iridium(III) complexes displayed 
percentages outside of acceptable limits, even after extensive drying, due to the hygroscopic 
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nature of the complexes 4.7-4.22. Recalculation of the percentages with the inclusion of water 
gave percentages within acceptable limits. 
 
4.3. In vitro Biological Activity 
The in vitro cytotoxicity of the monomeric and mononuclear (Table 4.2) and trimeric and 
trinuclear (Table 4.3) sulfonated salicylaldimine compounds 4.1-4.22 was established against 
WHCO1 human esophageal cancer cells.  
 
Monomeric and Mononuclear Compounds 4.1-4.3 and 4.7-4.14 
The monomeric ligand 4.1 and the mononuclear anionic complexes 4.2-4.3 displayed inactivity 
against WHCO1 cells. The rhodium(III) complex 4.2 displayed an IC50 value of 169.1 μM, while 
the iridium(III) analogue 4.3 exhibited an IC50 value in excess of 300 μM.  
However, the displacement of the metal chloro-ligand by varying N-donors, such as pyridine, 
4-methylpyridine, 4-phenylpyridine or 4-ferrocenylpyridine, results in a cationic rhodium(III) or 
iridium(III) metal center and the activity of these complexes increased several-fold. The 
complexes 4.5-4.8 and 4.9-4.12 exhibited superior activity to the anionic chlorido complexes 
4.2-4.3. 
This increase in activity due to the presence of an N-donor such as pyridine has been 
previously reported by Sadler and co-workers.[7] It was reported that an iridium(III) complex 
containing an N-donor ligand displayed a different method of action to that of cisplatin 
compared to the chloro-analogue. This activity was attributed to the iridium(III) complex 
containing an N-donor ligand having a greater ability to accumulate within the cancer cells. In 
addition to this, the iridium(III) complex containing an N-donor ligand generated higher levels 
of reactive oxygen species. The presence of the strongly bound pyridine-ligand results in a 
decreased rate of formation of the aqua species, when compared to that of the chloro-
analogue. The increase in activity of the pyridine-analogue is contrasted by the loss of activity 
when the metal chloro-ligand of a Ru(II) complex is substituted with pyridine.[8] 
In another reported study of iridium(III) complexes containing N-donor ligands by Sadler and 
co-workers it was observed that N-donor ligands with greater electron-donating abilities 
resulted in higher activities against tested cell lines.[9] The electron-donating ligand was 
thought to strengthen the M-pyridyl bond and resulted in fewer side reactions with molecules 
the complex might encounter on the way to the target site. No significant hydrolysis to form an 
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aqua species was observed, yet these iridium(III) complexes displayed potent activity against 
A2780, A549 (lung cancer) and MCF-7 (breast cancer). 
 
Table 4.2 IC50 values determined against WHCO1 human esophageal cancer cells for 
sulfonated N,O-salicylaldiminato compounds 4.1-4.3, 4.7-4.14 and cisplatin. 
Compound 
Number 
Metal Ligand 
IC50 ± SD (μM) 
WHCO1 
4.1 - - >300 
4.2 Rh Cl 169.10 ± 13.22 
4.3 Ir Cl >300 
4.7 Rh Na 37.27 ± 4.50 
4.8 Rh N-Meb 36.29 ± 5.47 
4.9 Rh N-Phc 24.90 ± 10.70 
4.10 Rh N-Fcd 31.86 ± 10.01 
4.11 Ir Na 58.02 ± 19.31 
4.12 Ir N-Meb 59.55 ± 23.72 
4.13 Ir N-Phc 49.48 ± 19.01 
4.14 Ir N-Fcd >270 
Cisplatin Pt - 9.2 ± 0.1[10] 
aN = Pyridine; bN-Me = 4-methylpyridine; cN-Ph = 4-phenylpyridine; dN-Fc = 4-ferrocenylpyridine. 
 
The mononuclear rhodium(III) complexes 4.7-4.10, containing N-donor type ligands display 
similar activities with IC50 values in the range 24.90 - 37.27 μM. These rhodium(III) complexes 
are more active than the iridium(III) analogues, 4.11-4.13, which displayed activities in the 
range 49.48 – 59.55 μM. The iridium(III) complex 4.14 containing the 4-ferrocenylpyridine 
ligand was inactive against the WHCO1 esophageal cancer cells with an IC50 value of 
>270 μM. The lack of activity of 4.14 was investigated by probing its stability in DMSO solution 
in the following section. The mononuclear complexes 4.2-4.3 and 4.7-4.14 were less active 
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against the WHCO1 esophageal cancer cells than cisplatin which has an IC50 value of 9.20 
μM.[10] 
 
 
Figure 4.14 Cytotoxicity of sulfonated N,O-salicylaldiminato compounds 4.1-4.3, 4.7-4.14 and 
cisplatin against WHCO1. 
 
Trimeric and Trinuclear Compounds 4.4-4.6 and 4.15-4.22 
The trimeric sulfonated salicylaldimine ligand 4.4, like the monomeric ligand 4.1, was also 
inactive against the WHCO1 esophageal cancer cells with an IC50 value in excess of 300 μM. 
However, upon coordination of the metal an increase in activity is once again observed. The 
trinuclear anionic complexes 4.5-4.6 display an increased activity in comparison to the free 
ligand 4.4.The trinuclear rhodium(III) anionic complex 4.5, with an IC50 of 43.87 μM, is more 
active than the iridium(III) analogue, with an IC50 value of 200.80 μM. This trend of the anionic 
rhodium(III) complex being more active than the anionic iridium(III) complex was also 
observed in the mononuclear series of 4.2-4.3. 
It is of interest that it is observed that the activity is once again significantly increased by the 
displacement of the metal chlorido-ligand by various N-donors (Figure 4.14). This effect is 
observed in all of the complexes 4.15-4.22, with the exception of complex 4.17, where a slight 
loss of activity is apparent. 
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Table 4.3 IC50 values determined against WHCO1 human esophageal cancer cells for 
sulfonated N,O-salicylaldiminato compounds 4.4-4.6, 4.15-4.22 and cisplatin. 
Compound  
Number 
Metal Ligand 
IC50 ± SD (μM) 
WHCO1 
4.4 - - >300 
4.5 3 Rh Cl 43.87 ± 31.86 
4.6 3 Ir Cl 200.80 ± 9.85 
4.15 3 Rh Na 30.61 ± 18.62 
4.16 3 Rh N-Meb 33.21 ± 16.28 
4.17 3 Rh N-Phc 54.96 ± 40.38 
4.18 3 Rh N-Fcd 0.56 ± 0.49 
4.19 3 Ir Na 12.96 ± 8.99 
4.20 3 Ir N-Meb 6.22 ± 4.49 
4.21 3 Ir N-Phc 9.57 ± 4.57 
4.22 3 Ir N-Fcd 49.46 ± 16.67 
Cisplatin Pt - 9.2 ± 0.1[10] 
aN = Pyridine; bN-Me = 4-methylpyridine; cN-Ph = 4-phenylpyridine; dN-Fc = 4-ferrocenylpyridine. 
 
The series of trinuclear iridium(III) complexes 4.19-4.21 have IC50 values in the range 
6.22 – 12.96 μM and have superior activity over the trinuclear rhodium(III) analogues 4.15-
4.17 with IC50 values in the range 30.61 – 54.96 μM (Figure 4.15). It has been previously 
reported that iridium(III)-Cp* complexes with N-donor ligands have potent antitumor 
activities.[11] As observed in both the mono- and trinuclear series the rhodium(III) complexes 
4.10 and 4.18 both have increased activity in comparison to the iridium(III) analogues 4.14 
and 4.22, against the WHCO1 cancer cells.  
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Figure 4.15 Cytotoxicity of sulfonated N,O-salicylaldiminato compounds 4.4-4.6, 4.15-4.22 
and cisplatin against WHCO1. 
 
The trinuclear iridium(III) complexes 4.19-4.21 are similar in activity to that of cisplatin against 
the WHCO1 cancer cells. The most active complex was the trinuclear rhodium(III) complex 
4.18, containing the 4-ferrocenylpyridine ligand, with an IC50 value of 0.56 μM. Interestingly a 
dinuclear ruthenium(II) complex with a N-ferrocenoyl pyridine ligand prepared by Süss-Fink 
and co-workers displayed remarkable antitumor activity and this potency was attributed to the 
complex’s redox ability.[12-13] 
 
4.4. Aqueous and DMSO Stability 
Due to the interesting trends and activity of these complexes the aqueous stability was 
investigated. The aim of these studies is to provide mechanistic insight to rationalize the 
observed biological activities of these complexes. The stability, and ability to form activated 
aqua species[14-15], of a select few complexes was monitored using 1H NMR spectroscopy over 
time at a physiological temperature of 37 oC. 
The mononuclear rhodium(III) complex 4.10 and mononuclear iridium(III) complex 4.14 
contain 4-ferrocenylpyridine and are bimetallic in nature. The rhodium(III) analogue 4.10 
displays a remarkable difference in activity against WHCO1 cells to that of the inactive 
iridium(III) analogue 4.14. This can be explained by the decrease in stability of 4.14 in DMSO, 
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as investigated by 1H NMR spectroscopy, in comparison to 4.10. However, in contrast to this, 
both 4.10 and 4.14 exhibited stability in a 50:50 mixture of CD3OD and H2O for 48 hours. 
The biologically inactive iridium(III) 4-ferrocenylpyridine complex 4.14 slowly allows 
dissociation of the 4-ferrocenylpyridine ligand in DMSO and displays full substitution of the 
metal chloro-ligand with DMSO within 48 hours, as observed by 1H NMR spectroscopy. The 
dissociation product renders the complex inactive against WHCO1, as observed by the high 
IC50 value. Similarly, the metal-chloro analogues 4.2-4.3 both undergo displacement of the 
metal chloro-ligand over 48 hours by DMSO, as observed by 1H NMR spectroscopy 
(Figure 4.16). This was confirmed by the addition of DMSO to a solution of 4.2 or 4.3 in 
CD3OD. In complex 4.14 the lability of the 4-ferrocenylpyridine ligand in DMSO and that of the 
metal-chloro ligand in complexes 4.2-4.3 could explain their similar lack of biological activities 
against WHCO1 cells.  
 
  
Figure 4.16 Expanded 1H NMR spectra of mononuclear (a) rhodium(III) complex 4.2 and (c) 
iridium(III) complex 4.3. Shifts due to DMSO coordination in CD3OD are shown for (b) 
rhodium(III) and (c) iridium(III) complexes. 
 
The rhodium(III) 4-ferrocenylpyridine complex 4.10 and the other N-donor-containing mono- 
and trinuclear complexes 4.7-4.9 and 4.11-4.22 all proved to be stable in DMSO for prolonged 
periods of time, up to 3 weeks. This stability towards DMSO might explain the similar biological 
activities of these complexes against WHCO1 cells. This is in contrast to the iridium(III) 
4-ferrocenylpyridine complex 4.14 possibly due to the ability of the 4-ferrocenylpyridine ligand 
to strongly coordinate to the rhodium(III) metal center in complex 4.10. It is of interest to note 
that the trinuclear iridium(III) complex 4.22 containing 4-ferrocenylpyridine did not undergo 
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dissociation of the 4-ferrocenylpyridine ligand this could explain the increased antitumor 
activity of the trinuclear complex compared to the mononuclear analogue 4.10. This increase 
in stability of the trinuclear complex 4.22 compared to 4.10 may be due to the nature of the 
trimeric ligand used. 
 
 
Figure 4.17 1H NMR spectra of trinuclear (a) rhodium(III) complex 4.18 and (c) mononuclear 
rhodium(III) complex 4.10 over 48 hours. 
 
As the activity of the trinuclear rhodium(III) complex 4.18 against the WHCO1 cancer cells was 
the highest within this series, investigations into the stability in solution and in the presence of 
50:50 DMSO and H2O were carried out by 1H NMR spectroscopy. After 48 hours in solution 
4.18 showed no signs of degradation or formation of the aqua species, as the 1H spectra 
remained unchanged over the tested time. Though 4.18 exhibits stability in DMSO, it has been 
reported that complexes may coordinate to other molecules.[16] 
 
4.5. Interactions with Model DNA 5'-GMP 
Due to the ability of many PGM anticancer complexes[17-18], and those tested in Chapters 2 
and 3 in this study, which interact with DNA base-pairs,[19-21] the ability of 4.18 to interact with 
5'-GMP was monitored using 1H NMR spectroscopy in a 50:50 mixture of (CD3)2SO and water 
at 37 oC for 48 hours. The trinuclear complex 4.18 was selected for this study as it was the 
most active against WHCO1 cancer cells. 
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The trinuclear sulfonated rhodium(III) complex 4.18 was reacted with 3 equivalents of the DNA 
base-pair, 5'-GMP. The base pair was observed to coordinate to the rhodium(III) metal via the 
N7 atom complex. In the 1H NMR spectrum of the reaction mixture, a downfield shift from 
δ 8.22 ppm (Figure 4.18a) to δ 8.49 ppm (Figure 4.18c) is observed for the proton H8 of the 
guanosine base pair which confirms that displacement of the N-ferrocenylpyridine ligand 
occurs over the 48 hours. 
 
 
Figure 4.18 1H NMR spectra of (a) 5′-GMP (cyan), (b) 4.18 (pink) and (c) reaction mixture of 
4.18 with 5'-GMP (purple). 
 
Observation of these shifts of signals in the 1H NMR spectrum have been previously reported 
and similar shifts have been observed for the interactions between other metal complexes and 
mononucleotides via the N7.[22] 
 
4.6. Overall Summary 
Four new anionic sulfonated rhodium(III) and iridium(III) complexes 4.2-4.3 and 4.5-4.6 were 
prepared from the ligands 4.1 and 4.4, which were prepared via Schiff base condensation. 
Sixteen new rhodium(III) and iridium(III) complexes 4.7-4.22 were synthesized from ligands 
4.1 and 4.4 and a variety of N-donor ligands were used to displace the metal-chloro ligand. 
These mononuclear and trinuclear complexes were isolated as tetraphenylborate salts. 
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Compounds 4.1-4.22 were isolated in poor to excellent yields and were characterized using a 
mixture of spectroscopic and analytical techniques. 1H NMR spectroscopy indicated that 
coordination of the ligand to the metal-arene takes place via the imine nitrogen and the 
phenolic oxygen in a bidentate manner. 
The ligands 4.1 and 4.4 are inactive as antitumor agents against the esophageal WHCO1 
cancer cell line. Upon coordination of the metal-arene to yield the anionic rhodium(III) and 
iridium(III) complexes 4.2-4.3 and 4.5-4.6 some antitumor activity is observed. The complexes 
4.7-4.22, containing N-donor ligands, exhibit significant activity against the WHCO1 cell line. 
An activity to size-dependent relationship was observed, in that the trinuclear complexes 4.5-
4.6 and 4.15-4.22 exhibited greater activity than the mononuclear complexes 4.2-4.3 and 4.7-
4.14. The trinuclear complexes 4.15-4.22 containing N-donor ligands display the greatest 
activity, while the most active complex in this series of sulfonated compounds is the sulfonated 
trinuclear rhodium(III) complex 4.18 containing N-ferrocenylpyridine. It is currently unclear as 
to why these trends exist. Future investigative studies will be performed to probe the method 
of action which may shed light on the observed activities. In the mononuclear series 4.2-4.3 
and 4.7-4.14 and the trinuclear anionic complexes 4.5-4.6 the rhodium(III) complexes all 
displayed superior antitumor activities over the iridium(III) analogues. However, the iridium(III) 
complexes 4.19-4.22 exhibited greater activities than the trinuclear rhodium(III) complexes 
4.15-4.17. Despite the inertness of the complex towards water and DMSO, 4.18 displays the 
ability to interact with 5'-GMP, via the N7 atom. 
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Chapter 5: Experimental 
 
5. General Remarks 
All solvents used were analytical grade and dried over molecular sieves. All reactions were 
carried out in air unless otherwise stated. All samples were dried under vacuum. 
1,2,3,4,5-Pentamethylcyclopentadiene, 1,3,5-tris(bromomethyl)benzene, 1,3,5-triaza-7-
phosphaadamantane, α-phellandrene, 2-pyridine carboxaldehyde, 4-aminophenylmethanol, 
4-methylpyridine, 4-phenylpyridine, benzaldehyde, benzyl chloride, HEPES buffer, histidine, 
nucleotide guanosine 5′-monophosphate, pyridine, Red Salmon testes DNA, salicylaldehyde, 
sodium acetate, sodium hexafluorouphosphate, sodium tetraphenylborate, triethylamine and 
trimesyl acid chloride were all purchased from Sigma-Aldrich and used as received. 
Ruthenium trichloride trihydrate, rhodium trichloride trihydrate and iridium chloride trihydrate 
were purchased from Heraeus SA. [Ru(η6-p-PriC6H4Me)Cl2]2,[1] [Rh(η5-C5Me5)Cl2]2[2] or 
[Ir(η5-C5Me5)Cl2]2[2] were prepared using known literature reported procedures. Deuterated 
solvents were purchased from Sigma-Aldrich. 
 
5.1. Instrumentation 
1H, 13C{1H}, 31P{1H}, [1H-13C] NMR spectra were recorded at ambient temperature on a Bruker 
Ultrashield 400 Plus spectrometer (1H:400.22 MHz; 13C{1H}: 100.65 MHz; 31P{1H}: 162.00 
MHz) and chemical shifts were referenced to tetramethylsilane (TMS) as an internal standard 
for 1H, and 13C{1H} NMR spectra and H3PO4 as an external standard for 31P{1H} NMR spectra. 
EI-MS was carried out on a JEOL GCMateII mass spectrometer. ESI-MS and HR-ESI-MS 
were carried out on a Waters API Quattro Micro Triple Quadrupole electrospray ionization 
mass spectrometer in the positive or negative mode.  
FT-IR spectra were recorded as KBr pellets or as pure solids by ATR using a Perkin-Elmer 
Spectrum 100 FT-IR spectrometer.  
EA were conducted with a Thermo Flash 1112 Series CHNS-O Analyser.  
Melting points were determined using a Büchi Melting Point Apparatus B-540.  
UV-Vis absorption studies were performed using a Cary UV-Vis spectrophotometer using a 
1 cm path length quartz cuvette to carry out the measurements. 
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The solubility of compounds were evaluated by dissolving accurately known masses into 
measured volumes of water.  
 
5.2. Synthesis of N,C-Benzaldimine, N,N-Pyridylimine and N,O-Salicylaldimine Ligands 
5.2.1. Preparation Monomeric Ligands (2.1-2.3) 
5.2.1.1. Preparation of 2.1 and 2.3 
4-(Benzylideneamino)benzyl alcohol, 2.1,[3] and 4-(salicylideneamino)benzyl alcohol, 2.3,[4] 
were synthesized using known literature reported procedures. 
 
5.2.1.2. 4-(Pyridylideneamino)benzyl alcohol (2.2) 
 
4-Aminophenylmethanol (523 mg, 4.24 mmol), dissolved in EtOH (15 ml), was reacted with 
2-pyridinecarboxaldehyde (0.500 g, 4.67 mmol) and the reaction mixture was stirred overnight 
at room temperature. The solvent was removed by rotary evaporation and yielded the crude 
product, which was dissolved in a minimal amount of dichloromethane and the ligand 2.2 was 
precipitated using hexane. The ligand was dried under vacuum for 12 hours. 
Pale brown solid, yield: 771 mg, 86%. MP.: 57.7-70.9oC. 1H NMR (CDCl3): δ(ppm) = 8.72 (d, 
1H, H11, 3J = 4 Hz), 8.59 (s, 1H, H6), 8.21 (d, 1H, H8, 3J= 8Hz), 7.82 (t, 1H, H9, 8 Hz), 7.42 (d, 
2H, H3, 3J = 8 Hz), 7.38 (m, 1H, H10), 7.28 (d, 2H, H4, 3J = 12 Hz), 4.73 (d, 2H, H1, 3J = 4 Hz), 
2.07 (b, 1H, -OH). 13C{1H} NMR (CDCl3): δ(ppm) = 160.42 (C6), 154.77 (C7), 150.42 (C5), 
149.59 (C11), 139.72 (C2), 136.55 (C9), 127.85 (C3), 124.98 (C10), 121.76 (C8), 121.21 (C4), 
64.83 (C1). FT-IR (KBr): 3253 (bs) ν(O-H), 1630 (s) ν(C=Nimine), 1583 (m) ν(C=Npyridyl), 1504 
(s) ν(aromatic C=C), 1021 (s) ν(C-O). EI-MS: m/z 212.07 [M]+. Elemental Analysis 
(Calculated for C13H12N2O): C, 73.57; H, 5.70; N, 13.20; Found: C, 71.87; H, 5.52; N, 13.84. 
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5.2.2. Preparation of Trimeric Ligands (2.4-2.6) 
General Procedure 
To a stirring solution of 2.1 (360 mg, 1.70 mmol for 2.4) or 2.2 (400 mg, 1.89 mmol for 2.5) or 
2.3 (400 mg, 1.76 mmol for 2.6) in DCM (20 ml), triethylamine (230 mg, 2.27 mmol for 2.4; 
765 mg, 7.56 mmol for 2.5 and 712 mg, 7.04 mmol for 2.6) and trimesyl chloride (150 mg, 
0.568 mmol for 2.4; 161 mg, 0.608 mmol for 2.5 and 150 mg, 0.568 mmol for 2.6) were added. 
The solution was stirred at room temperature overnight. The solvent was removed under 
reduced pressure and 2-butanone was added to the solid product. After filtration, the solvent 
was removed from the filtrate using rotary evaporation and the solid product was purified by 
dissolution in minimal DCM and precipitation with hexane. 
 
5.2.2.1. Tris(4-(2-benzylimine)benzyl)benzene-1,3,5-tricarboxylate ligand (2.4) 
 
Yellow solid, yield: 307 mg, 69%. MP.: 148ºC (decomposed). 1H NMR (CDCl3): δ(ppm) = 8.92 
(s, 3H, H1), 8.45 (s, 3H, H9), 7.88 (d, 6H, H11, 3J = 4 Hz), 7.47 (m, 15H, H6 H12 H13), 7.22 (d, 
6H, H7, 3J = 6 Hz), 5.41 (s, 6H, H4). 13C{1H} NMR (CDCl3): δ(ppm) = 164.79 (C3), 160.60 (C9), 
157.69 (C5), 136.27 (C8), 133.10 (C10), 128.71 (C11), 128.86 (C12 C13), 134.74 (C1), 131.38 
(C6), 130.25 (C2), 67.07 (C4). FT-IR (KBr): 1724 (s) ν(C=O), 1628 (m) ν(C=Nimine), 1577 (s) 
ν(aromatic C=C), 1231 (s) ν(C-C(O)-O). ESI-MS: m/z 266.15 [M+3H]3+. Elemental Analysis 
(Calculated for C51H39N3O6): C, 77.55; H, 4.98; N, 5.32; Found: C, 77.68; H, 4.78; N, 5.51. 
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5.2.2.2. Tris(4-(2-pyridylimine)benzyl)benzene-1,3,5-tricarboxylate ligand (2.5) 
 
Pale brown solid, yield: 443 mg, 92%. MP.: 151ºC (decomposed). 1H NMR (CDCl3): δ(ppm) 
= 8.95 (s, 3H, H1), 8.75 (d, 3H, H14, 3J = 4 Hz), 8.65 (s, 3H, H9), 7.92 (d, 3H, H11, 3J = 4 Hz), 
7.85 (t, 3H, H12, 3J = 4 Hz), 7.55 (m, 6H, H6), 7.41 (t, 3H, H13, 3J = 4 Hz), 7.31 (m, 6H, H7), 5.45 
(s, 6H, H4). 13C{1H} NMR (CDCl3): δ(ppm) = 165.25 (C3), 160.49 (C9), 149.65 (C14), 148.21 
(C10), 146.43 (C8), 137.06 (C11), 136.76 (C12), 134.72 (C5), 134.12 (C1), 130.43 (C2), 129.53 
(C6), 125.25 (C13), 67.00 (C4). FT-IR (KBr): 1719 (s) ν(C=O), 1597 (m) ν(C=Nimine), 1521 (s) 
ν(aromatic C=C), 1234 (s) ν(C-C(O)-O). ESI-MS: m/z 265.28 [M+3H]3+. Elemental Analysis 
(Calculated for C48H36N6O6): C, 72.72; H, 4.58; N, 10.60; Found: C, 72.45; H, 4.70; N, 10.08. 
 
5.2.2.3. Tris(4-(2-salicylaldimine)benzyl)benzene-1,3,5-tricarboxylate ligand (2.6) 
 
Yellow solid, yield: 473 mg, 99%. MP.: 115.5-119.8oC. 1H NMR (CDCl3): δ(ppm) = 13.01 (bs, 
3H, -OH), 8.85 (s, 3H, H1), 8.55 (s, 3H, H9), 7.46 (d, 6H, 3J = 8 Hz), 7.32 (d, 6H, H11, 3J = 8 
Hz), 7.23 (d, 3H, 3J = 8 Hz), 6.95 (d, 3H, 3J = 8 Hz), 6.87 (t, 3H, 3J = 8 Hz), 5.37 (s, 6H, H4). 
13C{1H} NMR (CDCl3): δ(ppm) = 164.58 (C3), 163.10 (C9), 161.28 (C15), 155.53 (C5), 148.97 
(C8), 136.82 (C2), 134.80, 133.29 (C13), 132.33 (C11), 129.62 (C6), 121.40 (C7), 119.73 (C10), 
119.05 (C12), 117.33 (C14), 66.94 (C4). FT-IR (KBr): 1728 (s) ν(C=O), 1622 (s) ν(C=N), 1602 
(s) ν(aromatic C=C), 1573 (s) ν(aromatic C=C), 1280 (s) ν(C-O), 1232 (s) ν(C-C(O)-O). ESI-
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MS: m/z 280.10 [M+3H]3+. Elemental Analysis (Calculated for C51H39N3O9): C, 73.11; H, 4.69; 
N, 5.02; Found: C, 73.45; H, 4.80; N, 4.40. 
 
5.3. Synthesis of Mononuclear Complexes 
5.3.1. Synthesis of Mononuclear N,C-Benzaldiminato Complexes (2.7-2.8) 
General Procedure 
The ligand 2.1 (50.0 mg, 0.237 mmol for 2.7 and 53.0 mg, 0.251 mmol for 2.8) was dissolved 
in MeOH (20 ml) and NaOAc added (20.4 mg, 0.285 mmol for 2.7 and 21.6 mg, 0.264 mmol 
for 2.8). [Rh(η5-C5Me5)Cl2]2 (73.0 mg, 0.118 mmol for 2.7) or [Ir(η5-C5Me5)Cl2]2 (100 mg, 0.126 
mmol for 2.8) was added to the solution which was stirred for 2 hours, after which the MeOH 
was removed by rotary evaporation yielding a solid residue. The residue was dissolved in 
acetone, filtered by gravity and the solvent of the filtrate was removed under reduced pressure. 
The solid products 2.7-2.8 were purified by dissolution in a minimal amount of DCM and 
precipitated using Et2O. 
 
5.3.1.1. 4-(Benzylaldimine)phenylmethanol rhodium(III) complex (2.7) 
 
Red solid, yield: 25.0 mg, 22%. MP.: 189ºC (decomposed). 1H NMR (CDCl3): δ(ppm) 8.17 (s, 
1H, H6), 7.85 (d, 1H, H8, 3J = 7 Hz), 7.62 (d, 2H, H3, 3J = 7 Hz), 7.53 (d, 1H, H11), 7.42 (d, 2H, 
H4, 3J = 6 Hz), 7.26 (t, 1H, H10, 3J = 8 Hz), 7.06 (t, 1H, H9, 3J = 7 Hz), 4.75 (s, 2H, H1), 1.43 (s, 
15H, H14). 13C{1H} NMR (CDCl3): δ(ppm) = 185.39 (C12), 172.29 (C6), 150.31 (C7), 146.31 (C5), 
140.21 (C2), 136.37 (C8), 131.42 (C10), 129.38 (C11), 127.56 (C3), 122.71 (C9), 122.20 (C4), 
96.24 (C13), 64.61 (C1), 8.93 (C14). FT-IR (KBr): 3380 (bs) ν(O-H), 2910 (m) ν(C-HCp*), 1588 (s) 
ν(C=N), 1542 (s) ν(aromatic C=C), 1432 (s) δ(C-H), 1376 δ(-CH3Cp*), 1154 (s) ν(C-O), 1050 
(s) ν(C-O). ESI-MS: m/z 448.11 [M-Cl]+. Elemental Analysis (Calculated for C24H27ClNORh): 
C, 59.58; H, 5.62; N, 2.89; Found: C, 59.59; H, 5.53; N, 2.98. 
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5.3.1.2. 4-(Benzylaldimine)phenylmethanol iridium(III) complex (2.8) 
 
Orange solid, yield: 94.0 mg, 65%. MP.: 184ºC (decomposed). 1H NMR (CDCl3): δ(ppm) 8.30 
(s, 1H, H6), 7.85 (d, 1H, H8, 3J = 8 Hz), 7.57 (d, 2H, H4, 3J = 12 Hz), 7.38 (d, 2H, H3, 3J = 8 Hz), 
7.62 (d, 1H, H11, 3J = 8 Hz), 7.20 (t, 1H, H9, 3J = 8 Hz), 7.03 (t, 1H, H10, 3J = 8 Hz), 4.75 (s, 2H, 
H1), 1.48 (s, 15H, H14). 13C{1H} NMR (CDCl3): δ(ppm) = 175.46 (C6), 170.59 (C12), 151.21 (C5), 
146.93 (C5), 140.03 (C2), 135.13 (C8), 132.48 (C9), 129.59 (C10), 127.46 (C3), 122.65 (C4), 
122.01 (C11), 89.21 (C13), 64.75 (C1), 8.76 (C14). FT-IR (KBr): 3392 (bs) ν(O-H), 2909 (m) ν(C-
HCp*), 1583 (s) ν(C=N), 1536 (s) ν(aromatic C=C), 1499 (s) δ(C-H), 1377 δ(-CH3Cp*), 1153 (s) 
ν(C-O), 1052 (s) ν(C-O). ESI-MS: m/z 538.17 [M-Cl]+. Elemental Analysis (Calculated for 
C24H27ClNOIr): C, 50.29; H, 4.75; N, 2.44; Found: C, 50.43; H, 4.83; N, 2.39. 
 
5.3.2. Synthesis of Mononuclear N,N-Pyridylimine Complexes (2.9-2.11) 
General Procedure 
The ligand 2.2 (83.0 mg, 0.495 mmol for 2.9; 53.0 mg, 0.251 mmol for 2.10 and 69.0 mg, 0.327 
mmol for 2.11) was dissolved in MeOH (20 ml) and reacted with [Rh(η5-C5Me5)Cl2]2 (146 mg, 
0.237 mmol for 2.9) or [Ir(η5-C5Me5)Cl2]2 (100 mg, 0.126 mmol for 2.10) or [Ru(η6-p-
PriC6H4Me)Cl2]2 (100 mg, 163 mmol for 2.11) and stirred for 30 minutes, after which the solvent 
was reduced by rotary evaporation. NaPF6 (83.0 mg, 0.495 mmol for 2.9; 44.0 mg, 0.264 mmol 
for 2.10 and 58.0 mg, 0.343 mmol for 2.11) was added to the concentrated solution, inducing 
the precipitation of the cationic complexes (2.9-2.11) which were filtered and collected using 
a Hirsch funnel. The solids were washed with diethyl ether prior to drying under reduced 
pressure. 
 
Experimental  Chapter 5 
 
117 | P a g e  
 
5.3.2.1. 4-(Pyridylaldimine)phenylmethanol rhodium(III) complex (2.9) 
 
Yellow solid, yield: 238 mg, 99%. MP.: 224ºC (decomposed). 1H NMR ((CD3)2CO): δ(ppm) = 
9.19 (d, 1H, H11, 3J = 8 Hz), 8.95 (s, 1H, H6), 8.43 (t, 1H, H9, 3J = 8 Hz), 8.41 (d, 1H, H8, 3J = 
4 Hz), 8.05 (t, 1H, H10, 3J = 8 Hz), 7.82 (d, 2H, H4, 3J = 8 Hz), 7.66 (d, 2H, H3, 3J = 8 Hz), 4.80 
(d, 2H, H1, 3J = 8 Hz), 4.43 (t, 1H, -OH, 3J = 8 Hz), 1.60 (s, 15H, C13). 13C{1H} NMR ((CD3)2CO): 
δ(ppm) = 166.62 (C6), 154.27 (C7), 152.78 (C11), 147.63 (C5), 144.55 (C2), 140.45 (C9), 129.90 
(C8), 129.80 (C10), 127.37 (C3), 122.41 (C4), 97.61 (C12), 63.07 (C1), 7.96 (C13). 31P{1H} NMR 
(CD3)2CO): δ(ppm) = -144.25 (sep, P-F). FT-IR (KBr): 3387 (bs) ν(O-H), 2918 (m) ν(C-HCp*), 
1598 (s) ν(C=Nimine), 1568 (s) ν(aromatic C=C), 1420 (s) δ(C-H), 1383 δ(-CH3Cp*), 1038 (s) 
ν(C-O). ESI-MS: m/z 485.09 [M-PF6]+. Elemental Analysis (Calculated for 
C23H27ClF6N2OPRh): C, 43.79; H, 4.31; N, 4.44; Found: C, 43.73; H, 4.00; N, 4.60. 
 
5.3.2.2. 4-(Pyridylaldimine)phenylmethanol iridium(III) complex (2.10) 
 
Bright orange solid, yield: 149 mg, 82%. MP.: 215ºC (decomposed). 1H NMR ((CD3)2CO): 
δ(ppm) = 9.35 (s, 1H, H6), 9.19 (d, 1H, H11, 3J = 8 Hz), 8.52 (d, 1H, H8, 3J = 8 Hz), 8.39 (t, 1H, 
H9, 3J = 8 Hz), 8.02 (t, 1H, H10, 3J = 8 Hz), 7.76 (d, 2H, H4, 3J = 8 Hz), 7.64 (d, 2H, H3, 3J = 8 
Hz), 4.79 (d, 2H, H1, 3J = 8 Hz), 4.46 (t, 1H, -OH, 3J = 8 Hz), 1.57 (s, 15H, C13). 13C{1H} NMR 
((CD3)2CO): δ(ppm) = 168.09 (C6), 155.90 (C7), 152.34 (C11), 148.00 (C5), 144.86 (C2), 140.61 
(C9), 130.43 (C10), 129.89 (C8), 127.30 (C3), 122.53 (C4), 90.35 (C12), 62.99 (C1), 7.66 (C13). 
31P{1H} NMR ((CD3)2CO): δ(ppm) = -144.24 (sep, P-F). FT-IR (KBr): 3411 (bs) ν(O-H), 2918 
(m) ν(C-HCp*), 1622 (s) ν(C=Nimine), 1561 (s) ν(aromatic C=C), 1417 (s) δ(C-H), 1387 δ(-
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CH3Cp*), 1035 (s) ν(C-O). ESI-MS: m/z 575.14 [M-PF6]+. Elemental Analysis (Calculated for 
C23H27ClF6IrN2OP): C, 38.36; H, 3.78; N, 3.89; Found: C, 38.07; H, 3.33; N, 3.05. 
 
5.3.2.3. 4-(Pyridylaldimine)phenylmethanol ruthenium(II) complex (2.11) 
 
Yellow solid, yield: 162 mg, 79%. MP.: 201ºC (decomposed). 1H NMR ((CD3)2CO): δ(ppm) = 
9.63 (d, 1H, H11, 3J = 8 Hz), 8.91 (s, 1H, H6), 8.39-8.33 (m, 2H, H9 H10), 7.90 (d, 1H, H8, 3J = 8 
Hz), 7.87 (d, 2H, H3, 3J = 8 Hz), 7.62 (d, 2H, H4, 3J = 8 Hz), 6.11 (d, 1H, H14A, 3J = 8 Hz), 5.77 
(d, 1H, H14B, 3J = 8 Hz), 5.73 (d, 1H, H15A, 3J = 8 Hz), 5.62 (d, 1H, H15B, 3J = 8 Hz), 4.79 (s, 2H, 
H1), 2.77-2.68 (m, 1H, H17), 2.30 (s, 3H, H12), 1.13 (d, 6H, H18, 3J = 4 Hz). 13C{1H} NMR 
((CD3)2CO): δ(ppm) = 167.65 (C6), 156.96 (C11), 156.09 (C7), 152.06 (C5), 145.83 (C2), 140.94 
(C9), 130.96 (C10), 129.93 (C8), 128.33 (C3), 123.42 (C4), 107.52 (C16), 105.15 (C13), 86.42 
(C14A), 86.75 (C14B), 87.37 (C15A), 87.80 (C15B), 63.98 (C1), 32.04 (C17), 22.46 (C18A), 22.29 
(C18B), 19.00 (C12). 31P{1H} NMR ((CD3)2CO): δ(ppm) = -144.21 (sep, P-F). FT-IR (KBr): 3435 
(bs) ν(O-H), 2918 (m) ν(C-Hp-Cy), 1628 (s) ν(C=Nimine), 1602 (s) ν(aromatic C=C), 1420 (s) δ(C-
H), 1389 δ(-CH3p-Cy), 1032 (s) ν(C-O). ESI-MS: m/z 483.08 [M-PF6]+. Elemental Analysis 
(Calculated for C23H26ClF6N2OPRu): C, 43.99; H, 4.17; N, 4.46; Found: C, 43.66; H, 3.88; N, 
4.63. 
 
5.3.3. Synthesis of Mononuclear N,O-Salicylaldiminato Complexes (2.12-2.14) 
General Procedure 
The ligand 2.3 (74.0 mg, 0.326 mmol for 2.12; 57.0 mg, 0.251 mmol for 2.13 and 50.0 mg, 
0.220 mmol for 2.14) was dissolved in MeOH (20 ml) and NaOAc added (28.0 mg, 0.342 mmol 
for 2.12; 22.0 mg, 0.264 mmol for 2.13 and 19.0 mg, 0.285 mmol for 2.14). [Rh(η5-C5Me5)Cl2]2 
(68.0 mg, 0.110 mmol for 2.12) or [Ir(η5-C5Me5)Cl2]2 (100 mg, 0.126 mmol for 2.13) or [Ru(η6-
p-PriC6H4Me)Cl2]2 (100 mg, 163 mmol for 2.14) was added to the solution which was stirred 
for 2 hours, after which the MeOH was removed by rotary evaporation yielding a solid residue. 
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The residue was dissolved in acetone, filtered by gravity and the solvent of the filtrate was 
removed under reduced pressure. The solid products 2.12-2.14 were purified by dissolution 
in a minimal amount of DCM and precipitated using Et2O. 
 
5.3.3.1. 4-(Salicylaldimine)phenylmethanol rhodium(III) complex (2.12) 
 
Red solid, yield: 87.0 mg, 79%. MP.: 185ºC (decomposed). 1H NMR (CDCl3): δ(ppm) 7.90 (s, 
1H, H6), 7.61 (d, 2H, H4, 3J = 8 Hz), 7.44 (d, 2H, H3, 3J = 8 Hz), 7.20-7.15 (m, 2H, H8 H10), 6.74 
(d, 1H, H11, 3J = 8 Hz), 6.37 (t, 1H, H9, 3J = 4Hz), 4.61 (s, 2H, H1), 1.34 (s, 15H, C14). 13C{1H} 
NMR (CDCl3): δ(ppm) = 166.34 (C12), 164.39 (C6), 153.83 (C5), 139.89 (C2), 135.32 (C8), 
135.20 (C10), 127.08 (C3), 124.86 (C4), 124.09 (C11), 114.07 (C9), 93.67 (C13), 64.53 (C1), 8.43 
(C14). FT-IR (KBr): 3280 (bs) ν(O-H), 2961 (m) ν(C-HCp*), 1617 (s) ν(C=N), 1598 (s) ν(aromatic 
C=C), 1446 (s) δ(C-H), 1318 δ(-CH3Cp*), 1153 (s) ν(C-O), 1018 (s) ν(C-O). ESI-MS: m/z 464.11 
[M-Cl]+. Elemental Analysis (Calculated for C24H27ClNO2Rh): C, 57.67; H, 5.44; N, 2.80; 
Found: C, 57.29; H, 5.43; N, 2.38. 
 
5.3.3.2. 4-(Salicylaldimine)phenylmethanol iridium(III) complex (2.13) 
 
Yellow solid, yield: 127 mg, 86%. MP.: 182ºC (decomposed). 1H NMR (CDCl3): δ(ppm) 7.99 
(s, 1H, H6), 7.67 (d, 2H, H4, 3J = 8 Hz), 7.37 (d, 2H, H3, 3J = 8 Hz), 7.33 (t, 1H, H10, 3J = 8 Hz), 
7.10 (d, 1H, H8, 3J = 8 Hz), 6.96 (d, 1H, H11, 3J = 8 Hz), 6.44 (t, 1H, H9, 3J = 8 Hz), 4.74 (s, 2H, 
H1), 1.31 (s, 15H, C14). 13C{1H} NMR (CDCl3): δ(ppm) = 163.95 (C12), 160.94 (C6), 155.02 (C5), 
140.11 (C2), 135.19 (C10), 134.50 (C8), 125.05 (C3), 126.79 (C4), 123.26 (C9), 114.95 (C11), 
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85.75 (C13), 64.46 (C1), 8.46 (C14). FT-IR (KBr): 3373 (bs) ν(O-H), 2918 (m) ν(C-HCp*), 1610 (s) 
ν(C=N), 1591 (s) ν(aromatic C=C), 1443 (s) δ(C-H), 1327 δ(-CH3Cp*), 1150 (s) ν(C-O), 1030 
(s) ν(C-O). ESI-MS: m/z 554.17 [M-Cl]+. Elemental Analysis (Calculated for C24H27ClIrNO2): 
C, 48.93; H, 4.62; N, 2.38; Found: C, 48.64; H, 4.40; N, 2.38. 
 
5.3.3.3. 4-(Salicylaldimine)phenylmethanol ruthenium(II) complex (2.14) 
 
Orange solid, yield: 106 mg, 65%. MP.: 205ºC (decomposed). 1H NMR (CDCl3): δ(ppm) 7.94 
(s, 1H, H6), 7.82 (d, 2H, H4, 3J = 12 Hz), 7.39 (d, 2H, H3, 3J = 8 Hz), 7.23 (t, 1H, H10, 3J = 12 
Hz), 7.05 (d, 1H, H8), 7.00 (d, 1H, H11, 3J = 8 Hz), 6.43 (t, 1H, H9, 3J = 8 Hz), 5.40 (d, 1H, H15A, 
3J = 8 Hz), 5.34 (d, 1H, H15B, 3J = 4 Hz), 5.10 (d, 1H, H16A, 3J = 4 Hz), 4.73 (s, 2H, H1), 4.30 (d, 
1H, H16B, 3J = 8 Hz), 2.56-2.52 (m, 1H, H18), 2.01 (s, 3H, H13), 1.12 (d, 3H, H19A, 3J = 8 Hz), 
1.08 (d, 3H, H19B, 3J = 8 Hz). 13C{1H} NMR (CDCl3): δ(ppm) = 165.37 (C12), 164.40 (C6), 157.41 
(C5), 141.45 (C2), 136.16 (C8), 135.27 (C10), 127.03 (C3), 123.72 (C4), 122.03 (C11), 113.51 
(C9), 100.62 (C17), 97.99 (C14), 86.64 (C15A), 83.44 (C15B), 83.13 (C16A), 81.48 (C16B), 62.94 
(C1), 30.44 (C18), 22.64 (C19A), 21.97 (C19B), 18.50 (C18). FT-IR (KBr): 3412 (bs) ν(O-H), 2984 
(m) ν(C-Hp-Cy), 1612 (s) ν(C=N), 1598 (s) ν(aromatic C=C), 1442 (s) δ(C-H), 1331 δ(-CH3p-Cy), 
1146 (s) ν(C-O), 1017 (s) ν(C-O). ESI-MS: m/z 462.10 [M-Cl]+. Elemental Analysis 
(Calculated for C24H26ClNO2Ru): C, 58.00; H, 5.27; N, 2.82; Found: C, 58.37; H, 5.30; N, 2.81. 
 
5.4. Synthesis of Trinuclear Complexes (2.15-2.22) 
5.4.1. Synthesis of Trinuclear N,C-Benzaldiminato Complexes (2.15-2.16) 
General Procedure 
The ligand 2.4 (71.0 mg, 0.0890 mmol for 2.15 and 66.1 mg, 0.0837 mmol for 2.16) was 
dissolved in MeOH (20 ml) and NaOAc added (23.0 mg, 0.279 mmol for 2.15 and 24.0 mg, 
0.293 mmol for 2.16). [Rh(η5-C5Me5)Cl2]2 (83.3 mg, 0.135 mmol for 2.15) or [Ir(η5-C5Me5)Cl2]2 
(100 mg, 0.126 mmol for 2.16) was added to the solution which was stirred for 2 hours, after 
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which the MeOH was removed by rotary evaporation yielding a solid residue. The residue was 
dissolved in acetone, filtered by gravity and the solvent of the filtrate was removed under 
reduced pressure. The solid products 2.15-2.16 were purified by dissolution in minimal DCM 
and precipitation by Et2O collected using a Hirsch funnel. 
 
5.4.1.1. Tris(4-(benzylaldimine)benzyl)benzene-1,3,5-tricarboxylate rhodium(III) 
complex (2.15) 
 
Red solid, yield: 34 mg, 36%. MP.: 216ºC (decomposed). 1H NMR (CD3Cl3): δ(ppm) = 8.91 
(s, 3H, H1), 8.46 (s, 3H, H9), 7.91 (m, 3H, H11), 7.49 (m, 9H, H7 H12), 7.23 (m, 9H, H6 H13), 7.00 
(m, 3H, H14), 5.42 (s, 6H, H4), 1.62 (s, 45H, C17). 13C{1H} NMR (CD3Cl3): δ(ppm) = 176.61 
(C15), 168.85 (C3),167.68 (C9), 147.96 (C8), 140.42 (C5), 132.06 (C1), 136.73 (C11), 133.63 
(C13), 129.81 (C6), 129.66 (C14), 128.92 (C2), 122.72 (C12), 98.68 (C16), 66.34 (C4), 8.59 (C17). 
FT-IR (KBr): 3029 (m) ν(C-HCp*), 1724 (s) ν(C=O), 1614 (s) ν(C=Nimine), 1578 (s) ν(aromatic 
C=C), 1451 (s) δ(C-H), 1374 δ(-CH3Cp*), 1230 (s) ν(C-C(O)-O). ESI-MS: m/z 500.11 [M-3Cl]3+. 
Elemental Analysis (Calculated for C81H81Cl3N3O6Rh3): C, 60.52; H, 5.08; N, 2.61; Found: C, 
60.61; H, 5.21; N, 2.45. 
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5.4.1.2. Tris(4-(benzylaldimine)benzyl)benzene-1,3,5-tricarboxylate iridium(III) complex 
(2.16) 
 
Pale brown solid, yield: 93 mg, 59%. MP.: 221ºC (decomposed). 1H NMR (CD3Cl3): δ(ppm) = 
8.91 (s, 3H, H1), 8.35 (s, 3H, H9), 7.92 (d, 3H, H11, J = 7 Hz), 7.66 (m, 3H, H7), 7.58 (d, 6H H7, 
J = 8 Hz), 7.40 (d, 6H, H6, J = 5 Hz), 7.32 (m, 3H, H13), 7.22 (m, 3H, H14), 5.39 (s, 6H, H4), 
1.50 (s, 45H, C17). 13C{1H} NMR (CD3Cl3): δ(ppm) = 176.07 (C15), 168.42 (C9), 166.61 (C3), 
149.39 (C8), 141.48 (C5), 133.45 (C1), 138.29 (C11), 132.49 (C13), 129.00 (C6 C14), 128.20 (C2), 
122.28 (C12), 84.84 (C16), 67.91 (C4), 8.37 (C17). FT-IR (KBr): 3091 (m) ν(C-HCp*), 1723 (s) 
ν(C=O), 1613 (s) ν(C=Nimine), 1579 (s) ν(aromatic C=C), 1450 (s) δ(C-H), 1379 δ(-CH3Cp*), 
1231 (s) ν(C-C(O)-O). ESI-MS: m/z 590.16 [M-3Cl]3+. Elemental Analysis (Calculated for 
C81H81Cl3Ir3N3O6): C, 51.87; H, 4.35; N, 2.24; Found: C, 51.99; H, 4.28; N, 2.19. 
 
5.4.2. Synthesis of Trinuclear N,N-Pyridylimine Complexes (2.17-2.19) 
General Procedure 
The ligand 2.5 (100 mg, 0.126 mmol for 2.17; 66.0 mg, 0.0837 mmol for 2.18 and 86.0 mg, 
0.109 mmol for 2.19) was dissolved in DCM and EtOH (50:50, 20 ml) and either 
[Rh(η5-C5Me5)Cl2]2 (121 mg, 0.196 mmol for 2.17) or [Ir(η5-C5Me5)Cl2]2 (100 mg, 0.126 mmol 
for 2.18) or [Ru(η6-p-PriC6H4Me)Cl2]2 (100 mg, 163 mmol for 2.19) was added to the solution, 
which was stirred for 2 hours, after which the solvent was reduced by rotary evaporation. 
NaPF6 (74.0 mg, 0.441 mmol for 2.17; 49.0 mg, 0.293 mmol for 2.18 and 64.0 mg, 0.381 mmol 
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for 2.19) was added to the concentrated solution causing the precipitation of the cationic 
complexes (2.17-2.19) which were filtered and collected using a Hirsch funnel. 
 
5.4.2.1. Tris(4-(pyridylimine)benzyl)benzene-1,3,5-tricarboxylate rhodium(III) complex 
(2.17) 
 
Yellow solid, yield: 75 mg, 29%. MP.: 227ºC (decomposed). 1H NMR ((CD3)2CO): δ(ppm) = 
9.19 (d, 3H, H14, 3J = 4 Hz), 8.95 (s, 3H, H9), 8.94 (s, 3H, H1), 8.40-8.31 (m, 6H, H11 H12), 8.03 
(m, 3H, H13), 7.91 (d, 6H, H7, 3J = 4 Hz), 7.84 (d, 6H, H6, 3J = 4 Hz), 5.61 (s, 6H, H4), 1.57 (s, 
45H, C16).13C{1H} NMR ((CD3)2CO): δ(ppm) = 168.49 (C9), 166.19 (C3), 154.20 (C10), 153.28 
(C14), 148.72 (C8), 140.99 (C12), 137.46 (C5), 133.93 (C1), 130.52 (C11 C13), 129.73 (C6), 128.44 
(C2), 122.88 (C7), 97.60 (C15), 66.91 (C4), 8.76 (C16). 31P{1H} NMR ((CD3)2CO): δ(ppm) = -
144.26 (sep, P-F). FT-IR (KBr): 3090 (m) ν(C-HCp*), 1728 (s) ν(C=O), 1617 (s) ν(C=Nimine), 
1596 (s) ν(aromatic C=C), 1452 (s) δ(C-H), 1377 δ(-CH3Cp*), 1238 (s) ν(C-C(O)-O). ESI-
MS: m/z 537.75 [M-3PF6]3+. Elemental Analysis (Calculated for C78H81Cl3F18N6O6P3Rh3): C, 
45.73; H, 3.99; N, 4.10; Found: C, 45.75; H, 4.08; N, 4.49. 
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5.4.2.2. Tris(4-(pyridylimine)benzyl) benzene-1,3,5-tricarboxylate iridium(III) complex 
(2.18) 
 
Brown solid, yield: 68 mg, 70%. MP.: 221ºC (decomposed). 1H NMR ((CD3)2CO): δ(ppm) = 
9.19 (d, 3H, H14, 3J = 4 Hz), 8.94 (s, 3H, H1), 8.40-8.31 (m, 6H, H11 H12), 8.03 (m, 3H, H13), 
7.91 (d, 6H, H7, 3J = 4 Hz), 7.84 (d, 6H, H6, 3J = 4 Hz), 5.61 (s, 6H, H4), 1.57 (s, 45H, C16). 
13C{1H} NMR ((CD3)2CO): δ(ppm) = 168.49 (C9), 166.19 (C3), 154.20 (C10), 153.28 (C14), 
148.72 (C8), 140.99 (C12), 137.46 (C5), 133.93 (C1), 130.52 (C11 C13), 129.73 (C6), 128.44 (C2), 
123.29 (C7), 97.60 (C15), 66.91 (C4), 8.76 (C16). 31P{1H} NMR ((CD3)2CO): δ(ppm) = -144.26 
(sep, P-F). FT-IR (KBr): 3090 (m) ν(C-HCp*), 1728 (s) ν(C=O), 1617 (s) ν(C=Nimine), 1596 (s) 
ν(aromatic C=C), 1452 (s) δ(C-H), 1377 δ(-CH3Cp*), 1238 (s) ν(C-C(O)-O). ESI-MS: m/z 627.14 
[M-3PF6]3+. Elemental Analysis (Calculated for C78H81F18Ir3N6O6P3): C, 40.44; H, 3.52; N, 
3.63; Found: C, 40.88; H, 3.68; N, 3.40. 
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5.4.2.3. Tris(4-(pyridylimine)benzyl) benzene-1,3,5-tricarboxylate ruthenium(II) complex 
(2.19) 
 
Yellow solid, yield: 86 mg, 77%. MP.: 194ºC (decomposed). 1H NMR ((CD3)2CO): δ(ppm) = 
9.66 (d, 3H, H14, 3J = 4 Hz), 8.99 (s, 3H, H1), 8.97 (s, 3H, H9), 8.38-8.36 (m, 6H, H12 H13), 8.01 
(d, 6H, H6, 3J = 8 Hz), 7.93 (m, 3H, H11), 7.84 (d, 6H, H7, 3J = 8 Hz), 6.14-6.11 (m, 3H, H17A), 
5.82-5.77 (m, 6H, H17B H18A), 5.66 (s, 9H, H18B H4), 2.82 (m, 3H, H20), 2.30 (s, 9H, H22), 1.13 (s, 
18H, H15). 13C{1H} NMR ((CD3)2CO): δ(ppm) = 167.44 (C9), 163.56 (C3), 154.56 (C10), 156.00 
(C14), 149.48 (C8), 139.98 (C12), 138.09 (C5), 134.42 (C1), 130.19 (C13), 129.96 (C2), 129.27 
(C6), 129.10 (C11), 122.91 (C7), 102.80 (C19), 98.68 (C16), 86.90 (C17A), 86.19 (C17B), 85.73 
(C18A), 85.46 (C18B), 66.29 (C4), 31.04 (C20), 21.46 (C22A), 21.28 (C22B), 17.99 (C15). 
31P{1H} NMR ((CD3)2CO): δ(ppm) = -144.20 (sep, P-F). FT-IR (KBr): 2970 (m) ν(C-Hp-Cy), 1729 
(s) ν(C=O), 1611 (m) ν(C=Nimine), 1508 (s) ν(aromatic C=C), 1445 (s) δ(C-H), 1383 δ(-CH3p-
Cy), 1236 (s) ν(C-C(O)-O). ESI-MS: m/z 536.17 [M-3PF6]3+. Elemental Analysis (Calculated 
for C78H78Cl3F18N6O6P3Ru3): C, 45.93; H, 3.85; N, 4.12; Found: C, 46.17; H, 3.66; N, 3.63. 
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5.4.3. Synthesis of Trinuclear N,O-Salicylaldiminato Complexes (2.20-2.22) 
General Procedure 
The ligand 2.6 (90.0 mg, 0.108 mmol for 2.20; 70.1 mg, 0.0837 mmol for 2.21 and 91.0 mg, 
0.109 mmol for 2.22) was dissolved in MeOH (20 ml) and NaOAc added (27.0 mg, 0.329 mmol 
for 2.20; 24.0 mg, 0.239 mmol for 2.21 and 31.0 mg, 0.381 mmol for 2.22). [Rh(η5-C5Me5)Cl2]2 
(100 mg, 0.162 mmol for 2.20) or [Ir(η5-C5Me5)Cl2]2 (100 mg, 0.126 mmol for 2.21) or [Ru(η6-
p-PriC6H4Me)Cl2]2 (100 mg, 163 mmol for 2.22) was added to the solution which was stirred 
for 2 hours, after which the MeOH was removed by rotary evaporation yielding a solid residue. 
The residue was dissolved in acetone, filtered by gravity and the solvent of the filtrate was 
removed under reduced pressure. The solid products 2.20-2.22 were purified by dissolution 
in minimal DCM and precipitation by Et2O. 
 
5.4.3.1. Tris(4-(salicylaldimine)benzyl) benzene-1,3,5-tricarboxylate rhodium(III) 
complex (2.20) 
 
Orange solid, yield: 93 mg, 52%. MP.: 226ºC (decomposed). 1H NMR (CDCl3): δ(ppm) = 8.95 
(s, 3H, H1), 7.96 (s, 3H, H9), 7.90 (d, 6H, H7, 3J = 12 Hz), 7.49 (d, 6H, H6, 3J = 4 Hz), 7.23 (t, 
3H, H12, 3J = 8 Hz), 7.04 (m, 6H, H14H11), 6.43 (t, 3H, H13, 3J = 8 Hz), 5.49 (s, 6H, H4), 1.32 (s, 
45H, C17). 13C{1H} NMR (CDCl3): δ(ppm) = 166.49 (C3), 164.66 (C15), 164.58 (C9), 154.64 (C8), 
135.38 (C11 C12), 134.88 (C1), 134.15 (C5), 131.38 (C2), 128.62 (C6), 124.20 (C14), 119.47 (C10), 
114.19 (C13), 93.64 (C16), 66.82 (C4), 8.44 (C17). FT-IR (KBr): 2961 (m) ν(C-HCp*), 1728 (s) 
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ν(C=O), 1612 (s) ν(C=N), 1600 (s) ν(aromatic C=C), 1463 (s) δ(C-H), 1377 δ(-CH3Cp*), 1231 
(s) ν(C-C(O)-O). ESI-MS: m/z 516.10 [M-3Cl]3+. Elemental Analysis (Calculated for 
C81H81Cl3N3O9Rh3): C, 58.76; H, 4.93; N, 2.54; Found: C, 58.92; H, 4.69; N, 2.30. 
 
5.4.3.2. Tris(4-(salicylaldimine)benzyl) benzene-1,3,5-tricarboxylate iridium(III) complex 
(2.21) 
 
Brown solid, yield: 70 mg, 43%. MP.: 236ºC (decomposed). 1H NMR (CDCl3): δ(ppm) = 8.93 
(s, 3H, H1), 8.01 (s, 3H, H9), 7.75 (d, 6H, H7, 3J = 8 Hz), 7.48 (d, 6H, H6, 3J = 8 Hz), 7.35 (t, 
3H, H13, 3J = 8 Hz), 7.09 (d, 3H, H11, 3J = 8 Hz), 6.97 (d, 3H, H14, 3J = 8 Hz), 6.45 (t, 3H, H12, 
3J = 8 Hz), 5.47 (s, 6H, H4), 1.32 (s, 45H, C17). 13C{1H} NMR (CDCl3): δ(ppm) = 167.55 (C3), 
164.10 (C15), 161.03 (C9), 150.30 (C8), 135.35 (C13), 134.89 (C1), 134.53 (C14), 132.27 (C5), 
131.37 (C2), 128.37 (C6), 123.39 (C11), 120.29 (C10), 115.04 (C12), 85.77 (C16), 66.75 (C4), 8.47 
(C17). FT-IR (KBr): 3051 (m) ν(C-HCp*), 1729 (s) ν(C=O), 1613 (s) ν(C=N), 1602 (s) ν(aromatic 
C=C), 1464 (s) δ(C-H), 1380 δ(-CH3Cp*), 1228 (s) ν(C-C(O)-O). ESI-MS: m/z 605.50 [M-3Cl]3+. 
Elemental Analysis (Calculated for C81H81Cl3Ir3N3O9): C, 50.58; H, 4.24; N, 2.18; Found: C, 
50.94; H, 3.99; N, 2.46. 
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5.4.3.3. Tris(4-(pyridylimine)benzyl) benzene-1,3,5-tricarboxylate ruthenium(II) complex 
(2.22) 
 
Orange solid, yield: 130 mg, 72%. MP.: 166ºC (decomposed). 1H NMR (CDCl3): δ(ppm) = 
8.98 (s, 3H, H1), 7.73 (s, 3H, H9), 7.71 (d, 6H, H7, 3J = 8 Hz), 7.54 (d, 6H, H6, 3J = 8 Hz),7.22 
(t, 3H, H13, 3J = 4 Hz), 6.99 (d, 3H, H11, 3J = 8 Hz), 6.92 (t, 3H, H12, 3J = 8 Hz), 6.42 (d, 3H, H14, 
3J = 4 Hz), 5.63 (d, 3H, H18A, 3J = 4 Hz), 5.41 (d, 3H, H18B, 3J = 4 Hz), 5.03 (d, 3H, H19A, 3J = 4 
Hz), 4.28 (d, 3H, H19B, 3J = 8 Hz), 2.60 (m, 3H, H21), 2.10 (s, 9H, H16), 1.15 (d, 9H, H22A, 3J = 8 
Hz), 1.11 (d, 9H, H22B, 3J = 8 Hz). 13C{1H} NMR (CDCl3): δ(ppm) = 165.40 (C3), 164.74 
(C15),164.46 (C9), 158.56 (C8), 135.73 (C13), 135.57 (C12), 135.00 (C1), 134.18 (C5), 131.38 
(C2), 128.90 (C6), 124.22 (C7), 122.71 (C11), 118.15 (C10), 114.37 (C14), 101.53 (C20), 98.18 
(C17), 83.31 (C18A), 80.50 (C18B), 78.96 (C19A), 78.08 (C19B), 66.86 (C4), 30.38 (C20), 22.71 
(C22A), 21.70 (C22B), 18.49 (C16). FT-IR (KBr): 2966 (m) ν(C-Hp-Cy), 1728 (s) ν(C=O), 1614 (m) 
ν(C=N), 1602 (s) ν(aromatic C=C), 1443 (s) δ(C-H), 1383 δ(-CH3p-Cy), 1231 (s) ν(C-C(O)-O). 
ESI-MS: m/z 514.10 [M-3Cl]3+. Elemental Analysis (Calculated for C81H78Cl3N3O9Ru3): C, 
59.07; H, 4.77; N, 2.55; Found: C, 58.89; H, 4.61; N, 2.60. 
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5.5. Synthesis of Alkylated PTA Ligands (3.1-3.2) 
5.5.1. Preparation of Monomeric Ligand (3.1) 
1-Benzyl-1,3,5-triaza-7-phosphaadamantan-1-ium chloride was prepared using known 
literature reported procedures.[5] 
 
5.5.2.  Synthesis of Trimeric Ligand (3.2) 
5.5.2.1. 1,3,5-tris(chloromethyl)benzene 
1,3,5-tris(chloromethyl)benzene was synthesized using known literature reported 
procedures.[6] 
 
5.5.2.2. 1,1',1''-(benzene-1,3,5-triyltris(methylene))tris(1,3,5-triaza-7-
phosphaadamantan-1-ium) chloride (3.2) 
 
1,3,5-tris(chloromethyl)benzene (99.9 mg, 0.447 mmol) was dissolved in acetone (10 ml) and 
excess PTA (281 mg, 1.79 mmol) was added. The reaction was refluxed overnight. A beige 
solid was isolated by suction filtration and washed with THF and DCM.  
Beige solid, yield: 302 mg, 97%. MP.: 180.2ºC (decomposed). 1H NMR (D2O): δ = 7.95 (s, 
3H, H1), 5.07-5.17 (12H, H4 N+CH2N), 4.78 (d, 2J = 12 Hz, 6H, H5 NCH2N), 4.47 (d, 2J = 3 Hz, 
6H, H6 N+CH2P), 4.38 (s, 6H, H3), 3.93-4.08 (m, 12H, H7 NCH2P). 13C NMR (D2O): δ = 139.38 
(C1), 127.67 (C1), 79.18 (C4 N+CH2N), 69.46 (C5 NCH2N), 65.23 (C3), 52.93 (d, JP-C = 24 Hz, 
C6 N+CH2P), 45.61 (d, JP-C = 14 Hz, C7 NCH2P). 31P NMR (D2O): δ = -82.07. HR-ESI-MS(+): 
196.0998 [M-3Cl]3+. Elemental Analysis (Calculated for C27H45Cl3N9P3.3H2O): C, 43.30; H, 
6.86; N, 16.83; Found: C, 43.03; H, 6.83; N, 16.88. S20oC = 44 mg/ml H2O. 
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5.5.3. Synthesis of Mononuclear Alkylated PTA Complexes (3.3-3.5) 
General Procedure 
3.1 (50.0 mg, 0.176 mmol for 3.3 and 3.4) was dissolved in EtOH (10 ml). [Rh(η5-C5Me5)Cl2]2 
(54.4 mg, 0.0881 mmol for 3.3) or [Ir(η5-C5Me5)Cl2]2 (70.2 mg, 0.0881 mmol for 3.4) was then 
added and stirred for 3 hours, filtered by gravity and then the filtrate removed under reduced 
pressure. Precipitation from MeOH/Et2O yielded the solid products 3.3-3.4. 
 
5.5.4. Mononuclear alkylated PTA rhodium(III) complex (3.3) 
 
Red solid. Yield: 90 mg, 57%. MP.: 167.4-169.8oC. 1H NMR (D2O): δ = 7.52-7.59 (m, 5H, H1-
H4), 4.98-5.18 (4H, H6 N+CH2N), 4.70 (d, 2J = 13 Hz, 1H, H7 NCH2N), 4.47 (d, 2J = 4 Hz, 2H, 
H8 N+CH2P), 4.38 (d, 2J = 6 Hz, 1H, H7 NCH2N), 4.34 (d, 2J = 2 Hz, 2H, H5), 4.16-4.51 (4H, H9 
NCH2P), 1.72 (d, JRh-H = 4 Hz, 15H, H11). 13C{1H} NMR (D2O): δ = 132.88 (C3), 131.33 (C1), 
129.60 (C2), 124.20 (C4), 101.95 (C10), 79.28 (C6 N+CH2N), 69.38 (C7 NCH2N), 66.47 (C5), 
51.48 (d, JP-C = 13 Hz, C8 N+CH2P), 46.08 (d, JP-C = 14 Hz, C9 NCH2P), 9.00 (C11). 31P{1H} 
NMR (D2O): δ = -24.63 (JRh-P = 150 Hz). HR-ESI-MS(+): m/z = 558.0898 [M-Cl]+. Elemental 
Analysis (Calculated for C23H34Cl3N3PRh.3H2O): C, 42.71; H, 6.23; N, 6.50; Found: C, 42.32; 
H, 6.29; N, 6.32. S20oC = 21 mg/ml H2O. 
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5.5.5. Mononuclear alkylated PTA iridium(III) complex (3.4) 
 
Yellow solid. Yield: 105 mg, 55%. MP.: 178.2-180.4oC. 1H NMR (D2O): δ = 7.54-7.60 (m, 5H, 
H1-H4), 4.98-5.22 (4H, H6 N+CH2N), 4.51-4.69 (2H, H7 NCH2N), 4.48 (d, 2J = 5 Hz, 2H, H8 
N+CH2P), 4.38 (d, 2J = 2 Hz, 2H, H5), 4.13-4.34 (4H, H9 NCH2P), 1.77 (d, JH-P = 4 Hz, 15H, 
H11) . 13C{1H} NMR (D2O): δ = 134.21 (C3), 132.30 (C1), 130.77 (C2), 126.38 (C4), 95.65 (C10), 
81.19 (C6 N+CH2N), 71.06 (C7 NCH2N), 66.90 (C5), 51.85 (d, JP-C = 22 Hz, C8 N+CH2P), 46.82 
(d, JP-C = 22 Hz, C9 NCH2P), 9.50 (C11). 31P{1H} NMR (D2O): δ = -48.77. HR-ESI-MS(+): 
646.1473 [M-Cl]+. Elemental Analysis (Calculated for C23H34Cl3IrN3P.3H2O): C, 37.53; H, 
5.48; N, 5.71; Found: C, 37.21; H, 5.49; N, 5.46. S20oC = 16 mg/ml H2O. 
 
5.5.6. Mononuclear alkylated PTA ruthenium(II) complex (3.5) 
The mononuclear alkylated PTA ruthenium(II) complex was synthesized using known 
literature reported procedures.[7] 
 
5.6. Synthesis of Trinuclear Complexes (3.6-3.8) 
General Procedure 
3.2 (50.0 mg, 0.0719 mmol for 3.6-3.8) was dissolved in a mixture of MeOH (5 ml) and DCM 
(5 ml). [Rh(η5-C5Me5)Cl2]2 (66.7 mg, 0.108 mmol for 3.6) or [Ir(η5-C5Me5)Cl2]2 (86.0 mg, 0.108 
mmol for 3.7) or [Ru(η6-p-PriC6H4Me)Cl2]2 (66.0 mg, 0.108 mmol for 3.8) was then added and 
stirred for 3 hours, filtered by gravity and then the filtrate removed under reduced pressure. 
Precipitation from MeOH/Et2O yielded the solid products 3.6-3.8. 
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5.6.1. Trinuclear alkylated PTA rhodium(III) complex (3.6) 
 
Red solid. Yield: 85 mg, 46%. MP.: 212.18ºC (decomposed). 1H NMR (D2O): δ = 7.87 (s, 3H, 
H1), 5.06-5.26 (12H, H4 N+CH2N), 4.96 (d, JH-P = 12 Hz, 6H, H5 NCH2N), 4.53 (d, JH-P = 9 Hz, 
6H, H6 N+CH2P), 4.43 (s, 6H, H3), 4.18-4.31 (12H, H7 NCH2P), 1.71 (s, 45H, H9). 13C{1H} NMR 
(D2O): δ = 143.72 (C1), 126.53 (C2), 102.02 (C8), 80.62 (C4 N+CH2N), 69.27 (C5 NCH2N), 65.02 
(C3), 49.45 (d, JP-C = 24 Hz, C6 N+CH2P), 45.82 (d, JP-C = 16 Hz, C7 NCH2P), 9.06 (d, J = 10 
Hz, C9). 31P{1H} NMR (D2O): δ = -22.89 (JRh-P = 151 Hz). HR-ESI-MS(+): 478.0514 [M-
5Cl+2H]3+. Elemental Analysis (Calculated for C57H90Cl9N9P3Rh3.8H2O): C, 38.76; H, 6.05; 
N, 7.14; Found: C, 38.73; H, 5.67; N, 6.78. S20oC = 12 mg/ml H2O. 
 
5.6.2. Trinuclear alkylated PTA iridium(III) complex (3.7) 
 
Yellow solid. Yield: 110 mg, 50%. MP.: 231.5ºC (decomposed). 1H NMR (D2O): δ = 7.91 (s, 
3H, H1), 5.07-5.28 (12H, H4 N+CH2N), 4.64 (6H, H5 NCH2N), 4.52 (d, JH-P = 17 Hz, 6H, H6 
N+CH2P), 4.32 (s, 6H, H3), 4.15-4.32 (d, JH-P = 11 Hz, 12H, H7 NCH2P), 1.74 (s, 45H, H9). 
13C{1H} NMR (D2O): δ = 143.72 (C1), 126.53 (C2), 95.32 (C8), 80.70 (C4 N+CH2N), 69.48 (C5 
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NCH2N), 65.03 (C3), 49.31 (d, JP-C = 24 Hz, C6 N+CH2P), 45.12 (d, JP-C = 10 Hz, C7 NCH2P), 
8.73 (C9). 31P{1H} NMR (D2O): δ = -46.52. HR-ESI-MS(+): 570.1178 [M-5Cl+2H]3+. Elemental 
Analysis (Calculated for C57H90Cl9N9P3Ir3.7H2O): C, 33.96; H, 5.20; N, 6.25; Found: C, 33.89; 
H, 5.17; N, 6.15. S20oC = 3 mg/ml H2O. 
 
5.6.3. Trinuclear alkylated PTA ruthenium(II) complex (3.8) 
 
Orange solid. Yield: 65 mg, 36%. MP.: 204.4ºC (decomposed). 1H NMR (D2O): δ = 7.80 (s, 
3H, H1), 5.86-5.92 (m, 12H, H10 H11), 5.02-5.24 (12H, H4 N+CH2N), 4.63 (6H, H5 NCH2N), 4.54 
(d, JH-P = 11 Hz, 6H, H6 N+CH2P), 4.29-4.93 (m, 18H, H3 H7 NCH2P), 2.61 (m, 3H, H13), 2.04 
(s, 9H, H8), 1.20 (d, 3J = 7 Hz, H14). 13C{1H} NMR (D2O): δ = 139.82 (C1), 127.67 (C1), 108.32 
(C12), 99.23 (C9), 89.04 (C10), 86.57 (C11), 80.57 (C4 N+CH2N), 69.11 (C5 NCH2N), 64.48 (C3), 
55.64 (d, JP-C = 15 Hz, C6 N+CH2P), 48.01 (d, JP-C = 17 Hz, C7 NCH2P), 30.78 (C13), 21.33 
(C14), 17.93 (C8). 31P{1H} NMR (D2O): δ = -82.07. HR-ESI-MS(+): 480.0599 [M-5Cl+2H]3+. 
Elemental Analysis (Calculated for C57H87Cl9N9P3Ru3.7H2O): C, 39.35; H, 5.85; N, 7.25; 
Found: C, 39.22; H, 6.06; N, 7.45. S20oC = 8 mg/ml H2O. 
 
5.7. Preparation of Monomeric and Trimeric Sulfonated Ligands (4.1 and 4.4) 
5.7.1.  5-Sulfonato propylsalicylaldimine (4.1) 
The monomeric ligand 5-sulfonato propylsalicylaldimine was synthesized using known 
literature reported procedures.[8] 
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5.7.2.  Tris-2-(5-sulfinatosalicylaldimine ethyl)amine (4.4) 
The trimeric ligand tris-2-(5-sulfinatosalicylaldimine ethyl)amine was synthesized using known 
literature reported procedures.[8] 
 
5.8. Preparation of Anionic Sulfonated Complexes (4.2-4.3 and 4.5-4.6) 
5.8.1.  Anionic Mononuclear Complexes (4.2-4.3) 
General Procedure 
4.1 (44.7 mg, 0.169 mmol for 4.2; 60.0 mg, 0.226 mmol for 4.3) was dissolved in EtOH (10 
ml). 1.1 molar equivalents of NaOAc (15.2 mg, 0.185 mmol for 4.2; 20.4 mg, 0.249 mmol for 
4.3) was added and stirred for 30 minutes. [Rh(η5-C5Me5)Cl2]2 (67.1 mg, 0.0843 mmol for 4.2) 
or [Ir(η5-C5Me5)Cl2]2 (76.9 mg, 0.124 mmol for 4.3) was then dissolved into the solution which 
was stirred overnight. The solution was then filtered by gravity and then the solvent of the 
filtrate removed using rotary evaporation. The solid residue was dissolved in DCM and filtered 
by gravity, after which the DCM was reduced and precipitation from MeOH/Et2O yielded the 
solid products 4.2-4.3. 
 
5.8.1.1. Mononuclear sulfonated rhodate(III) complex (4.2) 
 
Red solid. Yield: 72.0 mg, 59%. MP.: 247.1ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.02 
(s, 1H, H4), 7.45 (d, 1H, J = 2 Hz, H6), 7.38 (dd, 1H, J = 2 Hz, J = 9 Hz, H9), 6.61 (d, 1H, J = 9 
Hz, H8), 3.86 (t, 1H, J = 6 Hz, H3), 1.45 (m, 17H, H2 H12), 0.86 (t, 3H, J = 7 Hz, H1). 13C{1H} 
NMR ((CD3)2SO): δ = 166.01 (C7), 165.68 (C10), 163.58 (C4), 131.96 (C9), 131.55 (C6), 121.48 
(C8), 115.94 (C5), 92.60 (C11), 65.63 (C3), 23.45 (C2), 11.26 (C1), 8.22 (C11). FT-IR (ATR): 1623 
ν(C=Nimine). HR-ESI-MS(+): 502.0545 [M-Cl]+, 480.0714 [M-Cl-Na+H]+; HR-ESI-MS(-): 
514.0308 [M-Na]-, 478.0526 [M-Cl-Na-H]-. Elemental Analysis (Calculated for C-
20H26ClNNaO4RhS.1H2O): C, 43.22; H, 5.08; N, 2.52; S, 5.77; Found: C, 43.49; H, 5.26; N, 
2.61; S, 5.58. 
 
Experimental  Chapter 5 
 
135 | P a g e  
 
5.8.1.2. Mononuclear sulfonated iridate(III) complex (4.3) 
 
Yellow/brown solid. Yield: 71.2 mg, 67%. MP.: 210.9ºC (decomposed). 1H NMR ((CD3)2SO): 
δ = 8.05 (s, 1H, H4), 7.48 (d, 1H, J = 4 Hz, H6), 7.42 (d, 1H, J = 2 Hz, H9), 6.57 (d, 1H, J = 8 
Hz, H8), 3.92 (t, 1H, J = 7 Hz, H3), 1.47 (m, 17H, H2 H12), 0.88 (t, 3H, J = 7 Hz, H1). 13C{1H} 
NMR ((CD3)2SO): δ = 174.73 (C7), 164.12 (C10), 160.67 (C4), 131.50 (C9), 131.29 (C6), 120.43 
(C8), 114.07 (C5), 84.45 (C11), 68.42 (C3), 23.40 (C2), 11.16 (C1), 8.36 (C11). FT-IR (ATR): 1621 
ν(C=Nimine). HR-ESI-MS(+): 593.1130 [M-Cl]+, 570.1277 [M-Cl-Na+H]+; HR-ESI-MS(-): 
604.0961 [M-Na]-, 568.1196 [M-Cl-Na-H]-. Elemental Analysis (Calculated for 
C20H26ClIrNNaO4S.4H2O): C, 34.36; H, 4.90; N, 2.00; S, 4.59; Found: C, 34.16; H, 4.93; N, 
2.13; S, 4.80. 
 
5.8.2. Trinuclear Anionic Complexes (4.5-4.6) 
General Procedure 
4.4 (60.0 mg, 0.0768 mmol for 4.5; 39.2 mg, 0.0502 mmol for 4.6) was dissolved in EtOH (10 
ml). Excess NaOAc (20.8 mg, 0.0.254 mmol for 4.5; 12.8 mg, 0.156 mmol for 4.6) was added 
and stirred for 30 minutes. [Rh(η5-C5Me5)Cl2]2 (78.4 mg, 0.127 mmol for 4.5) or 
[Ir(η5-C5Me5)Cl2]2 (60.0 mg, 0.0753 mmol for 4.6) was then dissolved into the solution which 
was stirred overnight. The solution was then filtered by gravity and then the solvent of the 
filtrate removed using rotary evaporation. The solid residue was dissolved in DCM and filtered 
by gravity, after which the DCM was reduced and precipitation from MeOH/Et2O yielded the 
solid products 4.5-4.6. 
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5.8.2.1. Trinuclear sulfonated rhodate(III) complex (4.5) 
 
Red solid. Yield: 40.0 mg, 33%. MP.: 281.0ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.17 
(s, 3H, H3), 7.44 (m, 6H, H5 H8), 6.66 (d, J3 = 9 Hz, 3H, H6), 4.00 (m, 6H, H1), 1.43 (s, 51H, H2 
H11. 13C{1H} NMR ((CD3)2SO): δ = 171.90 (C6), 165.10 (C3), 132.03 (C7), 131.77 (C5), 121.75 
(C8), 119.21 (C4), 98.75 (C10), 62.11 (C1), 55.52 (C2), 8.53 (C11). FT-IR (ATR): 1618 ν(C=Nimine). 
HR-ESI-MS(+): 505.2332 [M-3Na+6H]3+, 373.1396 [M-3Cl+Na]4+. Elemental Analysis 
(Calculated for C57H69Cl3N4Na3O12Rh3S3.4H2O): C, 41.38; H, 4.69; N, 3.39; S, 5.81; Found: C, 
41.45; H, 4.73; N, 3.21; S, 5.69. 
 
5.8.2.2. Trinuclear sulfonated iridate(III) complex (4.6) 
 
Yellow/brown solid. Yield: 55.0 mg, 59%. MP.: 212.7ºC (decomposed). 1H NMR ((CD3)2SO): 
δ = 8.10 (s, 3H, H3), 7.47 (m, 6H, H5 H8), 6.58 (d, J3 = 9 Hz, 3H, H6), 4.33 (m, 6H, H1), 1.42 (s, 
51H, H2 H11). 13C{1H} NMR ((CD3)2SO): δ = 173.92 (C6), 164.49 (C9), 162.20 (C3), 131.60 (C7), 
131.21 (C5), 120.67 (C8), 119.99 (C4), 162.20 (C3), 84.41 (C10), 64.54 (C1), 55.67 (C2), 8.35 
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(C11). FT-IR (ATR): 1617 ν(C=Nimine). HR-ESI-MS(+): 583.1314 [M-3Cl]3+, 441.0615 [M-
3Cl+Na]4. Elemental Analysis (Calculated for C57H69Cl3Ir3N4Na3O12S3.3H2O): C, 35.95; H, 
3.97; N, 2.94; S, 5.05; Found: C, 36.06; H, 4.08; N, 2.87; S, 4.95. 
 
5.9. Preparation of Sulfonated Complexes (4.7-4.22) 
5.9.1. Mononuclear Sulfonated Complexes (4.7-4.14) 
General Procedure 
4.1 (36.7 mg, 0.138 mmol for 4.7-4.10; 40.0 mg, 0.151 mmol for 4.11-4.14) was dissolved in 
EtOH (10 ml). 3.3 molar equivalents of NaOAc (12.5 mg, 0.152 mmol for 4.7-4.10; 13.6 mg, 
0.166 mmol for 4.11-4.14) was added and stirred for 30 minutes. [Rh(η5-C5Me5)Cl2]2 (47.0 mg, 
0.0760 mmol for 4.7-4.10;) or [Ir(η5-C5Me5)Cl2]2 (66.1 mg, 0.0.829 mmol for 4.11-4.14) was 
then dissolved into the solution which was stirred overnight. Pyridine (12.0 mg, 0.152 mmol 
for 4.7; 13.1 mg, 0.166 mmol for 4.11), or 4-methylpyridine (14.2 mg, 0.152 mmol for 4.8; 15.4 
mg, 0.166 mmol for 4.12), or 4-phenylpyridine (23.6 mg, 0.152 mmol for 4.9; 25.7 mg, 0.166 
mmol for 4.13) or 4-ferrocenylpyridine (40.0 mg, 0.152 mmol for 4.10; 43.6 mg, 0.166 mmol 
for 4.14) was then added and stirred for 2 hours. NaBPh4 (52.0 mg, 0.152 mmol for 4.7-4.10; 
56.8 mg, 0.166 mmol for 4.11-4.14) was then added. The solution was then filtered by gravity 
and then the solvent of the filtrate removed using rotary evaporation. The solid residue was 
dissolved in DCM and filtered by gravity, after which iPrOH was added and the solvent was 
reduced and precipitation occurred to yield the solid products 4.7-4.10 and 4.11-4.14 which 
were dried under vacuum. 
 
5.9.1.1. Mononuclear sulfonated rhodium(III) pyridyl complex (4.7) 
 
Red solid. Yield: 55.1 mg, 44%. MP.: 151.4ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.63 
(d, 2H, J = 5 Hz, H13), 8.28 (s, 1H, H4), 7.95 (m, 1H, H15), 7.58 (d, 1H, J = 2 Hz, H6), 7.52 (dd, 
1H, J = 9 Hz, J = 2 Hz, H9), 7.50 (m, 2H, H14), 7.18 (m, 8H, H17), 6.92 (t, 8H, J = 8 Hz, H18), 
6.86 (d, 1H, J = 9 Hz, H8), 6.79 (t, 4H, J = 7 Hz, H19), 3.95 (m, 2H, H3), 1.49 (m, 17H, H2 H12), 
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0.81 (t, 3H, J = 7 Hz, H1). 13C{1H} NMR ((CD3)2SO): δ = 165.94 (C4), 164.06 (C16A), 163.57 
(C16B), 163.08 (C16C 4), 162.59 (C16D), 150.36 (C13), 137.70 (C15), 135.49 (C17), 132.51 (C9), 
132.44 (C6), 125.22 (C14), 125.20 (C18), 121.66 (C8), 121.44 (C19), 115.18 (C5), 95.08 (C11), 
61.97 (C3), 23.72 (C2), 10.83 (C1), 7.98 (C12). FT-IR (ATR): 1621 ν(C=Nimine). HR-ESI-MS(+): 
480.0728 [M-BPh4-NC5H5-Na+H]+; HR-ESI-MS(-): 478.0545 [M-BPh4-NC5H5-Na-H]-. 
Elemental Analysis (Calculated for C49H51BN2NaO4RhS.2½H2O): C, 62.23; H, 5.97; N, 2.96; 
S, 3.39; Found: C, 62.13; H, 6.01; N, 2.82; S, 3.32. 
 
5.9.1.2. Mononuclear sulfonated rhodium(III) 4-methylpyridyl complex (4.8) 
 
Red solid. Yield: 78.2 mg, 62%. MP.: 165.1ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.47 
(d, 2H, J = 6 Hz, H13), 8.27 (s, 1H, H4), 7.56 (s, 1H, H6), 7.51 (dd, 1H, J = 9 Hz, J = 2 Hz, H9), 
7.40 (m, 2H, H14), 7.21 (m, 8H, H18), 6.93 (t, 8H, J = 7 Hz, H19), 6.86 (d, 1H, J = 9 Hz, H8), 6.80 
(t, 4H, J = 7 Hz, H20), 3.94 (m, 2H, H3), 2.38 (s, 3H, H16), 1.49 (m, 17H, H2 H12), 0.83 (t, 3H, J 
= 7 Hz, H1). 13C{1H} NMR ((CD3)2SO): δ = 165.89 (C4), 164.05 (C17A), 163.56 (C17B), 163.06 
(C17C), 162.57 (C17D), 149.46 (C13), 135.47 (C18), 132.47 (C9), 132.39 (C6), 126.45 (C14), 125.18 
(C19), 121.63 (C8), 121.42 (C20), 94.97 (C11), 61.95 (C3), 23.75 (C2), 20.40 (C16), 10.83 (C1), 
7.98 (C12). FT-IR (ATR): 1619 ν(C=Nimine). HR-ESI-MS(+): 480.0709 [M-BPh4-NC5H4CH3-
Na+H]+; HR-ESI-MS(-): 478.0551 [M-BPh4-NC5H4CH3-Na-H]-. Elemental Analysis 
(Calculated for C50H53BN2NaO4RhS.2½H2O): C, 62.57; H, 6.09; N, 2.92; S, 3.34; Found: C, 
62.54; H, 6.23; N, 2.96; S, 3.26. 
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5.9.1.3. Mononuclear sulfonated rhodium(III) 4-phenylpyridyl complex (4.9) 
 
Red solid. Yield: 80.9 mg, 60%. MP.: 152.6ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.67 
(d, 2H, J = 6 Hz, H13), 8.27 (s, 1H, H4), 7.88 (m, 2H, H14), 7.84 (d, 2H, H17), 7.54 (m, 4H, H19 
H18 H9), 7.10 (m, 8H, H21), 6.92 (t, 8H, J = 8 Hz, H22), 6.89 (d, 1H, J = 9 Hz, H8), 6.79 (t, 4H, J 
= 7 Hz, H23), 3.96 (m, 2H, H3), 1.51 (m, 17H, H2 H12), 0.81 (t, 3H, J = 7 Hz, H1). 13C{1H} NMR 
((CD3)2SO): δ = 165.94 (C4), 164.06 (C16A), 163.57 (C16B), 163.08 (C16C 4), 162.60 (C16D), 
150.79 (C13), 135.97 (C19), 135.49 (C21), 132.51 (C9), 132.45 (C6), 129.30 (C18), 126.93 (C17), 
125.22 (C22), 121.70 (C8 C14), 121.44 (C23), 115.18 (C5), 95.09 (C11), 61.97 (C3), 23.71 (C2), 
10.81 (C1), 8.00 (C12). FT-IR (ATR): 1610 ν(C=Nimine). HR-ESI-MS(+): 480.0717 [M-BPh4-
NC5H4Ph-Na+H]+; HR-ESI-MS(-): 478.0512 [M-BPh4-NC5H4Ph-Na-H]-. Elemental Analysis 
(Calculated for C55H55BN2NaO4RhS.2H2O): C, 65.22; H, 5.87; N, 2.77; S, 3.17; Found: C, 
65.18; H, 5.85; N, 2.70; S, 3.28. 
 
5.9.1.4. Mononuclear sulfonated rhodium(III) 4-ferrocenylpyridyl complex (4.10) 
 
Red solid. Yield: 81.3 mg, 54%. MP.: 170.1ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.41 
(d, 2H, J = 5 Hz, H13), 8.26 (s, 1H, H4), 7.69 (m, 2H, H14), 7.59 (s, 1H, H6), 7.54 (d, 2H, H9), 
7.18 (m, 8H, H21), 6.92 (t, 8H, J = 7 Hz, H22), 6.87 (d, 1H, J = 9 Hz, H8), 6.79 (t, 4H, J = 7 Hz, 
H23), 5.02 (m, 2H, H17), 4.57 (m, 2H, H18), 4.03 (m, 7H, H19 H3), 1.50 (m, 17H, H2 H12), 0.75 (t, 
3H, J = 7 Hz, H1). 13C{1H} NMR ((CD3)2SO): δ = 165.94 (C4), 164.06 (C16A), 163.57 (C16B), 
163.08 (C16C 4), 162.60 (C16D), 150.79 (C13), 135.97 (C19), 135.49 (C21), 132.51 (C9), 132.45 
(C6), 129.30 (C18), 126.93 (C17), 125.22 (C22), 121.70 (C8 C14), 121.44 (C23), 115.18 (C5), 95.09 
(C11), 61.97 (C3), 23.71 (C2), 10.81 (C1), 8.00 (C12). FT-IR (ATR): 1609 ν(C=Nimine). HR-ESI-
MS(+): 743.1104 [M-BPh4-Na+H]+, 480.0713 [M-BPh4-NC5H4Fc-Na+H]+; HR-ESI-MS(-): 
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478.0512 [M-BPh4-NC5H4Fc-Na-H]-. Elemental Analysis (Calculated for C-
59H59BFeN2NaO4RhS.2½H2O): C, 62.72; H, 5.71; N, 2.48; S, 2.84; Found: C, 62.73; H, 5.76; 
N, 2.58; S, 2.71. 
 
5.9.1.5. Mononuclear sulfonated iridium(III) pyridyl complex (4.11) 
 
Yellow solid. Yield: 90.4 mg, 60%. MP.: 174.7ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.65 
(m, 2H, H13), 8.34 (s, 1H, H4), 7.95 (m, 1H, H15), 7.65 (s, 1H, H6), 7.59 (dd, 1H, J = 9 Hz, J = 2 
Hz, H9), 7.54 (m, 2H, H14), 7.18 (m, 8H, H17), 6.92 (t, 8H, J = 7 Hz, H18), 6.85 (m, 1H, H8), 6.79 
(t, 4H, J = 7 Hz, H19), 3.95 (m, 2H, H3), 1.53 (m, 17H, H2 H12), 0.86 (m, 3H, H1). 13C{1H} NMR 
((CD3)2SO): δ = 163.82 (C16A), 163.66 (C4), 163.50 (C16B), 163.17 (C16C 4), 162.84 (C16D), 
150.30 (C13), 137.31 (C15), 135.50 (C17), 132.77 (C9), 131.99 (C6), 125.24 (C18 C14), 120.94 
(C8), 121.46 (C19), 115.43 (C5), 87.18 (C11), 69.71 (C3), 23.47 (C2), 10.75 (C1), 8.03 (C12). FT-
IR (ATR): 1618 ν(C=Nimine). HR-ESI-MS(+): 570.1290 [M-BPh4-NC5H4-Na+H]+, 647.2484 [M-
BPh4-Na+H]+; HR-ESI-MS(-): 663.3276 [M-BPh4-Na-H]-. Elemental Analysis (Calculated for 
C49H51BIrN2NaO4S.3H2O): C, 56.37; H, 5.50; N, 2.68; S, 3.07; Found: C, 56.35; H, 5.70; N, 
2.65; S, 3.04. 
 
5.9.1.6. Mononuclear sulfonated iridium(III) 4-methylpyridyl complex (4.12) 
 
Yellow solid. Yield: 77.2 mg, 51%. MP.: 185.6ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.50 
(m, 2H, H13), 8.30 (s, 1H, H4), 7.61 (s, 2H, H6), 7.59 (d, 1H, J = 9 Hz, H9), 7.43 (m, 2H, H14), 
7.18 (m, 8H, H18), 6.92 (t, 8H, J = 7 Hz, H19), 6.85 (d, 1H, J = 7 Hz, H8), 6.79 (t, 4H, J = 7 Hz, 
H20), 3.94 (m, 2H, H3), 2.38 (s, 3H, H16), 1.50 (m, 17H, H2 H12), 0.84 (m, 3H, H1). 13C{1H} NMR 
((CD3)2SO): δ = 163.82 (C17A), 163.50 (C17B), 163.44 (C4), 163.17 (C17C), 162.84 (C17D), 150.06 
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(C13), 135.50 (C18), 132.68 (C9), 131.87 (C6), 127.44 (C14), 125.23 (C19), 120.81 (C8), 121.46 
(C20), 115.18 (C5), 86.75 (C11), 67.02 (C3), 23.77 (C2), 20.43 (C16), 10.73 (C1), 8.03 (C12). FT-
IR (ATR): 1618 ν(C=Nimine). HR-ESI-MS(+): 570.1274 [M-BPh4-NC5H5CH3-Na+H]+; (ESI-): 
568.1215 [M-BPh4-NC5H4CH3-Na-H]-, 682.1128 [M-BPh4-2H]-. Elemental Analysis 
(Calculated for C50H53BIrN2NaO4S.3H2O): C, 56.76; H, 5.62; N, 2.65; S, 3.03; Found: C, 56.77; 
H, 5.65; N, 2.65; S, 3.19. 
 
5.9.1.7. Mononuclear sulfonated iridium(III) 4-phenylpyridyl complex (4.13) 
 
Yellow solid. Yield: 102.0 mg, 63%. MP.: 179.9ºC (decomposed). 1H NMR ((CD3)2SO): δ = 
8.89 (m, 2H, H13), 8.36 (s, 1H, H4), 7.95 (m, 1H, H19), 7.85 (d, 2H, J = 6 Hz, H17), 7.66 (s, 1H, 
H6), 7.60 (dd, J = 9 Hz, J = 2 Hz, 2H, H14), 7.55 (m, 3H, H9 H18), 7.18 (m, 8H, H21), 6.92 (t, 8H, 
J = 8 Hz, H22), 6.85 (d, 1H, J = 9 Hz, H8), 6.79 (t, 4H, J = 7 Hz, H23), 3.93 (m, 2H, H3), 1.55 (m, 
17H, H2 H12), 0.86 (m, 3H, H1). 13C{1H} NMR ((CD3)2SO): δ = 164.06 (C16A), 163.80 (C4), 
163.55 (C16B), 163.06 (C16C), 162.57 (C16D), 150.55 (C13), 135.46 (C21), 132.79 (C19), 129.25 
(C6 C9), 127.27 (C18), 126.88 (C17), 125.20 (C22), 121.41 (C23), 120.88 (C8 C14), 114.95 (C5), 
92.79 (C11), 66.60 (C3), 23.63 (C2), 10.73 (C1), 8.02 (C12). FT-IR (ATR): 1612 ν(C=Nimine). HR-
ESI-MS(+): 570.1288 [M-BPh4-NC5H4Ph-Na+H]+; HR-ESI-MS(-): 750.1047 [M-BPh4-2H]-, 
568.1277 [M-BPh4-NC5H5Ph-Na-H]-. Elemental Analysis (Calculated for C-
55H55BIrN2NaO4S.3½H2O): C, 58.80; H, 5.53; N, 2.48; S, 2.84; Found: C, 58.69; H, 5.47; N, 
2.47; S, 2.83. 
 
5.9.1.8. Mononuclear sulfonated iridium(III) 4-ferrocenylpyridyl complex (4.14) 
 
Red solid. Yield: 138.7 mg, 78%. MP.: 183.6ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.46 
(d, 2H, J = 5 Hz, H13), 8.28 (s, 1H, H4), 7.73 (m, 2H, H14), 7.65 (s, 1H, H6), 7.61 (d, 2H, H9), 
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7.18 (m, 8H, H21), 6.92 (t, 8H, J = 7 Hz, H22), 6.87 (d, 1H, J = 9 Hz, H8), 6.79 (t, 4H, J = 7 Hz, 
H23), 5.02 (m, 2H, H17), 4.61 (m, 2H, H18), 4.04 (m, 7H, H19 H3), 1.50 (m, 17H, H2 H12), 0.73 (t, 
3H, J = 7 Hz, H1). 13C{1H} NMR ((CD3)2SO): δ = 164.02 (C16A), 163.52 (C16B), 163.45 (C4), 
163.03 (C16C 4), 162.54 (C16D), 149.77 (C13), 135.44 (C21), 132.55 (C8), 131.75 (C6), 126.57 
(C14), 125.15 (C22), 122.55 (C15), 122.45 (C9), 121.38 (C23), 116.23 (C15), 92.69 (C11), 78.58 
(C16), 71.58 (C17), 70.00 (C19), 67.52 (C3), 67.15 (C18), 23.66 (C2), 10.73 (C1), 7.99 (C12). FT-
IR (ATR): 1609 ν(C=Nimine). HR-ESI-MS(+): 570.1283 [M-BPh4-NC5H5Fc-Na+H]+; HR-ESI-
MS(-): 568.1294 [M-BPh4-NC5H4Fc-Na-H]-, 831.6250 [M-BPh4-Na-H]-. Elemental Analysis 
(Calculated for C59H59BFeIrN2NaO4S.4H2O): C, 56.87; H, 5.42; N, 2.25; S, 2.57; Found: C, 
56.88; H, 5.37; N, 2.39; S, 2.73. 
 
5.9.2. Trinuclear Sulfonated Complexes (4.15-4.22) 
General Procedure 
4.2 (30.0 mg, 0.0384 mmol for 4.15-4.16; 53.6 mg, 0.0686 mmol for 4.17; 18.0 mg, 0.0230 
mmol for 4.18 and 4.22; 20.8 mg, 0.0266 mmol for 4.19-4.21) was dissolved in EtOH (10 ml). 
Excess NaOAc (10.4 mg, 0.127 mmol for 4.15-4.16; 18.6 mg, 0.227 mmol for 4.17; 12.5 mg, 
0.152 mmol for 4.18 and 4.22; 7.21 mg, 0.0879 mmol for 4.19-4.21) was added and stirred for 
30 minutes. [Rh(η5-C5Me5)Cl2]2 (39.2 mg, 0.0634 mmol for 4.15-4.16; 70.0 mg, 0.113 mmol 
for 4.17; 47.0 mg, 0.0760 mmol for 4.18) or [Ir(η5-C5Me5)Cl2]2 (35.0 mg, 0.0439 mmol for 4.19-
4.21; 60.6 mg, 0.0760 mmol for 4.22) was then dissolved into the solution which was stirred 
overnight. Pyridine (10.0 mg, 0.127 mmol for 4.15; 6.95 mg, 0.0879 mmol for 4.19), or 
4-methylpyridine (11.8 mg, 0.127 mmol for 4.16; 8.19 mg, 0. 0879 mmol for 4.20), or 
4-phenylpyridine (35.2 mg, 0.227 mmol for 4.17; 13.6 mg, 0. 0879 mmol for 4.21) or 
4-ferrocenylpyridine (40.0 mg, 0.152 mmol for 4.18 and 4.22) was then added and stirred for 
2 hours. NaBPh4 (43.4 mg, 0.127 mmol for 4.15-4.16; 77.5 mg, 0.227 mmol for 4.17; 26.0 mg, 
0.152 mmol for 4.18 and 4.22; 30.1 mg, 0.0879 mmol for 4.19-4.21) was then added. The 
solution was then filtered by gravity and then the solvent of the filtrate removed using rotary 
evaporation. The solid residue was dissolved in DCM and filtered by gravity, after which iPrOH 
was added and the solvent was reduced and precipitation occurred to yield the solid products 
4.15-4.22 which were dried under vacuum. 
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5.9.2.1. Trinuclear sulfonated rhodium(III) pyridyl complex (4.15) 
 
Red solid. Yield: 23.0 mg, 22%. MP.: 141.9ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.70 
(m, 6H, H12), 8.16 (s, 3H, H3), 7.75 (m, 9H, H14 H13), 7.48 (m, 6H, H5 H8), 7.18 (m, 24H, H16), 
6.92 (t, 24H, J = 7 Hz, H18), 6.79 (m, 15H, H19 H7), 4.02 (m, 6H, H1), 1.55 (s, 51H, H2 H11). 
13C{1H} NMR ((CD3)2SO): δ = 164.05 (C15A), 163.57 (C15B), 163.32 (C3), 163.07 (C15C), 162.58 
(C15D), 152.79 (C12), 138.98 (C14), 135.48 (C16), 129.27 (C8), 128.85 (C5), 126.61 (C13), 125.21 
(C17), 122.82 (C7), 121.42 (C18), 115.16 (C4), 97.91 (C10), 69.73 (C1), 61.95 (C2), 8.73 (C11). 
FT-IR (ATR): 1617 ν(C=Nimine), 1602 ν(C=Npyr). HR-ESI-MS(+): 373.1400 [M-3BPh4-
3NC5H5+Na]4+. Elemental Analysis (Calculated for C144H144B3N7Na3O12Rh3S3.2H2O): C, 
63.89; H, 5.51; N, 3.62; S, 3.55; Found: C, 64.01; H, 5.71; N, 3.51; S, 3.46. 
 
5.9.2.2. Trinuclear sulfonated rhodium(III) 4-methylpyridyl complex (4.16) 
 
Red solid. Yield: 44.9 mg, 43%. MP.: 156.9ºC (decomposed). 1H NMR ((CD3)2SO): δ = 8.53 
(d, 6H, H12, J = 6 Hz), 8.25 (s, 3H, H3), 7.61 (m, 6H, H5 H8), 7.52 (m, 6H, H13), 7.18 (m, 24H, 
H17), 6.92 (m, 27H, H18 H7), 6.78 (t, 12H, H19, J = 7 Hz), 3.98 (m, 6H, H1), 2.73 (s, 9H, H15), 
1.56 (s, 51H, H2 H11). 13C{1H} NMR ((CD3)2SO): δ = 164.05 (C16A), 163.35 (C16B), 163.05 (C16C), 
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162.99 (C3), 162.57 (C16D), 152.06 (C12), 140.61 (C14), 135.46 (C17), 132.61 (C8), 132.47 (C5), 
127.42 (C13), 127.17 (C18), 120.65 (C7), 121.41 (C19), 114.51 (C4), 93.85 (C10), 71.57 (C1), 
61.93 (C2), 20.54 (C15), 7.98 (C11). FT-IR (ATR): 1615 ν(C=Nimine), 1600 ν(C=Npyr). HR-ESI-
MS(+): 373.1400 [M-3BPh4-3NC5H4CH3+Na]4+. Elemental Analysis (Calculated for C-
147H150B3N7Na3O12Rh3S3.H2O): C, 64.65; H, 5.61; N, 3.59; S, 3.52; Found: C, 64.68; H, 5.73; 
N, 3.49; S, 3.48. 
 
5.9.2.3. Trinuclear sulfonated rhodium(III) 4-phenylpyridyl complex (4.17) 
 
Orange solid. Yield: 70.0 mg, 35%. MP.: 201.4ºC (decomposed). ). 1H NMR ((CD3)2SO): δ = 
8.64 (m, 6H, H12), 8.20 (s, 3H, H3), 7.83 (m, 6H, H13 H16), 7.54 (m, 6H, H5 H8), 7.54 (m, 9H, H17 
H18), 7.18 (m, 24H, H17), 6.92 (m, 27H, H18 H7), 6.78 (t, 12H, H19, J = 7 Hz), 3.92 (m, 6H, H1), 
1.50 (s, 51H, H2 H11). 13C{1H} NMR ((CD3)2SO): δ = 164.05 (C19A), 163.55 (C19B), 163.06 (C19C), 
163.65 (C3), 162.57 (C19D), 149.58 (C12), 135.70 (C18), 135.46 (C20), 132.48 (C8), 132.37 (C5), 
129.35 (C17), 126.85 (C16), 125.18 (C21),121.42 (C7 C13 C22), 115.15 (C4), 94.32 (C10), 72.47 
(C1), 61.94 (C2), 8.01 (C11). FT-IR (ATR): 1609 ν(C=Nimine + pyr). HR-ESI-MS(+): 373.1398 [M-
3BPh4-3NC5H4Ph+Na]4+. Elemental Analysis (Calculated for C-
162H156B3N7Na3O12Rh3S3.2H2O): C, 66.29; H, 5.49; N, 3.34; S, 3.28; Found: C, 66.35; H, 5.55; 
N, 3.51; S, 3.17. 
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5.9.2.4. Trinuclear sulfonated rhodium(III) 4-ferrocenylpyridyl complex (4.18) 
 
 
Orange solid. Yield: 62.1 mg, 84%. MP.: 173.3ºC (decomposed). 1H NMR ((CD3)2SO): δ = 
8.44 (d, 6H, H12, J = 6 Hz), 8.20 (s, 3H, H3), 7.84 (d, 3H, H8, J = 7 Hz), 7.83 (s, 3H, H5), 7.53 
(m, 6H, H13), 7.18 (m, 24H, H20), 6.93 (m, 27H, H21 H7), 6.79 (t, 12H, H22, J = 7 Hz), 5.11 (s, 
6H, H16), 4.67 (s, 6H, H17), 4.09 (s, 15H, H18), 4.04 (m, 6H, H1), 1.61 (s, 51H, H2 H11). 13C{1H} 
NMR ((CD3)2SO): δ = 163.74 (C19A), 163.42 (C19B), 163.09 (C19C), 162.76 (C19D), 162.03 (C3), 
151.67 (C12), 135.40 (C20), 128.87 (C8), 128.75 (C5), 125.09 (C21), 123.28 (C7), 122.62 (C14), 
122.43 (C13), 121.32 (C22), 115.09 (C4), 94.60 (C10), 77.46 (C15), 71.70 (C16), 70.17 (C18), 69.99 
(C1), 67.67 (C17), 61.86 (C2), 8.18 (C11). FT-IR (ATR): 1608 ν(C=Nimine + pyr). HR-ESI-MS(+): 
756.2974 [M-3BPh4]3+, 373.1404 [M-3BPh4-3NC5H4Fc+Na]4+. Elemental Analysis 
(Calculated for C174H168B3Fe3N7Na3O12Rh3S3.H2O): C, 64.48; H, 5.29; N, 3.03; S, 2.97; Found: 
C, 64.58; H, 5.37; N, 3.19; S, 3.09. 
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5.9.2.5. Trinuclear sulfonated iridium(III) pyridyl complex (4.19) 
 
Pale brown solid. Yield: 63.1 mg, 81%. MP.: 167.8ºC (decomposed). 1H NMR ((CD3)2SO): δ 
= 8.78 (d, 6H, H12, J = 5 Hz), 8.50 (s, 3H, H3), 8.20 (t, 3H, H14, J = 8 Hz), 7.77 (m, 6H, H7 H8), 
7.30 (d, 6H, H13, J = 7 Hz), 7.18 (m, 24H, H16), 7.07 (d, 3H, H8, J = 7 Hz), 6.92 (t, 24H, J = 7 
Hz, H17), 6.79 (t, 12H, J = 7 Hz, H19), 4.18 (m, 6H, H1), 1.56 (s, 51H, H2 H11). 13C{1H} NMR 
((CD3)2SO): δ = 171.87 (C6), 164.05 (C15A), 163.56 (C15B), 163.06 (C15C), 162.57 (C15D), 161.33 
(C3), 153.71 (C12), 139.05 (C14), 135.47 (C16), 129.29 (C5), 128.89 (C8), 125.21 (C17), 125.18 
(C13), 122.47 (C7), 121.42 (C18), 115.15 (C4), 93.60 (C10), 64.59 (C1), 54.31 (C2), 8.03 (C11). 
FT-IR (ATR): 1619 ν(C=Nimine), 1605 ν(C=Npyr). HR-ESI-MS(+): 405.1155 [M-3BPh4-3NC5H5-
3Na+5K+4CH3CN]5+, 442.0894 [M-3BPh4-3NC5H5+Na]4+. Elemental Analysis (Calculated for 
C144H144B3Ir3N7Na3O12S3.3H2O): C, 58.14; H, 5.01; N, 3.30; S, 3.23; Found: C, 58.25; H, 5.19; 
N, 3.21; S, 3.41. 
 
5.9.2.6. Trinuclear sulfonated iridium(III) 4-methylpyridyl complex (4.20) 
 
Pale brown solid. Yield: 60.9 mg, 77%. MP.: 172.7ºC (decomposed). 1H NMR ((CD3)2SO): δ 
= 8.60 (d, 6H, H12, J = 7 Hz), 8.43 (s, 3H, H3), 7.61 (m, 12H, H13 H5 H7), 7.18 (m, 24H, H17), 
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6.92 (t, 27H, H18 H8, J = 7 Hz), 6.78 (t, 12H, H19, J = 7 Hz), 4.15 (m, 6H, H1), 2.34 (s, 9H, H15), 
1.57 (s, 51H, H2 H11). 13C{1H} NMR ((CD3)2SO): δ = 175.86 (C6), 164.04 (C16A), 163.54 (C16B), 
163.05 (C16C), 162.57 (C16D), 161.31 (C3), 153.71 (C12), 140.76 (C14), 135.46 (C17), 129.25 
(C5), 128.89 (C8), 125.19 (C17), 127.23 (C13), 121.41 (C7 C19), 115.15 (C4), 94.26 (C10), 60.26 
(C1), 53.77 (C2), 22.79 (C15), 7.81 (C11). FT-IR (ATR): 1618 ν(C=Nimine + pyr). HR-ESI-MS(+): 
405.1007 [M-3BPh4-3NC5H4CH3-3Na+5K+4CH3CN]5+. Elemental Analysis (Calculated for C-
147H150B3Ir3N7Na3O12S33H2O): C, 58.17; H, 5.18; N, 3.23; S, 3.17; Found: C, 58.23; H, 5.25; N, 
3.17; S, 3.18. 
 
5.9.2.7. Trinuclear sulfonated iridium(III) 4-phenylpyridyl complex (4.21) 
 
Pale brown solid. Yield: 60.0 mg, 71%. MP.: 172.4ºC (decomposed). 1H NMR ((CD3)2SO): δ 
= 8.77 (d, 6H, H12, J = 6 Hz), 8.65 (s, 3H, H3), 7.95 (m, 3H, H18), 7.84 (d, 6H, H16, J = 5 Hz), 
7.74 (m, 6H, H7 H5), 7.60 (m, 6H, H13), 7.53 (m, 9H, H17 H8), 7.18 (m, 24H, H20), 6.92 (t, 24H, 
H21, J = 7 Hz), 6.78 (t, 12H, H22, J = 7 Hz), 4.12 (m, 6H, H1), 1.60 (s, 51H, H2 H11). 13C{1H} 
NMR ((CD3)2SO): δ = 163.77 (C19A), 163.44 (C19B), 163.12 (C19C), 162.79 (C19D), 160.87 
(C3),153.60 (C12), 135.42 (C20), 130.93 (C18),129.40 (C8), 129.08 (C5), 127.23 (C16), 126.68 
(C17), 125.11 (C21), 121.35 (C22), 121.09 (C7 C13), 115.12 (C4), 94.28 (C10), 68.64 (C1), 62.00 
(C2), 7.85 (C11). FT-IR (ATR): 1611 ν(C=Nimine + pyr). HR-ESI-MS(+): 405.0974 [M-3BPh4-
3NC5H4Ph-3Na+5K+4CH3CN]5+. Elemental Analysis (Calculated for C-
162H156B3Ir3N7Na3O12S3.4H2O): C, 60.07; H, 5.10; N, 3.03; S, 2.97; Found: C, 59.98; H, 5.11; 
N, 3.10; S, 3.05. 
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5.9.2.8. Trinuclear sulfonated iridium(III) 4-ferrocenylpyridyl complex (4.22) 
 
Orange solid. Yield: 77.0 mg, 96%. MP.: 172.9ºC (decomposed). 1H NMR ((CD3)2SO): δ = 
8.49 (d, 6H, H12, J = 6 Hz), 8.42 (s, 3H, H3), 7.83 (m, 6H, H5 H7), 7.57 (m, 6H, H13), 7.18 (m, 
24H, H20), 6.93 (m, 27H, H21 H8), 6.79 (t, 12H, H22, J = 7 Hz), 5.12 (s, 6H, H16), 4.69 (s, 6H, 
H17), 4.10 (m, 21H, H18 H1), 1.61 (s, 51H, H2 H11). 13C{1H} NMR ((CD3)2SO): δ = 163.75 (C19A), 
163.42 (C19B), 163.09 (C19C), 162.77 (C19D), 161.31 (C3), 152.30 (C12), 135.41 (C20), 128.76 
(C8), 128.35 (C5), 125.11 (C21), 123.49 (C7), 122.94 (C14), 123.16 (C13), 121.33 (C22), 115.10 
(C4), 94.12 (C10), 77.04 (C15), 71.96 (C16), 70.28 (C18), 69.57 (C1), 67.69 (C17), 61.87 (C2), 7.79 
(C11). FT-IR (ATR): 1611 ν(C=Nimine + pyr). HR-ESI-MS(+): 405.0922 [M-3BPh4-3NC5H4Fc-
3Na+5K+4CH3CN]5+. Elemental Analysis (Calculated for C174H168B3Ir3N7Na3O12S3.2H2O): C, 
59.25; H, 4.92; N, 2.78; S, 2.73; Found: C, 59.18; H, 4.98; N, 2.88; S, 2.65. 
 
5.10. X-ray Crystallography 
Single-crystal X-ray diffraction data were collected on a Nonius Kappa-CCD diffractometer 
using graphite monochromated MoK radiation ( = 0.71073 Å). Temperature was controlled 
by an Oxford Cryostream cooling system (Oxford Cryostat). The strategy for the data 
collections was evaluated using the Bruker Nonius "Collect” program. Data were scaled and 
reduced using DENZO-SMN software.[9] Absorption correction was performed using 
SADABS.[10] The structure was solved by direct methods and refined employing full-matrix 
least-squares with the program SHELXL-97[11] refining on F2. The diagrams were produced 
using the program PovRay[12] and graphic interface X-seed.[13]  
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Table 1. Crystallographic and structure refinement parameters for complexes (2.7-2.9) 
Compound Number 2.7 2.8 2.9 
Chemical formula C24H27ClNORh C24H27ClIrNO C23H27ClF6N2OPRh 
Formula weight 483.83 573.14 630.80 
Crystal system Triclinic Triclinic Triclinic 
Space group P-1 P-1 P-1 
Crystal colour and shape Orange block Red block Yellow block 
Crystal size (mm) 0.17x0.13x0.04 0.10x0.08x0.07 0.16x0.09x0.04 
a (Å) 8.5513(7) 10.9174(5) 8.4081(17) 
b (Å) 8.6221(7) 13.4833(4) 11.002(2) 
c (Å) 16.2053(12) 15.0954(7) 13.926(3) 
α (o) 99.6580(10) 99.470(2) 88.55(3) 
β (o) 96.9070(10) 103.502(2) 88.94(3) 
γ (o) 115.1960(10) 92.553(2) 75.95(3) 
V (Å3) 1040.92(14) 2123.23(15) 1249.2(4) 
Z 2 4 2 
T 173(2) 173(2) 173(2) 
Dc (gcm-3) 1.554 1.793 1.677 
μ (mm-1) 0.963 6.428 0.919 
Unique reflections 5222 9631 5702 
Reflections used 4593 6877 4780 
Goodness-of-fit 1.045 1.041 1.063 
 
All non-hydrogen atoms were refined anisotropically. In 2.7 all hydrogen atoms, except H1, 
were placed in idealised positions and refined in riding models with Uiso assigned the values 
to be 1.2 or 1.5 times those of their parent atoms and the constraint distances of C-H ranging 
from 0.95 Å to 0.99 Å. The hydrogen H1 was located in the electron difference maps and 
refined freely. In 2.8 all hydrogen atoms, except H1A and H1B, were placed in idealised 
positions and refined in riding models with Uiso assigned the values to be 1.2 or 1.5 times Ueq 
of the atoms to which they are attached and the constraint distances of C-H ranging from 0.95 
Å to 0.99 Å. The hydrogen H1A and H1B were located in the difference Fourier maps and 
refined with bond length constraint d(O-H) = 0.97 Å and with Uiso(H) = 1.5xUeq(O). In 2.9 all 
non-hydrogen atoms, except F4 and F6, were refined anisotropically. The fluorine atoms F4 
and F6 were refined with isotropic displacement parameters due to their high thermal motions. 
In 2.10 the oxygen atom O1 was restrained with similar anisotropic displacement parameters 
as C1 due to high temperature factor shown by O1. In 2.11 and 2.14 the hydrogen atoms, 
except H1, were placed in idealised positions and refined in riding models with Uiso assigned 
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the values to be 1.2 or 1.5 times Ueq of the atoms to which they are attached and the constraint 
distances of C-H ranging from 0.95 Å to 1.00 Å. The hydrogen H1 was located in the difference 
Fourier maps and in 2.9 refined with bond length constraint d(O1-H1) = 0.97 Å, while in 2.10 
refined with Uiso (H1) = Ueq (O1) and in 2.12 and 2.13 refined independently. 
Table 2. Crystallographic and structure refinement parameters for complexes (2.10-2.12) 
Compound Number 2.10 2.11 2.12 
Chemical formula C23H27ClF6IrN2OP C23H26ClF6N2OPRu C24H27ClNO2Rh 
Formula weight 720.09 627.95 499.83 
Crystal system Triclinic Triclinic Orthorhombic 
Space group P-1 P-1 Pna21 
Crystal colour and shape Red block Orange plate Red block 
Crystal size (mm) 0.10x0.08x0.07 0.13x0.11x0.09 0.22x0.11x0.03 
a (Å) 8.4054(2) 8.9720(3) 17.9479(13) 
b (Å) 11.0226(4) 10.8592(4) 15.1006(11) 
c (Å) 13.9230(4) 13.9422(4) 7.9655(6) 
α (o) 88.786(2) 74.505(2) 90 
β (o) 89.410(2) 82.981(2) 90 
γ (o) 75.696(2) 72.044(2) 90 
V (Å3) 1249.2(4) 1244.07(7) 2158.8(3) 
Z 2 2 4 
T 173(2) 173(2) 173(2) 
Dc (gcm-3) 1.914 1.676 1.538 
μ (mm-1) 5.577 0.866 0.935 
Unique reflections 5683 6176 5097 
Reflections used 5125 6176 4166 
Goodness-of-fit 1.068 1.013 1.050 
 
In 2.7 the structure was refined to R factor of 0.0261, the highest peak is 0.61 e Å-3, 0.87 Å 
from Rh1 and the deepest hole is -0.51 e Å-3, 0.95 Å from Rh1. In 2.8 the structure was refined 
to R factor of 0.0204, the highest peak is 2.48 e Å-3, 0.93 Å from Ir1B or 2.37 e Å-3, 1.03 Å 
from Ir1A and the deepest hole is -0.89 e Å-3, 0.89 Å from Ir1B or -0.84 e Å-3, 0.97 Å from Ir1A. 
In 2.9 the structure was refined to R factor of 0.0486, the highest peak is 3.15 e Å-3, 0.63 Å 
from F4 and the deepest hole is -1.43 e Å-3, 0.63 Å from F4. In 2.10 the structure was refined 
to R factor of 0.0204, the highest peak is 1.57 e Å-3, 0.93 Å from N2 and the deepest hole is -
0.79 e Å-3, 0.84 Å from Ir1. In 2.11 the structure was refined to R factor of 0.0420, the highest 
peak is 2.45 e Å-3, 0.88 Å from Ru1 and the deepest hole is -0.85 e Å-3, 0.80 Å from Ru1. In 
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2.12 the structure was refined to R factor of 0.0386, the highest peak is 1.37 e Å-3, 0.48 Å from 
H1A and the deepest hole is -0.60 e Å-3, 0.65 Å from O1. In 2.13 the structure was refined to 
R factor of 0.0240, the highest peak is 0.41 e Å-3, 0.78 Å from Ir1 and the deepest hole is -
0.53 e Å-3, 0.40 Å from Ir1. In 2.14 the structure was refined to R factor of 0.0259, the highest 
peak is 0.51 e Å-3, 0.82 Å from Ru1 and the deepest hole is -0.37 e Å-3, 0.76 Å from Ru1. 
CCDC Numbers for the complexes are: 2.9: 1026858; 2.10: 1026859; 2.11: 1035358; 2.12: 
1026860; 2.13: 1026861; 2.14: 1035356. 
Table 3. Crystallographic and structure refinement parameters for complexes (2.13-2.14) 
Compound Number 2.13 2.14 
Chemical formula C24H27ClIrNO2 C24H26ClNO2Ru 
Formula weight 589.12 496.98 
Crystal system Monoclinic Monoclinic 
Space group P21 Cc 
Crystal colour and shape Orange block Orange block 
Crystal size (mm) 0.16x0.12x0.04 0.18x0.13x0.12 
a (Å) 7.4741(7) 15.6588(7) 
b (Å) 15.7546(13) 16.4313(8) 
c (Å) 9.86.11(8) 8.8012(4) 
α (o) 90 90 
β (o) 112.149(2) 109 
γ (o) 90 90 
V (Å3) 1075.47(16) 2133.79(17) 
Z 2 4 
T 173(2) 173(2) 
Dc (gcm-3) 1.819 1.547 
μ (mm-1) 6.352 0.880 
Unique reflections 5344 6270 
Reflections used 4941 27056 
Goodness-of-fit 1.039 1.013 
 
5.11. NMR Experiments 
5.11.1. Stability Investigation 
The mononuclear complexes, 2.10 and 2.13, and the trimeric complex 2.16 were dissolved in 
(CD3)2SO and H2O, in a 50:50 ratio, and warmed at 37 oC, to mimic physiological conditions. 
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The sample was monitored by 1H NMR spectroscopy for aquatic stability at varying times up 
to 24 hours.  
The mononuclear iridium(III) complex 3.4 was dissolved in D2O and monitored by 1H and 
31P{1H} NMR spectroscopy for aqueous stability for 48 hours. 
The mononuclear sulfonated anionic complexes 4.3-4.4 were dissolved in (CD3)2SO and 
monitored by 1H NMR spectroscopy for stability for 48 hours, while the mononuclear 
sulfonated complexes 4.7-4.14 were dissolved in (CD3)2SO and monitored by 1H NMR 
spectroscopy daily for 3 weeks. The trinuclear sulfonated complex 4.18 was dissolved in a 
50:50 mixture of (CD3)2SO and monitored by 1H NMR spectroscopy for 48 hours. 
 
5.11.2. Interactions with 5'-GMP 
The N,N- mononuclear complex, 2.10, and the N,O- mononuclear complex, 2.13, and an 
equimolar amount of 5'-GMP were dissolved in (CD3)2SO and H2O, in a 50:50 ratio, and 
warmed at 37 oC, to mimic physiological conditions. The mixture was monitored by 1H NMR 
spectroscopy for interactions with the model DNA at varying times up to 24 hours. 
The mononuclear iridium(III) complex, 3.4, and an equimolar amount of 5'-GMP were 
dissolved together in D2O and warmed to 37 oC, to mimic physiological conditions. The 
samples were monitored using 1H and 31P{1H} NMR spectroscopy to monitor interactions. 
The trinuclear sulfonated complex 4.18 and an equimolar amount of 5'-GMP were dissolved 
in (CD3)2SO and H2O, in a 50:50 ratio, and warmed at 37 oC. The mixture was monitored by 
1H NMR spectroscopy for interactions with the model DNA at varying times up to 48 hours. 
 
5.11.3. Interactions with Histidine 
The mononuclear Ir complex, 3.4, and an equimolar amount of Histidine were dissolved 
together in D2O and warmed to 37 oC, to mimic physiological conditions. The samples were 
monitored using 1H NMR spectroscopy to monitor interactions. 
 
5.12. UV-Vis Absorption Studies 
Absorption studies of a 0.33 mM solution of 3.4 in H2O with 0.2 mM HEPES buffer, pH 7.4 
were performed in the range 350-250 nm. Solutions of Red Salmon testes DNA sodium salt 
were prepared fresh before each experiment using milli-Q water. 50 µL aliquots of 45 nM DNA 
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stock solution were added to 3.4 to make the DNA concentrations: 2.14, 4.09, 5.87, 7.50, 9.00, 
10.4, 11.7 and 12.9 nM. 
 
5.13. Biological Studies 
5.13.1. Cell Culture  
Human A2780 and A2780cisR ovarian cancer cells and KMST-6 cells were obtained from the 
European Collection of Cell Cultures (Salisbury, UK). A2780 and A2780cisR cells were grown 
routinely in RPMI-1640 medium, KMST-6 cells in DMEM medium, both media supplemented 
with 10% fetal calf serum (FCS) and antibiotics (Penicillin Streptomycin) at 37 °C and 5% CO2. 
Cytotoxicity was determined using the WST-1 assay (WST-1 = (4-[3-(4-Iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio)-1,3-benzene disulfonate). Cells were seeded in 96-well plates as 
monolayers with 100 μL of cell solution (approximately 5 000 cells) per well and pre-incubated 
for 24 h in medium supplemented with 10% FCS. Compounds were prepared as DMSO 
solutions then immediately dissolved in the culture medium and serially diluted to the 
appropriate concentration, to give a final DMSO concentration of 0.5%. 100 μL of drug solution 
was added to each well and the plates were incubated for another 24 h. Subsequently, WST-
1 (10 μL solution) was added to the cells and the plates were incubated for a further 3 h. The 
WST-1 tetrazolium salt is cleaved to a soluble formazan by a cellular mechanism, succinate-
tetrazolium reductase system (EC 1.3.99.1), which occurs primarily at the cell surface. This 
bioreduction depends largely on the cellular production of NAD(P)H within metabolically intact 
and viable cells. The optical density, directly proportional to the number of surviving cells, was 
quantified at 450 nm, and background correction was performed at 600 nm, using a multiwell 
plate reader and the fraction of surviving cells was calculated from the absorbance of 
untreated control cells. Evaluation is based on means from three microcultures per 
concentration level. 
The WHCO1 oesophageal cancer cell-line was derived from a biopsy of primary oesophageal 
squamous cell carcinoma of South African origin [14]. Cells were cultured at 37 °C under 5 % 
CO2 without antibiotics in DMEM (Dulbecco’s Modified Eagle Medium) containing 10 % FBS 
(Gibco). Cytotoxicity of compounds was evaluated using the standard MTT 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) cellular viability assay. Briefly 
cells were seeded at a density of 2.5 x 103 cells per well in 96 well plates and allowed to settle 
overnight. A stock solution of each compound in water (2 mM) was prepared. The compound 
was then added to the cells in triplicate to a concentration of 200 M. After a 48 h incubation 
period, 10 L of 5 mg/mL MTT was added and incubated with the cells for 4 h. The reaction 
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was then quenched by addition of 100 L 10 % SLS in 0.01 M HCl to solubilize the formazan 
crystals. The plates were read at 595 nm on a Multiscan FC plate reader (Thermo Scientific), 
and data was analysed using Graphpad Prism 4 software, sigmoidal dose-response variable 
slope curve fitting. 
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Chapter 6: Conclusions and Future 
Outlook 
6. Conclusions 
6.1 Synthesis 
New mono- and trinuclear PGM complexes containing rhodium(III), iridium(III) and 
ruthenium(II) were synthesized and characterized using an array of spectroscopic and 
analytical techniques. These complexes are subdivided into three main series, based on the 
ligand type used. 
Firstly, three Schiff base ligands were used to prepare three new trimeric ester containing 
ligands 2.4-2.6. From these ligands eight mono- and eight trinuclear PGM complexes 2.7-2.22 
were prepared. The characterization of these C,N-benzaldiminato, N,N-pyridylimine or 
N,O-salicylaldiminato complexes revealed that the ligands act as bidentate donors to the metal 
center. Single crystal X-ray diffraction was used to confirm this for the mononuclear 
complexes. 
Secondly, A new water soluble cationic trimeric ligand 3.2 was prepared from the alkylation of 
PTA. The monomeric analogue 3.1 was also prepared. Both cationic ligands were metallated 
at the phosphorous of the alkylated PTA moiety, this was confirmed by the appropriate 
downfield shifts observed in the 31P NMR spectra. Three mono- and three trinuclear water 
soluble PGM complexes 3.3-3.8, were afforded. 
Thirdly, a trimeric water soluble sulfonated ligand 4.2 was prepared via Schiff base 
condensation. The monomeric analogue was similarly prepared 4.1. Two mono- and two 
trinuclear anionic PGM N,O-salicylaldiminato complexes 4.3-4.6 were prepared from the 
sulfonated ligands. A further eight mono- and eight trinuclear sulfonated complexes 4.7-4.22 
were also synthesized from the same ligands. Displacement of the metal-chloro ligand was 
achieved with a selection of N-donor ligands and the complexes isolated as tetraphenylborate 
salts. 
 
6.2. In vitro Antitumor Activity and Biological Evaluation 
The ester containing trinuclear PGM complexes, mononuclear analogues and ligands were 
evaluated for in vitro antitumor activity. The monomeric ligands 2.1-2.3 were inactive, whilst 
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the more lipophilic trimeric ligands 2.4-2.6 displayed some slight activity. All the complexes 
2.7-2.22 exhibited moderate to high activity against the human ovarian cisplatin sensitive 
A2780 and cisplatin resistant A2780cisR cancer cells. The trinuclear complexes 2.15-2.22 
exhibited greater activity than the mononuclear analogues. The trinuclear cationic N,N-
pyridylimine containing complexes 2.17-2.18 were the most active. All complexes 2.7-2.22 
exhibited roughly similar activities in both the cisplatin sensitive and cisplatin resistant cell 
lines with the exception of one, which suggests that these complexes may have a different 
mode of action to that of cisplatin. The trinuclear C,N-benzaldiminato complexes 2.15-2.16 
showed poor selectivity towards non-tumorigenic human KMST-6 skin cells, whilst the N,N-
pyridylimine and N,O-salicylaldiminato complexes 2.17-2.22 were moderately selective. NMR 
studies performed showed that the most active complex 2.18 and mononuclear analogue 2.10 
are inert in aqueous environments. The most active mononuclear N,O-salicylaldiminato 
complex 2.13 displayed the ability to interact with 5′-GMP while on the other hand the most 
active N,N-pyridylimine complex 2.10 did not, as observed by NMR studies. 
The cationic alkylated PTA compounds 3.1-3.8 were evaluated for in vitro antitumor activity 
against the human esophageal cancer cell line WHCO1. The ligands 3.1-3.2 were inactive 
against the tumor cells. The metal complexes 3.3-3.8 displayed activity against the 
esophageal cancer cells and a nuclearity dependent activity relationship was observed for the 
rhodium(III) and ruthenium(II) complexes. However, the most active against the esophageal 
cancer cells for this series was the mononuclear iridium(III) complex 3.4. NMR studies 
revealed the stability of the most active complex 3.4 in an aqueous environment and the ability 
to interact with small molecules of biological importance, such as 5′-GMP and L-histidine. 
UV-Vis titrations were used to investigate the ability of 3.4 to interact with double stranded 
DNA. 
The mono- and trinuclear water soluble anionic sulfonated complexes, ligands and mono- and 
trinuclear sulfonated complexes containing N-donor ligands were evaluated for in vitro 
antitumor activity against WHCO1 cancer cells. The water soluble ligands 4.1-4.2 displayed 
no activity against the esophageal cancer cells, while the anionic mono- and trinuclear metal-
chloro containing complexes 4.3-4.6 exhibited poor activity. The displacement of the metal-
chloro ligand by N-donor ligands resulted in a significant increase in activity. The sulfonated 
trinuclear complexes containing N-donor ligands 4.7-4.22 were the most active. NMR studies 
suggest that the anionic complexes 4.3-4.4 undergo displacement of the metal-chloro ligand 
by DMSO, which may explain their lack of activity. The sulfonated complexes containing N-
donor ligands 4.7-4.22 all, with the exception of 4.14, exhibit stability and inertness in an 
aqueous environment over an extended time period, as shown by NMR studies. Similarly, 
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NMR studies show the ability of the most active trinuclear complex 4.18 to interact with 5’-
GMP. 
 
6.3. Future Outlook 
This study has displayed the great potential of PGM complexes as antitumor agents. Further 
exploration into different types of polymeric scaffolds or ligands may result in the fine tuning 
and increase in in vitro antitumor activity. Amide based scaffolds could be attempted to 
increase the water solubility[1-2] of complexes or polyether imines (PETIM) to lower the 
toxicity[3-4] of the ligands used. 
In this study the ruthenium-arene was limited to p-cymene while the rhodium(III) and iridium(III) 
systems were only prepared with a pentamethylcyclopentadienyl ligand. Other arenes or Cp 
rings could be investigated to explore the influential role of this moiety on the complex’s 
activity. These could include a cyclohexyl ring, hexamethylbenzyl ring, biphenyl ring or a glycol 
containing ring. These modifications allow for minor changes of the polarity[5] which may result 
in desired increases in activity. 
The ligands prepared in this study were limited to low-valent dendrimer type scaffolds. These 
ligands could easily be converted in higher-valent dendrimers with minor synthetic 
modifications. Dendrimers have previously exhibited significant cellular permeability and 
retentions and these desirable properties encourage antitumor activity.[6] 
NMR studies were performed in this investigation to probe the ability of the most active PGM 
complexes herein reported to interact with model DNA, 5′-GMP. These studies could be 
extended to include a wider selection of biologically important molecules to include those of 
amino acids, which are the fundamental building blocks of all proteins, and even small proteins 
or enzymes that these complexes may encounter within the blood. 
Only in vitro antitumor activities were studied in this research. In vivo experiments would 
naturally be the next step forward for these potential drugs. A concourse of other important 
biological assays could be performed to better understand the biological activity of these 
complexes. Cellular uptake studies would allow for an understanding of each complex’s ability 
to cross the cellular membrane. This could allow for any relationships between activity and 
uptake to be identified. Other DNA binding experiments such as those associated with gel 
electrophoresis would bring further understanding to these complexes ability to bind to DNA 
and these may be assayed in the presence of other molecules which would competitively bind 
to the DNA. Circular Dichroism studies could be performed, which would allow of qualitative 
identification of the type of interactions or binding of these complexes with DNA.  
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All of these investigations when coupled together will assist in trying to understand the 
potential methods of action if these complexes as antitumor agents 
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